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This report consolidates previous recommendations and adds new ones for infection control in dental settings. Recommendations
are provided regarding 1) educating and protecting dental health-care personnel; 2) preventing transmission of bloodborne patho-
gens; 3) hand hygiene; 4) personal protective equipment; 5) contact dermatitis and latex hypersensitivity; 6) sterilization and
disinfection of patient-care items; 7) environmental infection control; 8) dental unit waterlines, biofilm, and water quality; and
9) special considerations (e.g., dental handpieces and other devices, radiology, parenteral medications, oral surgical procedures, and
dental laboratories). These recommendations were developed in collaboration with and after review by authorities on infection
control from CDC and other public agencies, academia, and private and professional organizations.
• hand-hygiene products and surgical hand antisepsis;
• contact dermatitis and latex hypersensitivity;
• sterilization of unwrapped instruments;
• dental water-quality concerns (e.g., dental unit waterline
biofilms; delivery of water of acceptable biological quality
for patient care; usefulness of flushing waterlines; use of
sterile irrigating solutions for oral surgical procedures;
handling of community boil-water advisories);
• dental radiology;
• aseptic technique for parenteral medications;
• preprocedural mouth rinsing for patients;
• oral surgical procedures;
• laser/electrosurgery plumes;
• tuberculosis (TB);
• Creutzfeldt-Jakob disease (CJD) and other prion-related
diseases;
• infection-control program evaluation; and
• research considerations.
These guidelines were developed by CDC staff members in
collaboration with other authorities on infection control. Draft
documents were reviewed by other federal agencies and profes-
sional organizations from the fields of dental health care, public
health, and hospital epidemiology and infection control. A Fed-
eral Register notice elicited public comments that were consid-
ered in the decision-making process. Existing guidelines and
published research pertinent to dental infection-control prin-
Introduction
This report consolidates recommendations for preventing
and controlling infectious diseases and managing personnel
health and safety concerns related to infection control in den-
tal settings. This report 1) updates and revises previous CDC
recommendations regarding infection control in dental set-
tings (1,2); 2) incorporates relevant infection-control measures
from other CDC guidelines; and 3) discusses concerns not
addressed in previous recommendations for dentistry. These
updates and additional topics include the following:
• application of standard precautions rather than universal
precautions;
• work restrictions for health-care personnel (HCP) infected
with or occupationally exposed to infectious diseases;
• management of occupational exposures to bloodborne
pathogens, including postexposure prophylaxis (PEP) for
work exposures to hepatitis B virus (HBV), hepatitis C
virus (HCV); and human immunodeficiency virus (HIV);
• selection and use of devices with features designed to pre-
vent sharps injury;
The material in this report originated in the National Center for Chronic
Disease Prevention and Health Promotion, James S. Marks, M.D.,
M.P.H., Director; and the Division of Oral Health, William R. Maas,
D.D.S., M.P.H., Director.
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ciples and practices were reviewed. Wherever possible, recom-
mendations are based on data from well-designed scientific stud-
ies. However, only a limited number of studies have characterized
risk factors and the effectiveness of prevention measures for
infections associated with dental health-care practices.
Some infection-control practices routinely used by health-
care practitioners cannot be rigorously examined for ethical or
logistical reasons. In the absence of scientific evidence for such
practices, certain recommendations are based on strong theo-
retical rationale, suggestive evidence, or opinions of respected
authorities based on clinical experience, descriptive studies, or
committee reports. In addition, some recommendations are
derived from federal regulations. No recommendations are
offered for practices for which insufficient scientific evidence
or lack of consensus supporting their effectiveness exists.
Background
In the United States, an estimated 9 million persons work in
health-care professions, including approximately 168,000 den-
tists, 112,000 registered dental hygienists, 218,000 dental
assistants (3), and 53,000 dental laboratory technicians (4).
In this report, dental health-care personnel (DHCP) refers to
all paid and unpaid personnel in the dental health-care setting
who might be occupationally exposed to infectious materials,
including body substances and contaminated supplies, equip-
ment, environmental surfaces, water, or air. DHCP include
dentists, dental hygienists, dental assistants, dental laboratory
technicians (in-office and commercial), students and trainees,
contractual personnel, and other persons not directly involved
in patient care but potentially exposed to infectious agents (e.g.,
administrative, clerical, housekeeping, maintenance, or vol-
unteer personnel). Recommendations in this report are
designed to prevent or reduce potential for disease transmis-
sion from patient to DHCP, from DHCP to patient, and from
patient to patient. Although these guidelines focus mainly on
outpatient, ambulatory dental health-care settings, the recom-
mended infection-control practices are applicable to all set-
tings in which dental treatment is provided.
Dental patients and DHCP can be exposed to pathogenic
microorganisms including cytomegalovirus (CMV), HBV,
HCV, herpes simplex virus types 1 and 2, HIV, Mycobacte-
rium tuberculosis, staphylococci, streptococci, and other viruses
and bacteria that colonize or infect the oral cavity and respira-
tory tract. These organisms can be transmitted in dental set-
tings through 1) direct contact with blood, oral fluids, or other
patient materials; 2) indirect contact with contaminated
objects (e.g., instruments, equipment, or environmental sur-
faces); 3) contact of conjunctival, nasal, or oral mucosa with
droplets (e.g., spatter) containing microorganisms generated
from an infected person and propelled a short distance (e.g.,
by coughing, sneezing, or talking); and 4) inhalation of air-
borne microorganisms that can remain suspended in the air
for long periods (5).
Infection through any of these routes requires that all of the
following conditions be present:
• a pathogenic organism of sufficient virulence and in
adequate numbers to cause disease;
• a reservoir or source that allows the pathogen to survive
and multiply (e.g., blood);
• a mode of transmission from the source to the host;
• a portal of entry through which the pathogen can enter
the host; and
• a susceptible host (i.e., one who is not immune).
Occurrence of these events provides the chain of infection (6).
Effective infection-control strategies prevent disease transmis-
sion by interrupting one or more links in the chain.
Previous CDC recommendations regarding infection con-
trol for dentistry focused primarily on the risk of transmission
of bloodborne pathogens among DHCP and patients and use
of universal precautions to reduce that risk (1,2,7,8). Univer-
sal precautions were based on the concept that all blood and
body fluids that might be contaminated with blood should be
treated as infectious because patients with bloodborne infec-
tions can be asymptomatic or unaware they are infected (9,10).
Preventive practices used to reduce blood exposures, particu-
larly percutaneous exposures, include 1) careful handling of
sharp instruments, 2) use of rubber dams to minimize blood
spattering; 3) handwashing; and 4) use of protective barriers
(e.g., gloves, masks, protective eyewear, and gowns).
The relevance of universal precautions to other aspects of
disease transmission was recognized, and in 1996, CDC
expanded the concept and changed the term to standard pre-
cautions. Standard precautions integrate and expand the ele-
ments of universal precautions into a standard of care designed
to protect HCP and patients from pathogens that can be spread
by blood or any other body fluid, excretion, or secretion (11).
Standard precautions apply to contact with 1) blood; 2) all
body fluids, secretions, and excretions (except sweat), regard-
less of whether they contain blood; 3) nonintact skin; and 4)
mucous membranes. Saliva has always been considered a
potentially infectious material in dental infection control; thus,
no operational difference exists in clinical dental practice
between universal precautions and standard precautions.
In addition to standard precautions, other measures (e.g.,
expanded or transmission-based precautions) might be neces-
sary to prevent potential spread of certain diseases (e.g., TB,
influenza, and varicella) that are transmitted through airborne,
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droplet, or contact transmission (e.g., sneezing, coughing, and
contact with skin) (11). When acutely ill with these diseases,
patients do not usually seek routine dental outpatient care.
Nonetheless, a general understanding of precautions for dis-
eases transmitted by all routes is critical because 1) some DHCP
are hospital-based or work part-time in hospital settings;
2) patients infected with these diseases might seek urgent treat-
ment at outpatient dental offices; and 3) DHCP might
become infected with these diseases. Necessary transmission-
based precautions might include patient placement (e.g., iso-
lation), adequate room ventilation, respiratory protection (e.g.,
N-95 masks) for DHCP, or postponement of nonemergency
dental procedures.
DHCP should be familiar also with the hierarchy of con-
trols that categorizes and prioritizes prevention strategies (12).
For bloodborne pathogens, engineering controls that elimi-
nate or isolate the hazard (e.g., puncture-resistant sharps con-
tainers or needle-retraction devices) are the primary strategies
for protecting DHCP and patients. Where engineering con-
trols are not available or appropriate, work-practice controls
that result in safer behaviors (e.g., one-hand needle recapping
or not using fingers for cheek retraction while using sharp
instruments or suturing), and use of personal protective equip-
ment (PPE) (e.g., protective eyewear, gloves, and mask) can
prevent exposure (13). In addition, administrative controls
(e.g., policies, procedures, and enforcement measures targeted
at reducing the risk of exposure to infectious persons) are a
priority for certain pathogens (e.g., M. tuberculosis), particu-
larly those spread by airborne or droplet routes.
Dental practices should develop a written infection-control
program to prevent or reduce the risk of disease transmission.
Such a program should include establishment and implemen-
tation of policies, procedures, and practices (in conjunction
with selection and use of technologies and products) to pre-
vent work-related injuries and illnesses among DHCP as well
as health-care–associated infections among patients. The pro-
gram should embody principles of infection control and
occupational health, reflect current science, and adhere to rel-
evant federal, state, and local regulations and statutes. An
infection-control coordinator (e.g., dentist or other DHCP)
knowledgeable or willing to be trained should be assigned
responsibility for coordinating the program. The effectiveness
of the infection-control program should be evaluated on a day-
to-day basis and over time to help ensure that policies, proce-
dures, and practices are useful, efficient, and successful (see
Program Evaluation).
Although the infection-control coordinator remains respon-
sible for overall management of the program, creating and main-
taining a safe work environment ultimately requires the
commitment and accountability of all DHCP. This report is
designed to provide guidance to DHCP for preventing disease
transmission in dental health-care settings, for promoting a safe
working environment, and for assisting dental practices in
developing and implementing infection-control programs. These
programs should be followed in addition to practices and pro-
cedures for worker protection required by the Occupational
Safety and Health Administration’s (OSHA) standards for
occupational exposure to bloodborne pathogens (13),
including instituting controls to protect employees from
exposure to blood or other potentially infectious materials
(OPIM), and requiring implementation of a written exposure-
control plan, annual employee training, HBV vaccinations, and
postexposure follow-up (13). Interpretations and enforcement
procedures are available to help DHCP apply this OSHA stan-
dard in practice (14). Also, manufacturer’s Material Safety Data
Sheets (MSDS) should be consulted regarding correct proce-
dures for handling or working with hazardous chemicals (15).
Previous Recommendations
This report includes relevant infection-control measures from
the following previously published CDC guidelines and rec-
ommendations:
• CDC. Guideline for disinfection and sterilization in
health-care facilities: recommendations of CDC and the
Healthcare Infection Control Practices Advisory Commit-
tee (HICPAC). MMWR (in press).
• CDC. Guidelines for environmental infection control in
health-care facilities: recommendations of CDC and the
Healthcare Infection Control Practices Advisory Commit-
tee (HICPAC). MMWR 2003;52(No. RR-10).
• CDC. Guidelines for the prevention of intravascular
catheter-related infections. MMWR 2002;51(No. RR-10).
• CDC. Guideline for hand hygiene in health-care settings:
recommendations of the Healthcare Infection Control
Practices Advisory Committee and the HICPAC/SHEA/
APIC/IDSA Hand Hygiene Task Force. MMWR 2002;51
(No. RR-16).
• CDC. Updated U.S. Public Health Service guidelines for
the management of occupational exposures to HBV, HCV,
and HIV and recommendations for postexposure prophy-
laxis. MMWR 2001;50(No. RR-11).
• Mangram AJ, Horan TC, Pearson ML, Silver LC, Jarvis
WR, Hospital Infection Control Practices Advisory Com-
mittee. Guideline for prevention of surgical site infection,
1999. Infect Control Hosp Epidemiol 1999;20:250–78.
• Bolyard EA, Tablan OC, Williams WW, Pearson ML,
Shapiro CN, Deitchman SD, Hospital Infection Control
Practices Advisory Committee. Guideline for infection
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control in health care personnel, 1998. Am J Infect Con-
trol 1998;26:289–354.
• CDC. Immunization of health-care workers: recommen-
dations of the Advisory Committee on Immunization Prac-
tices (ACIP) and the Hospital Infection Control Practices
Advisory Committee (HICPAC). MMWR 1997;46(No.
RR-18).
• Rutala WA, Association for Professionals in Infection
Control and Epidemiology, Inc. APIC guideline for selec-
tion and use of disinfectants. Am J Infect Control
1996;24:313–42.
• Garner JS, Hospital Infection Control Practices Advisory
Committee. Guideline for isolation precautions in hospi-
tals. Infect Control Hosp Epidemiol 1996;17:53–80.
• Larson EL, 1992, 1993, and 1994 Guidelines Committee.
APIC guideline for handwashing and hand antisepsis in
health-care settings. Am J Infect Control 1995;23:251–69.
• CDC. Guidelines for preventing the transmission of
Mycobacterium tuberculosis in health-care facilities, 1994.
MMWR 1994;43(No. RR-13).
• CDC. Recommendations for preventing transmission of
human immunodeficiency virus and hepatitis B virus to
patients during exposure-prone invasive procedures.
MMWR 1991;40(No. RR-8).
• Garner JS. CDC guideline for prevention of surgical
wound infections, 1985. Supersedes guideline for preven-
tion of surgical wound infections published in 1982.
(Originally published in November 1985). Revised.
Infect Control 1986;7:193–200.
• Garner JS, Favero MS. CDC guideline for handwashing
and hospital environmental control, 1985. Infect Control
1986;7:231–43.
Selected Definitions
Alcohol-based hand rub: An alcohol-containing preparation
designed for reducing the number of viable microorganisms
on the hands.
Antimicrobial soap: A detergent containing an antiseptic agent.
Antiseptic: A germicide used on skin or living tissue for the
purpose of inhibiting or destroying microorganisms (e.g.,
alcohols, chlorhexidine, chlorine, hexachlorophene, iodine,
chloroxylenol [PCMX], quaternary ammonium compounds,
and triclosan).
Bead sterilizer: A device using glass beads 1.2–1.5 mm
diameter and temperatures 217ºC–232ºC for brief exposures
(e.g., 45 seconds) to inactivate microorganisms. (This term is
actually a misnomer because it has not been cleared by the
Food and Drug Administration [FDA] as a sterilizer).
Bioburden: Microbiological load (i.e., number of viable
organisms in or on an object or surface) or organic material on
a surface or object before decontamination, or sterilization.
Also known as bioload or microbial load.
Colony-forming unit (CFU): The minimum number (i.e.,
tens of millions) of separable cells on the surface of or in semi-
solid agar medium that give rise to a visible colony of progeny.
CFUs can consist of pairs, chains, clusters, or as single cells
and are often expressed as colony-forming units per milliliter
(CFUs/mL).
Decontamination: Use of physical or chemical means to
remove, inactivate, or destroy pathogens on a surface or item
so that they are no longer capable of transmitting infectious
particles and the surface or item is rendered safe for handling,
use, or disposal.
Dental treatment water: Nonsterile water used during dental
treatment, including irrigation of nonsurgical operative sites
and cooling of high-speed rotary and ultrasonic instruments.
Disinfectant: A chemical agent used on inanimate objects
(e.g., floors, walls, or sinks) to destroy virtually all recognized
pathogenic microorganisms, but not necessarily all microbial
forms (e.g., bacterial endospores). The U.S. Environmental
Protection Agency (EPA) groups disinfectants on the basis of
whether the product label claims limited, general, or hospital
disinfectant capabilities.
Disinfection: Destruction of pathogenic and other kinds of
microorganisms by physical or chemical means. Disinfection
is less lethal than sterilization, because it destroys the majority
of recognized pathogenic microorganisms, but not necessarily
all microbial forms (e.g., bacterial spores). Disinfection does
not ensure the degree of safety associated with sterilization
processes.
Droplet nuclei: Particles <5 µm in diameter formed by dehy-
dration of airborne droplets containing microorganisms that
can remain suspended in the air for long periods of time.
Droplets: Small particles of moisture (e.g., spatter) generated
when a person coughs or sneezes, or when water is converted
to a fine mist by an aerator or shower head. These particles,
intermediate in size between drops and droplet nuclei, can
contain infectious microorganisms and tend to quickly settle
from the air such that risk of disease transmission is usually
limited to persons in close proximity to the droplet source.
Endotoxin: The lipopolysaccharide of gram-negative bacte-
ria, the toxic character of which resides in the lipid protein.
Endotoxins can produce pyrogenic reactions in persons
exposed to their bacterial component.
Germicide: An agent that destroys microorganisms, especially
pathogenic organisms. Terms with the same suffix (e.g., viru-
cide, fungicide, bactericide, tuberculocide, and sporicide) indi-
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cate agents that destroy the specific microorganism identified
by the prefix. Germicides can be used to inactivate microor-
ganisms in or on living tissue (i.e., antiseptics) or on environ-
mental surfaces (i.e., disinfectants).
Hand hygiene: General term that applies to handwashing,
antiseptic handwash, antiseptic hand rub, or surgical hand
antisepsis.
Health-care–associated infection: Any infection associated with
a medical or surgical intervention. The term health-care–
associated replaces nosocomial, which is limited to adverse
infectious outcomes occurring in hospitals.
Hepatitis B immune globulin (HBIG): Product used for pro-
phylaxis against HBV infection. HBIG is prepared from plasma
containing high titers of hepatitis B surface antibody (anti-
HBs) and provides protection for 3–6 mos.
Hepatitis B surface antigen (HBsAg): Serologic marker on the
surface of HBV detected in high levels during acute or chronic
hepatitis. The body normally produces antibodies to surface
antigen as a normal immune response to infection.
Hepatitis B e antigen (HBeAg): Secreted product of the nucleo-
capsid gene of HBV found in serum during acute and chronic
HBV infection. Its presence indicates that the virus is replicat-
ing and serves as a marker of increased infectivity.
Hepatitis B surface antibody (anti-HBs): Protective antibody
against HBsAg. Presence in the blood can indicate past infec-
tion with, and immunity to, HBV, or immune response from
hepatitis B vaccine.
Heterotrophic bacteria: Those bacteria requiring an organic
carbon source for growth (i.e., deriving energy and carbon from
organic compounds).
High-level disinfection: Disinfection process that inactivates
vegetative bacteria, mycobacteria, fungi, and viruses but not
necessarily high numbers of bacterial spores. FDA further
defines a high-level disinfectant as a sterilant used for a shorter
contact time.
Hospital disinfectant: Germicide registered by EPA for use
on inanimate objects in hospitals, clinics, dental offices, and
other medical-related facilities. Efficacy is demonstrated against
Salmonella choleraesuis, Staphylococcus aureus, and Pseudomo-
nas aeruginosa.
Iatrogenic: Induced inadvertently by HCP, medical (includ-
ing dental) treatment, or diagnostic procedures. Used particu-
larly in reference to an infectious disease or other complication
of treatment.
Immunization: Process by which a person becomes immune,
or protected against a disease. Vaccination is defined as the
process of administering a killed or weakened infectious
organism or a toxoid; however, vaccination does not always
result in immunity.
Implantable device: Device placed into a surgically or natu-
rally formed cavity of the human body and intended to
remain there for >30 days.
Independent water reservoir: Container used to hold water or
other solutions and supply it to handpieces and air and water
syringes attached to a dental unit. The independent reservoir,
which isolates the unit from the public water system, can be
provided as original equipment or as a retrofitted device.
Intermediate-level disinfection: Disinfection process that
inactivates vegetative bacteria, the majority of fungi, myco-
bacteria, and the majority of viruses (particularly enveloped
viruses) but not bacterial spores.
Intermediate-level disinfectant: Liquid chemical germicide
registered with EPA as a hospital disinfectant and with a label
claim of potency as tuberculocidal (Appendix A).
Latex: Milky white fluid extracted from the rubber tree
Hevea brasiliensis that contains the rubber material cis-1,4
polyisoprene.
Low-level disinfection: Process that inactivates the majority
of vegetative bacteria, certain fungi, and certain viruses, but
cannot be relied on to inactivate resistant microorganisms (e.g.,
mycobacteria or bacterial spores).
Low-level disinfectant: Liquid chemical germicide registered
with EPA as a hospital disinfectant. OSHA requires low-level
hospital disinfectants also to have a label claim for potency
against HIV and HBV if used for disinfecting clinical contact
surfaces (Appendix A).
Microfilter: Membrane filter used to trap microorganisms
suspended in water. Filters are usually installed on dental unit
waterlines as a retrofit device. Microfiltration commonly
occurs at a filter pore size of 0.03–10 µm. Sediment filters
commonly found in dental unit water regulators have pore
sizes of 20–90 µm and do not function as microbiological
filters.
Nosocomial: Infection acquired in a hospital as a result of
medical care.
Occupational exposure: Reasonably anticipated skin, eye,
mucous membrane, or parenteral contact with blood or OPIM
that can result from the performance of an employee’s duties.
OPIM: Other potentially infectious materials. OPIM is an
OSHA term that refers to 1) body fluids including semen,
vaginal secretions, cerebrospinal fluid, synovial fluid, pleural
fluid, pericardial fluid, peritoneal fluid, amniotic fluid, saliva
in dental procedures; any body fluid visibly contaminated with
blood; and all body fluids in situations where differentiating
between body fluids is difficult or impossible; 2) any unfixed
tissue or organ (other than intact skin) from a human (living
or dead); and 3) HIV-containing cell or tissue cultures, organ
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cultures; HIV- or HBV-containing culture medium or other
solutions; and blood, organs, or other tissues from experimen-
tal animals infected with HIV or HBV.
Parenteral: Means of piercing mucous membranes or skin
barrier through such events as needlesticks, human bites, cuts,
and abrasions.
Persistent activity: Prolonged or extended activity that pre-
vents or inhibits proliferation or survival of microorganisms
after application of a product. This activity can be demon-
strated by sampling a site minutes or hours after application
and demonstrating bacterial antimicrobial effectiveness when
compared with a baseline level. Previously, this property was
sometimes termed residual activity.
Prion: Protein particle lacking nucleic acid that has been
implicated as the cause of certain neurodegenerative diseases
(e.g., scrapie, CJD, and bovine spongiform encephalopathy
[BSE]).
Retraction: Entry of oral fluids and microorganisms into
waterlines through negative water pressure.
Seroconversion: The change of a serological test from nega-
tive to positive indicating the development of antibodies in
response to infection or immunization.
Sterile: Free from all living microorganisms; usually described
as a probability (e.g., the probability of a surviving microor-
ganism being 1 in 1 million).
Sterilization: Use of a physical or chemical procedure to
destroy all microorganisms including substantial numbers of
resistant bacterial spores.
Surfactants: Surface-active agents that reduce surface tension
and help cleaning by loosening, emulsifying, and holding soil
in suspension, to be more readily rinsed away.
Ultrasonic cleaner: Device that removes debris by a process
called cavitation, in which waves of acoustic energy are propa-
gated in aqueous solutions to disrupt the bonds that hold par-
ticulate matter to surfaces.
Vaccination: See immunization.
Vaccine: Product that induces immunity, therefore protect-
ing the body from the disease. Vaccines are administered
through needle injections, by mouth, and by aerosol.
Washer-disinfector: Automatic unit that cleans and thermally
disinfects instruments, by using a high-temperature cycle rather
than a chemical bath.
Wicking: Absorption of a liquid by capillary action along a
thread or through the material (e.g., penetration of liquids
through undetected holes in a glove).
Review of Science Related
to Dental Infection Control
Personnel Health Elements
of an Infection-Control Program
A protective health component for DHCP is an integral part
of a dental practice infection-control program. The objectives
are to educate DHCP regarding the principles of infection
control, identify work-related infection risks, institute preven-
tive measures, and ensure prompt exposure management and
medical follow-up. Coordination between the dental practice’s
infection-control coordinator and other qualified health-care
professionals is necessary to provide DHCP with appropriate
services. Dental programs in institutional settings, (e.g., hos-
pitals, health centers, and educational institutions) can coor-
dinate with departments that provide personnel health services.
However, the majority of dental practices are in ambulatory,
private settings that do not have licensed medical staff and
facilities to provide complete on-site health service programs.
In such settings, the infection-control coordinator should
establish programs that arrange for site-specific infection-
control services from external health-care facilities and pro-
viders before DHCP are placed at risk for exposure. Referral
arrangements can be made with qualified health-care profes-
sionals in an occupational health program of a hospital, with
educational institutions, or with health-care facilities that
offer personnel health services.
Education and Training
Personnel are more likely to comply with an infection-
control program and exposure-control plan if they understand
its rationale (5,13,16). Clearly written policies, procedures,
and guidelines can help ensure consistency, efficiency, and
effective coordination of activities. Personnel subject to occu-
pational exposure should receive infection-control training on
initial assignment, when new tasks or procedures affect their
occupational exposure, and at a minimum, annually (13).
Education and training should be appropriate to the assigned
duties of specific DHCP (e.g., techniques to prevent cross-
contamination or instrument sterilization). For DHCP who
perform tasks or procedures likely to result in occupational
exposure to infectious agents, training should include 1) a
description of their exposure risks; 2) review of prevention strat-
egies and infection-control policies and procedures; 3) discus-
sion regarding how to manage work-related illness and injuries,
including PEP; and 4) review of work restrictions for the
exposure or infection. Inclusion of DHCP with minimal
exposure risks (e.g., administrative employees) in education
and training programs might enhance facilitywide understand-
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ing of infection-control principles and the importance of the
program. Educational materials should be appropriate in con-
tent and vocabulary for each person’s educational level, lit-
eracy, and language, as well as be consistent with existing federal,
state, and local regulations (5,13).
Immunization Programs
DHCP are at risk for exposure to, and possible infection
with, infectious organisms. Immunizations substantially
reduce both the number of DHCP susceptible to these dis-
eases and the potential for disease transmission to other DHCP
and patients (5,17). Thus, immunizations are an essential part
of prevention and infection-control programs for DHCP, and
a comprehensive immunization policy should be implemented
for all dental health-care facilities (17,18). The Advisory Com-
mittee on Immunization Practices (ACIP) provides national
guidelines for immunization of HCP, which includes DHCP
(17). Dental practice immunization policies should incorpo-
rate current state and federal regulations as well as recommen-
dations from the U.S. Public Health Service and professional
organizations (17) (Appendix B).
On the basis of documented health-care–associated trans-
mission, HCP are considered to be at substantial risk for
acquiring or transmitting hepatitis B, influenza, measles,
mumps, rubella, and varicella. All of these diseases are vac-
cine-preventable. ACIP recommends that all HCP be vacci-
nated or have documented immunity to these diseases (5,17).
ACIP does not recommend routine immunization of HCP
against TB (i.e., inoculation with bacille Calmette-Guérin vac-
cine) or hepatitis A (17). No vaccine exists for HCV. ACIP
guidelines also provide recommendations regarding immuni-
zation of HCP with special conditions (e.g., pregnancy, HIV
infection, or diabetes) (5,17).
Immunization of DHCP before they are placed at risk for
exposure remains the most efficient and effective use of vac-
cines in health-care settings. Some educational institutions and
infection-control programs provide immunization schedules
for students and DHCP. OSHA requires that employers make
hepatitis B vaccination available to all employees who have
potential contact with blood or OPIM. Employers are also
required to follow CDC recommendations for vaccinations,
evaluation, and follow-up procedures (13). Nonpatient-care
staff (e.g., administrative or housekeeping) might be included,
depending on their potential risk of coming into contact with
blood or OPIM. Employers are also required to ensure that
employees who decline to accept hepatitis B vaccination sign
an appropriate declination statement (13). DHCP unable or
unwilling to be vaccinated as required or recommended should
be educated regarding their exposure risks, infection-control
policies and procedures for the facility, and the management
of work-related illness and work restrictions (if appropriate)
for exposed or infected DHCP.
Exposure Prevention and Postexposure
Management
Avoiding exposure to blood and OPIM, as well as protec-
tion by immunization, remain primary strategies for reducing
occupationally acquired infections, but occupational exposures
can still occur (19). A combination of standard precautions,
engineering, work practice, and administrative controls is the
best means to minimize occupational exposures. Written poli-
cies and procedures to facilitate prompt reporting, evaluation,
counseling, treatment, and medical follow-up of all occupa-
tional exposures should be available to all DHCP. Written
policies and procedures should be consistent with federal, state,
and local requirements addressing education and training,
postexposure management, and exposure reporting (see Pre-
venting Transmission of Bloodborne Pathogens).
DHCP who have contact with patients can also be exposed
to persons with infectious TB, and should have a baseline tu-
berculin skin test (TST), preferably by using a two-step test,
at the beginning of employment (20). Thus, if an unprotected
occupational exposure occurs, TST conversions can be distin-
guished from positive TST results caused by previous expo-
sures (20,21). The facility’s level of TB risk will determine the
need for routine follow-up TSTs (see Special Considerations).
Medical Conditions, Work-Related Illness,
and Work Restrictions
DHCP are responsible for monitoring their own health sta-
tus. DHCP who have acute or chronic medical conditions
that render them susceptible to opportunistic infection should
discuss with their personal physicians or other qualified
authority whether the condition might affect their ability to
safely perform their duties. However, under certain circum-
stances, health-care facility managers might need to exclude
DHCP from work or patient contact to prevent further trans-
mission of infection (22). Decisions concerning work restric-
tions are based on the mode of transmission and the period of
infectivity of the disease (5) (Table 1). Exclusion policies should
1) be written, 2) include a statement of authority that defines
who can exclude DHCP (e.g., personal physicians), and 3) be
clearly communicated through education and training. Poli-
cies should also encourage DHCP to report illnesses or expo-
sures without jeopardizing wages, benefits, or job status.
With increasing concerns regarding bloodborne pathogens and
introduction of universal precautions, use of latex gloves among
HCP has increased markedly (7,23). Increased use of these gloves
has been accompanied by increased reports of allergic reactions
to natural rubber latex among HCP, DHCP, and patients
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TABLE 1. Suggested work restrictions for health-care personnel infected with or exposed to major infectious diseases in health-





Acute stage (diarrhea with other symptoms)




Personnel with acute or chronic hepatitis B
surface antigenemia who do not perform
exposure-prone procedures
Personnel with acute or chronic hepatitis B

















Restrict from patient contact and contact with patient’s
environment.
No restriction
Restrict from patient contact, contact with patient’s
environment, and food-handling.
Restrict from care of patients at high risk.
Restrict from care of infants, neonates, and
immunocompromised patients and their environments.
Restrict from patient contact, contact with patient’s
environment, and food-handing.
No restriction†; refer to state regulations. Standard
precautions should always be followed.
Do not perform exposure-prone invasive procedures until
counsel from a review panel has been sought; panel
should review and recommend procedures that personnel
can perform, taking into account specific procedures as
well as skill and technique. Standard precautions should
always be observed. Refer to state and local regulations
or recommendations.
No restrictions on professional activity.† HCV-positive
health-care personnel should follow aseptic technique
and standard precautions.
No restriction
Restrict from patient contact and contact with patient’s
environment.
Evaluate need to restrict from care of patients at high risk.
Do not perform exposure-prone invasive procedures until
counsel from an expert review panel has been sought;
panel should review and recommend procedures that
personnel can perform, taking into account specific
procedures as well as skill and technique. Standard
precautions should always be observed. Refer to state









Until symptoms resolve; consult with local and state health
authorities regarding need for negative stool cultures
Until symptoms resolve
Until 7 days after onset of jaundice
Until hepatitis B e antigen is negative
Until lesions heal
Until 7 days after the rash appears
From fifth day after first exposure through twenty-first day
after last exposure, or 4 days after rash appears
Until 24 hours after start of effective therapy
Until 9 days after onset of parotitis
From twelfth day after first exposure through twenty-sixth
day after last exposure, or until 9 days after onset of
parotitis
Source: Adapted from Bolyard EA, Hospital Infection Control Practices Advisory Committee. Guidelines for infection control in health care personnel, 1998. Am J Infect Control
1998;26:289–354.
* Modified from recommendations of the Advisory Committee on Immunization Practices (ACIP).
†
Unless epidemiologically linked to transmission of infection.
§
Those susceptible to varicella and who are at increased risk of complications of varicella (e.g., neonates and immunocompromised persons of any age).
¶
Patients at high risk as defined by ACIP for complications of influenza.
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Source: Adapted from Bolyard EA, Hospital Infection Control Practices Advisory Committee. Guidelines for infection control in health care personnel, 1998. Am J Infect Control
1998;26:289–354.
* Modified from recommendations of the Advisory Committee on Immunization Practices (ACIP).
†
Unless epidemiologically linked to transmission of infection.
§
Those susceptible to varicella and who are at increased risk of complications of varicella (e.g., neonates and immunocompromised persons of any age).
¶
Patients at high risk as defined by ACIP for complications of influenza.
TABLE 1. (Continued) Suggested work restrictions for health-care personnel infected with or exposed to major infectious diseases
in health-care settings, in the absence of state and local regulations*










Active, draining skin lesions
Carrier state








Localized, in healthy person
Generalized or localized in immunosup-
pressed person
Postexposure (susceptible personnel)
Viral respiratory infection, acute febrile
Restrict from patient contact
Exclude from duty




Restrict from contact with patients and patient’s
environment or food handling.
No restriction unless personnel are epidemiologically
linked to transmission of the organism






Cover lesions, restrict from care of patients§ at high risk
Restrict from patient contact
Restrict from patient contact
Consider excluding from the care of patients at high risk¶
or contact with such patients’ environments during
community outbreak of respiratory syncytial virus and
influenza
Until treated and observed to be free of adult and
immature lice
From beginning of catarrhal stage through third week
after onset of paroxysms, or until 5 days after start of
effective antibiotic therapy
Until 5 days after start of effective antibiotic therapy
Until 5 days after rash appears
From seventh day after first exposure through twenty-first
day after last exposure
Until lesions have resolved
Until 24 hours after adequate treatment started
Until proved noninfectious
Until all lesions dry and crust
From tenth day after first exposure through twenty-first
day (twenty-eighth day if varicella-zoster immune globulin
[VZIG] administered) after last exposure.
Until all lesions dry and crust
Until all lesions dry and crust
From tenth day after first exposure through twenty-first day
(twenty-eighth day if VZIG administered) after last exposure;
or, if varicella occurs, when lesions crust and dry
Until acute symptoms resolve
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(24–30), as well as increased reports of irritant and allergic con-
tact dermatitis from frequent and repeated use of hand-hygiene
products, exposure to chemicals, and glove use.
DHCP should be familiar with the signs and symptoms of
latex sensitivity (5,31–33). A physician should evaluate DHCP
exhibiting symptoms of latex allergy, because further exposure
could result in a serious allergic reaction. A diagnosis is made
through medical history, physical examination, and diagnos-
tic tests. Procedures should be in place for minimizing latex-
related health problems among DHCP and patients while
protecting them from infectious materials. These procedures
should include 1) reducing exposures to latex-containing
materials by using appropriate work practices, 2) training and
educating DHCP, 3) monitoring symptoms, and 4) substitut-
ing nonlatex products where appropriate (32) (see Contact
Dermatitis and Latex Hypersensitivity).
Maintenance of Records, Data Management,
and Confidentiality
The health status of DHCP can be monitored by maintain-
ing records of work-related medical evaluations, screening tests,
immunizations, exposures, and postexposure management.
Such records must be kept in accordance with all applicable
state and federal laws. Examples of laws that might apply
include the Privacy Rule of the Health Insurance Portability
and Accountability Act (HIPAA) of 1996, 45 CFR 160 and
164, and the OSHA Occupational Exposure to Bloodborne
Pathogens; Final Rule 29 CFR 1910.1030(h)(1)(i–iv) (34,13).
The HIPAA Privacy Rule applies to covered entities, includ-
ing certain defined health providers, health-care clearinghouses,
and health plans. OSHA requires employers to ensure that
certain information contained in employee medical records is
1) kept confidential; 2) not disclosed or reported without the
employee’s express written consent to any person within or
outside the workplace except as required by the OSHA stan-
dard; and 3) maintained by the employer for at least the dura-
tion of employment plus 30 years. Dental practices that
coordinate their infection-control program with off-site pro-
viders might consult OSHA’s Bloodborne Pathogen standard
and employee Access to Medical and Exposure Records stan-
dard, as well as other applicable local, state, and federal laws,
to determine a location for storing health records (13,35).
Preventing Transmission
of Bloodborne Pathogens
Although transmission of bloodborne pathogens (e.g., HBV,
HCV, and HIV) in dental health-care settings can have seri-
ous consequences, such transmission is rare. Exposure to
infected blood can result in transmission from patient to
DHCP, from DHCP to patient, and from one patient to
another. The opportunity for transmission is greatest from
patient to DHCP, who frequently encounter patient blood and
blood-contaminated saliva during dental procedures.
Since 1992, no HIV transmission from DHCP to patients
has been reported, and the last HBV transmission from DHCP
to patients was reported in 1987. HCV transmission from
DHCP to patients has not been reported. The majority of
DHCP infected with a bloodborne virus do not pose a risk to
patients because they do not perform activities meeting the
necessary conditions for transmission. For DHCP to pose a
risk for bloodborne virus transmission to patients, DHCP must
1) be viremic (i.e., have infectious virus circulating in the blood-
stream); 2) be injured or have a condition (e.g., weeping der-
matitis) that allows direct exposure to their blood or other
infectious body fluids; and 3) enable their blood or infectious
body fluid to gain direct access to a patient’s wound, trauma-
tized tissue, mucous membranes, or similar portal of entry.
Although an infected DHCP might be viremic, unless the sec-
ond and third conditions are also met, transmission cannot
occur.
The risk of occupational exposure to bloodborne viruses is
largely determined by their prevalence in the patient popula-
tion and the nature and frequency of contact with blood and
body fluids through percutaneous or permucosal routes of
exposure. The risk of infection after exposure to a bloodborne
virus is influenced by inoculum size, route of exposure, and
susceptibility of the exposed HCP (12). The majority of
attention has been placed on the bloodborne pathogens HBV,
HCV, and HIV, and these pathogens present different levels
of risk to DHCP.
Hepatitis B Virus
HBV is a well-recognized occupational risk for HCP (36,37).
HBV is transmitted by percutaneous or mucosal exposure to
blood or body fluids of a person with either acute or chronic
HBV infection. Persons infected with HBV can transmit the
virus for as long as they are HBsAg-positive. The risk of HBV
transmission is highly related to the HBeAg status of the source
person. In studies of HCP who sustained injuries from needles
contaminated with blood containing HBV, the risk of devel-
oping clinical hepatitis if the blood was positive for both HBsAg
and HBeAg was 22%–31%; the risk of developing serologic
evidence of HBV infection was 37%–62% (19). By compari-
son, the risk of developing clinical hepatitis from a needle con-
taminated with HBsAg-positive, HBeAg-negative blood was
1%–6%, and the risk of developing serologic evidence of HBV
infection, 23%–37% (38).
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Blood contains the greatest proportion of HBV infectious
particle titers of all body fluids and is the most critical vehicle
of transmission in the health-care setting. HBsAg is also found
in multiple other body fluids, including breast milk, bile, cere-
brospinal fluid, feces, nasopharyngeal washings, saliva, semen,
sweat, and synovial fluid. However, the majority of body flu-
ids are not efficient vehicles for transmission because they con-
tain low quantities of infectious HBV, despite the presence of
HBsAg (19). The concentration of HBsAg in body fluids can
be 100–1,000-fold greater than the concentration of infec-
tious HBV particles (39).
Although percutaneous injuries are among the most effi-
cient modes of HBV transmission, these exposures probably
account for only a minority of HBV infections among HCP.
In multiple investigations of nosocomial hepatitis B outbreaks,
the majority of infected HCP could not recall an overt percu-
taneous injury (40,41), although in certain studies, approxi-
mately one third of infected HCP recalled caring for a patient
who was HBsAg-positive (42,43). In addition, HBV has been
demonstrated to survive in dried blood at room temperature
on environmental surfaces for <1 week (44). Thus, HBV
infections that occur in HCP with no history of nonoccupa-
tional exposure or occupational percutaneous injury might have
resulted from direct or indirect blood or body fluid exposures
that inoculated HBV into cutaneous scratches, abrasions,
burns, other lesions, or on mucosal surfaces (45–47). The
potential for HBV transmission through contact with envi-
ronmental surfaces has been demonstrated in investigations of
HBV outbreaks among patients and HCP in hemodialysis units
(48–50).
Since the early 1980s, occupational infections among HCP
have declined because of vaccine use and adherence to univer-
sal precautions (51). Among U.S. dentists, >90% have been
vaccinated, and serologic evidence of past HBV infection
decreased from prevaccine levels of 14% in 1972 to approxi-
mately 9% in 1992 (52). During 1993–2001, levels remained
relatively unchanged (Chakwan Siew, Ph.D., American Den-
tal Association, Chicago, Illinois, personal communication,
June 2003). Infection rates can be expected to decline further
as vaccination rates remain high among young dentists and as
older dentists with lower vaccination rates and higher rates of
infection retire.
Although the potential for transmission of bloodborne
infections from DHCP to patients is considered limited
(53–55), precise risks have not been quantified by carefully
designed epidemiologic studies (53,56,57). Reports published
during 1970–1987 describe nine clusters in which patients
were thought to be infected with HBV through treatment by
an infected DHCP (58–67). However, transmission of HBV
from dentist to patient has not been reported since 1987, pos-
sibly reflecting such factors as 1) adoption of universal precau-
tions, 2) routine glove use, 3) increased levels of immunity as
a result of hepatitis B vaccination of DHCP, 4) implementa-
tion of the 1991 OSHA bloodborne pathogen standard (68),
and 5) incomplete ascertainment and reporting. Only one case
of patient-to-patient transmission of HBV in the dental set-
ting has been documented (CDC, unpublished data, 2003).
In this case, appropriate office infection-control procedures
were being followed, and the exact mechanism of transmis-
sion was undetermined.
Because of the high risk of HBV infection among HCP,
DHCP who perform tasks that might involve contact with
blood, blood-contaminated body substances, other body flu-
ids, or sharps should be vaccinated (2,13,17,19,69). Vaccina-
tion can protect both DHCP and patients from HBV infection
and, whenever possible, should be completed when dentists
or other DHCP are in training and before they have contact
with blood.
Prevaccination serological testing for previous infection is
not indicated, although it can be cost-effective where preva-
lence of infection is expected to be high in a group of potential
vacinees (e.g., persons who have emigrated from areas with
high rates of HBV infection). DHCP should be tested for anti-
HBs 1–2 months after completion of the 3-dose vaccination
series (17). DHCP who do not develop an adequate antibody
response (i.e., anti-HBs <10 mIU/mL) to the primary vaccine
series should complete a second 3-dose vaccine series or be
evaluated to determine if they are HBsAg-positive (17).
Revaccinated persons should be retested for anti-HBs at the
completion of the second vaccine series. Approximately half
of nonresponders to the primary series will respond to a sec-
ond 3-dose series. If no antibody response occurs after the
second series, testing for HBsAg should be performed (17).
Persons who prove to be HBsAg-positive should be counseled
regarding how to prevent HBV transmission to others and
regarding the need for medical evaluation. Nonresponders to
vaccination who are HBsAg-negative should be considered
susceptible to HBV infection and should be counseled regard-
ing precautions to prevent HBV infection and the need to
obtain HBIG prophylaxis for any known or probable parenteral
exposure to HBsAg-positive blood.
Vaccine-induced antibodies decline gradually over time, and
60% of persons who initially respond to vaccination will lose
detectable antibodies over 12 years. Even so, immunity con-
tinues to prevent clinical disease or detectable viral infection
(17). Booster doses of vaccine and periodic serologic testing to
monitor antibody concentrations after completion of the vac-
cine series are not necessary for vaccine responders (17).
12 MMWR December 19, 2003
Hepatitis D Virus
An estimated 4% of persons with acute HBV infection are
also infected with hepatitis Delta virus (HDV). Discovered in
1977, HDV is a defective bloodborne virus requiring the pres-
ence of HBV to replicate. Patients coinfected with HBV and
HDV have substantially higher mortality rates than those
infected with HBV alone. Because HDV infection is depen-
dent on HBV for replication, immunization to prevent HBV
infection, through either pre- or postexposure prophylaxis, can
also prevent HDV infection (70).
Hepatitis C Virus
Hepatitis C virus appears not to be transmitted efficiently
through occupational exposures to blood. Follow-up studies
of HCP exposed to HCV-infected blood through percutane-
ous or other sharps injuries have determined a low incidence
of seroconversion (mean: 1.8%; range, 0%–7%) (71–74). One
study determined transmission occurred from hollow-bore
needles but not other sharps (72). Although these studies have
not documented seroconversion associated with mucous mem-
brane or nonintact skin exposure, at least two cases of HCV
transmission from a blood splash to the conjunctiva (75,76)
and one case of simultaneous transmission of HCV and HIV
after nonintact skin exposure have been reported (77).
Data are insufficient to estimate the occupational risk of
HCV infection among HCP, but the majority of studies indi-
cate the prevalence of HCV infection among dentists, sur-
geons, and hospital-based HCP is similar to that among the
general population, approximately 1%–2% (78–86). In a study
that evaluated risk factors for infection, a history of uninten-
tional needlesticks was the only occupational risk factor inde-
pendently associated with HCV infection (80).
No studies of transmission from HCV-infected DHCP to
patients have been reported, and the risk for such transmis-
sion appears limited. Multiple reports have been published
describing transmission from HCV-infected surgeons, which
apparently occurred during performance of invasive procedures;
the overall risk for infection averaged 0.17% (87–90).
Human Immunodeficiency Virus
In the United States, the risk of HIV transmission in dental
settings is extremely low. As of December 2001, a total of 57
cases of HIV seroconversion had been documented among
HCP, but none among DHCP, after occupational exposure to
a known HIV-infected source (91). Transmission of HIV to
six patients of a single dentist with AIDS has been reported,
but the mode of transmission could not be determined
(2,92,93). As of September 30, 1993, CDC had information
regarding test results of >22,000 patients of 63 HIV-infected
HCP, including 33 dentists or dental students (55,93). No
additional cases of transmission were documented.
Prospective studies worldwide indicate the average risk of
HIV infection after a single percutaneous exposure to
HIV-infected blood is 0.3% (range: 0.2%–0.5%) (94). After
an exposure of mucous membranes in the eye, nose, or mouth,
the risk is approximately 0.1% (76). The precise risk of trans-
mission after skin exposure remains unknown but is believed
to be even smaller than that for mucous membrane exposure.
Certain factors affect the risk of HIV transmission after an
occupational exposure. Laboratory studies have determined if
needles that pass through latex gloves are solid rather than
hollow-bore, or are of small gauge (e.g., anesthetic needles
commonly used in dentistry), they transfer less blood (36). In
a retrospective case-control study of HCP, an increased risk
for HIV infection was associated with exposure to a relatively
large volume of blood, as indicated by a deep injury with a
device that was visibly contaminated with the patient’s blood,
or a procedure that involved a needle placed in a vein or artery
(95). The risk was also increased if the exposure was to blood
from patients with terminal illnesses, possibly reflecting the
higher titer of HIV in late-stage AIDS.
Exposure Prevention Methods
Avoiding occupational exposures to blood is the primary
way to prevent transmission of HBV, HCV, and HIV, to HCP
in health-care settings (19,96,97). Exposures occur through
percutaneous injury (e.g., a needlestick or cut with a sharp
object), as well as through contact between potentially infec-
tious blood, tissues, or other body fluids and mucous mem-
branes of the eye, nose, mouth, or nonintact skin (e.g., exposed
skin that is chapped, abraded, or shows signs of dermatitis).
Observational studies and surveys indicate that percutane-
ous injuries among general dentists and oral surgeons occur
less frequently than among general and orthopedic surgeons
and have decreased in frequency since the mid-1980s (98–102).
This decline has been attributed to safer work practices, safer
instrumentation or design, and continued DHCP education
(103,104). Percutaneous injuries among DHCP usually
1) occur outside the patient’s mouth, thereby posing less risk
for recontact with patient tissues; 2) involve limited amounts
of blood; and 3) are caused by burs, syringe needles, labora-
tory knives, and other sharp instruments (99–102,105,106).
Injuries among oral surgeons might occur more frequently
during fracture reductions using wires (104,107). Experience,
as measured by years in practice, does not appear to affect the
risk of injury among general dentists or oral surgeons
(100,104,107).
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The majority of exposures in dentistry are preventable, and
methods to reduce the risk of blood contacts have included
use of standard precautions, use of devices with features engi-
neered to prevent sharp injuries, and modifications of work
practices. These approaches might have contributed to the
decrease in percutaneous injuries among dentists during
recent years (98–100,103). However, needlesticks and other
blood contacts continue to occur, which is a concern because
percutaneous injuries pose the greatest risk of transmission.
Standard precautions include use of PPE (e.g., gloves, masks,
protective eyewear or face shield, and gowns) intended to pre-
vent skin and mucous membrane exposures. Other protective
equipment (e.g., finger guards while suturing) might also
reduce injuries during dental procedures (104).
Engineering controls are the primary method to reduce
exposures to blood and OPIM from sharp instruments and
needles. These controls are frequently technology-based and
often incorporate safer designs of instruments and devices (e.g.,
self-sheathing anesthetic needles and dental units designed to
shield burs in handpieces) to reduce percutaneous injuries
(101,103,108).
Work-practice controls establish practices to protect DHCP
whose responsibilities include handling, using, assembling, or
processing sharp devices (e.g., needles, scalers, laboratory util-
ity knives, burs, explorers, and endodontic files) or sharps dis-
posal containers. Work-practice controls can include removing
burs before disassembling the handpiece from the dental unit,
restricting use of fingers in tissue retraction or palpation dur-
ing suturing and administration of anesthesia, and minimiz-
ing potentially uncontrolled movements of such instruments
as scalers or laboratory knives (101,105).
As indicated, needles are a substantial source of percutane-
ous injury in dental practice, and engineering and work-
practice controls for needle handling are of particular
importance. In 2001, revisions to OSHA’s bloodborne patho-
gens standard as mandated by the Needlestick Safety and Pre-
vention Act of 2000 became effective. These revisions clarify
the need for employers to consider safer needle devices as they
become available and to involve employees directly respon-
sible for patient care (e.g., dentists, hygienists, and dental
assistants) in identifying and choosing such devices (109). Safer
versions of sharp devices used in hospital settings have become
available (e.g., blunt suture needles, phlebotomy devices, and
butterfly needles), and their impact on reducing injuries has
been documented (110–112). Aspirating anesthetic syringes
that incorporate safety features have been developed for den-
tal procedures, but the low injury rates in dentistry limit
assessment of their effect on reducing injuries among DHCP.
Work-practice controls for needles and other sharps include
placing used disposable syringes and needles, scalpel blades,
and other sharp items in appropriate puncture-resistant con-
tainers located as close as feasible to where the items were used
(2,7,13,113–115). In addition, used needles should never be
recapped or otherwise manipulated by using both hands, or
any other technique that involves directing the point of a needle
toward any part of the body (2,7,13,97,113,114). A one-
handed scoop technique, a mechanical device designed for
holding the needle cap to facilitate one-handed recapping, or
an engineered sharps injury protection device (e.g., needles
with resheathing mechanisms) should be employed for recap-
ping needles between uses and before disposal
(2,7,13,113,114). DHCP should never bend or break needles
before disposal because this practice requires unnecessary
manipulation. Before attempting to remove needles from
nondisposable aspirating syringes, DHCP should recap them
to prevent injuries. For procedures involving multiple injec-
tions with a single needle, the practitioner should recap the
needle between injections by using a one-handed technique or
use a device with a needle-resheathing mechanism. Passing a
syringe with an unsheathed needle should be avoided because
of the potential for injury.
Additional information for developing a safety program and
for identifying and evaluating safer dental devices is available at
• http://www.cdc.gov/OralHealth/infectioncontrol/
forms.htm (forms for screening and evaluating safer den-
tal devices), and
• http://www.cdc.gov/niosh/topics/bbp (state legislation on
needlestick safety).
Postexposure Management and Prophylaxis
Postexposure management is an integral component of a
complete program to prevent infection after an occupational
exposure to blood. During dental procedures, saliva is pre-
dictably contaminated with blood (7,114). Even when blood
is not visible, it can still be present in limited quantities and
therefore is considered a potentially infectious material by
OSHA (13,19). A qualified health-care professional should
evaluate any occupational exposure incident to blood or OPIM,
including saliva, regardless of whether blood is visible, in den-
tal settings (13).
Dental practices and laboratories should establish written,
comprehensive programs that include hepatitis B vaccination
and postexposure management protocols that 1) describe the
types of contact with blood or OPIM that can place DHCP at
risk for infection; 2) describe procedures for promptly report-
ing and evaluating such exposures; and 3) identify a health-
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care professional who is qualified to provide counseling and
perform all medical evaluations and procedures in accordance
with current recommendations of the U.S. Public Health Ser-
vice (PHS), including PEP with chemotherapeutic drugs when
indicated. DHCP, including students, who might reasonably
be considered at risk for occupational exposure to blood or
OPIM should be taught strategies to prevent contact with blood
or OPIM and the principles of postexposure management,
including PEP options, as part of their job orientation and
training. Educational programs for DHCP and students should
emphasize reporting all exposures to blood or OPIM as soon
as possible, because certain interventions have to be initiated
promptly to be effective. Policies should be consistent with
the practices and procedures for worker protection required
by OSHA and with current PHS recommendations for man-
aging occupational exposures to blood (13,19).
After an occupational blood exposure, first aid should be
administered as necessary. Puncture wounds and other inju-
ries to the skin should be washed with soap and water;
mucous membranes should be flushed with water. No evidence
exists that using antiseptics for wound care or expressing fluid
by squeezing the wound further reduces the risk of bloodborne
pathogen transmission; however, use of antiseptics is not con-
traindicated. The application of caustic agents (e.g., bleach)
or the injection of antiseptics or disinfectants into the wound
is not recommended (19). Exposed DHCP should immedi-
ately report the exposure to the infection-control coordinator
or other designated person, who should initiate referral to the
qualified health-care professional and complete necessary
reports. Because multiple factors contribute to the risk of
infection after an occupational exposure to blood, the follow-
ing information should be included in the exposure report,
recorded in the exposed person’s confidential medical record,
and provided to the qualified health-care professional:
• Date and time of exposure.
• Details of the procedure being performed, including where
and how the exposure occurred and whether the exposure
involved a sharp device, the type and brand of device, and
how and when during its handling the exposure occurred.
• Details of the exposure, including its severity and the type
and amount of fluid or material. For a percutaneous injury,
severity might be measured by the depth of the wound,
gauge of the needle, and whether fluid was injected; for a
skin or mucous membrane exposure, the estimated vol-
ume of material, duration of contact, and the condition
of the skin (e.g., chapped, abraded, or intact) should be
noted.
• Details regarding whether the source material was known
to contain HIV or other bloodborne pathogens, and, if
the source was infected with HIV, the stage of disease,
history of antiretroviral therapy, and viral load, if known.
• Details regarding the exposed person (e.g., hepatitis B vac-
cination and vaccine-response status).
• Details regarding counseling, postexposure management,
and follow-up.
Each occupational exposure should be evaluated individually
for its potential to transmit HBV, HCV, and HIV, based on
the following:
• The type and amount of body substance involved.
• The type of exposure (e.g., percutaneous injury, mucous
membrane or nonintact skin exposure, or bites resulting
in blood exposure to either person involved).
• The infection status of the source.
• The susceptibility of the exposed person (19).
All of these factors should be considered in assessing the risk
for infection and the need for further follow-up (e.g., PEP).
During 1990–1998, PHS published guidelines for PEP and
other management of health-care worker exposures to HBV,
HCV, or HIV (69,116–119). In 2001, these recommenda-
tions were updated and consolidated into one set of PHS guide-
lines (19). The new guidelines reflect the availability of new
antiretroviral agents, new information regarding the use and
safety of HIV PEP, and considerations regarding employing
HIV PEP when resistance of the source patient’s virus to
antiretroviral agents is known or suspected. In addition, the
2001 guidelines provide guidance to clinicians and exposed
HCP regarding when to consider HIV PEP and recommen-
dations for PEP regimens (19).
Hand Hygiene
Hand hygiene (e.g., handwashing, hand antisepsis, or surgi-
cal hand antisepsis) substantially reduces potential pathogens
on the hands and is considered the single most critical mea-
sure for reducing the risk of transmitting organisms to
patients and HCP (120–123). Hospital-based studies have
demonstrated that noncompliance with hand hygiene prac-
tices is associated with health-care–associated infections and
the spread of multiresistant organisms. Noncompliance also
has been a major contributor to outbreaks (123). The preva-
lence of health-care–associated infections decreases as adher-
ence of HCP to recommended hand hygiene measures
improves (124–126).
The microbial flora of the skin, first described in 1938, con-
sist of transient and resident microorganisms (127). Transient
flora, which colonize the superficial layers of the skin, are easier
to remove by routine handwashing. They are often acquired
by HCP during direct contact with patients or contaminated
environmental surfaces; these organisms are most frequently
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associated with health-care–associated infections. Resident flora
attached to deeper layers of the skin are more resistant to
removal and less likely to be associated with such infections.
The preferred method for hand hygiene depends on the type
of procedure, the degree of contamination, and the desired
persistence of antimicrobial action on the skin (Table 2). For
routine dental examinations and nonsurgical procedures,
handwashing and hand antisepsis is achieved by using either a
plain or antimicrobial soap and water. If the hands are not
visibly soiled, an alcohol-based hand rub is adequate.
The purpose of surgical hand antisepsis is to eliminate tran-
sient flora and reduce resident flora for the duration of a pro-
cedure to prevent introduction of organisms in the operative
wound, if gloves become punctured or torn. Skin bacteria can
rapidly multiply under surgical gloves if hands are washed with
soap that is not antimicrobial (127,128). Thus, an antimicro-
bial soap or alcohol hand rub with persistent activity should
be used before surgical procedures (129–131).
Agents used for surgical hand antisepsis should substantially
reduce microorganisms on intact skin, contain a nonirritating
antimicrobial preparation, have a broad spectrum of activity,
be fast-acting, and have a persistent effect (121,132–135).
Persistence (i.e., extended antimicrobial activity that prevents
or inhibits survival of microorganisms after the product is
applied) is critical because microorganisms can colonize on
hands in the moist environment underneath gloves (122).
Alcohol hand rubs are rapidly germicidal when applied to
the skin but should include such antiseptics as chlorhexidine,
quaternary ammonium compounds, octenidine, or triclosan
to achieve persistent activity (130). Factors that can influence
the effectiveness of the surgical hand antisepsis in addition to
the choice of antiseptic agent include duration and technique
of scrubbing, as well as condition of the hands, and techniques
used for drying and gloving. CDC’s 2002 guideline on hand
hygiene in health-care settings provides more complete infor-
mation (123).
Selection of Antiseptic Agents
Selecting the most appropriate antiseptic agent for hand
hygiene requires consideration of multiple factors. Essential
performance characteristics of a product (e.g., the spectrum
and persistence of activity and whether or not the agent is fast-
acting) should be determined before selecting a product.
Delivery system, cost per use, reliable vendor support and sup-
ply are also considerations. Because HCP acceptance is a
major factor regarding compliance with recommended hand
hygiene protocols (122,123,147,148), considering DHCP
needs is critical and should include possible chemical allergies,







Water and nonantimicrobial soap (e.g.,
plain soap†)
Water and antimicrobial soap (e.g.,
chlorhexidine, iodine and iodophors,
chloroxylenol [PCMX], triclosan)
Alcohol-based hand rub¶
Water and antimicrobial soap (e.g.,
chlorhexidine, iodine and iodophors,
chloroxylenol [PCMX], triclosan)
Water and non-antimicrobial soap (e.g.,
plain soap†) followed by an alcohol-based
surgical hand-scrub product with
persistent activity
Purpose




and reduce resident flora
Remove or destroy
transient microorganisms
and reduce resident flora
Remove or destroy
transient microorganisms
and reduce resident flora
(persistent effect)
Indication*
Before and after treating each patient
(e.g., before glove placement and after
glove removal). After barehanded
touching of inanimate objects likely to be
contaminated by blood or saliva. Before
leaving the dental operatory or the dental
laboratory. When visibly soiled.¶ Before
regloving after removing gloves that are
torn, cut, or punctured.
Before donning sterile surgeon’s gloves
for surgical procedures††
* (7,9,11,13,113,120–123,125,126,136–138).
† Pathogenic organisms have been found on or around bar soap during and after use (139). Use of liquid soap with hands-free dispensing controls is preferable.
§ Time reported as effective in removing most transient flora from the skin. For most procedures, a vigorous rubbing together of all surfaces of premoistened lathered hands and
fingers for >15 seconds, followed by rinsing under a stream of cool or tepid water is recommended (9,120,123,140,141). Hands should always be dried thoroughly before
donning gloves.
¶ Alcohol-based hand rubs should contain 60%–95% ethanol or isopropanol and should not be used in the presence of visible soil or organic material. If using an alcohol-based
hand rub, apply adequate amount to palm of one hand and rub hands together, covering all surfaces of the hands and fingers, until hands are dry. Follow manufacturer’s
recommendations regarding the volume of product to use. If hands feel dry after rubbing them together for 10–15 seconds, an insufficient volume of product likely was applied.
The drying effect of alcohol can be reduced or eliminated by adding 1%–3% glycerol or other skin-conditioning agents (123).
** After application of alcohol-based surgical hand-scrub product with persistent activity as recommended, allow hands and forearms to dry thoroughly and immediately don sterile
surgeon’s gloves (144,145). Follow manufacturer instructions (122,123,137,146).
†† Before beginning surgical hand scrub, remove all arm jewelry and any hand jewelry that may make donning gloves more difficult, cause gloves to tear more readily (142,143),
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skin integrity after repeated use, compatibility with lotions used,
and offensive agent ingredients (e.g., scent). Discussing spe-
cific preparations or ingredients used for hand antisepsis is
beyond the scope of this report. DHCP should choose from
commercially available HCP handwashes when selecting agents
for hand antisepsis or surgical hand antisepsis.
Storage and Dispensing of Hand Care
Products
Handwashing products, including plain (i.e., non-
antimicrobial) soap and antiseptic products, can become con-
taminated or support the growth of microorganisms (122).
Liquid products should be stored in closed containers and dis-
pensed from either disposable containers or containers that
are washed and dried thoroughly before refilling. Soap should
not be added to a partially empty dispenser, because this prac-
tice of topping off might lead to bacterial contamination
(149,150). Store and dispense products according to manu-
facturers’ directions.
Lotions
The primary defense against infection and transmission of
pathogens is healthy, unbroken skin. Frequent handwashing
with soaps and antiseptic agents can cause chronic irritant con-
tact dermatitis among DHCP. Damage to the skin changes
skin flora, resulting in more frequent colonization by staphy-
lococci and gram-negative bacteria (151,152). The potential
of detergents to cause skin irritation varies considerably, but
can be reduced by adding emollients. Lotions are often rec-
ommended to ease the dryness resulting from frequent
handwashing and to prevent dermatitis from glove use
(153,154). However, petroleum-based lotion formulations can
weaken latex gloves and increase permeability. For that reason,
lotions that contain petroleum or other oil emollients should
only be used at the end of the work day (122,155). Dental
practitioners should obtain information from lotion manu-
facturers regarding interaction between lotions, gloves, dental
materials, and antimicrobial products.
Fingernails and Artificial Nails
Although the relationship between fingernail length and
wound infection is unknown, keeping nails short is consid-
ered key because the majority of flora on the hands are found
under and around the fingernails (156). Fingernails should be
short enough to allow DHCP to thoroughly clean underneath
them and prevent glove tears (122). Sharp nail edges or bro-
ken nails are also likely to increase glove failure. Long artificial
or natural nails can make donning gloves more difficult and
can cause gloves to tear more readily. Hand carriage of gram-
negative organisms has been determined to be greater among
wearers of artificial nails than among nonwearers, both before
and after handwashing (157–160). In addition, artificial fin-
gernails or extenders have been epidemiologically implicated
in multiple outbreaks involving fungal and bacterial infections
in hospital intensive-care units and operating rooms (161–
164). Freshly applied nail polish on natural nails does not
increase the microbial load from periungual skin if fingernails
are short; however, chipped nail polish can harbor added bac-
teria (165,166).
Jewelry
Studies have demonstrated that skin underneath rings is more
heavily colonized than comparable areas of skin on fingers
without rings (167–170). In a study of intensive-care nurses,
multivariable analysis determined rings were the only substan-
tial risk factor for carriage of gram-negative bacilli and Staphy-
lococcus aureus, and the concentration of organisms correlated
with the number of rings worn (170). However, two other
studies demonstrated that mean bacterial colony counts on
hands after handwashing were similar among persons wearing
rings and those not wearing rings (169,171). Whether wear-
ing rings increases the likelihood of transmitting a pathogen is
unknown; further studies are needed to establish whether rings
result in higher transmission of pathogens in health-care set-
tings. However, rings and decorative nail jewelry can make
donning gloves more difficult and cause gloves to tear more
readily (142,143). Thus, jewelry should not interfere with glove
use (e.g., impair ability to wear the correct-sized glove or alter
glove integrity).
Personal Protective Equipment
PPE is designed to protect the skin and the mucous mem-
branes of the eyes, nose, and mouth of DHCP from exposure
to blood or OPIM. Use of rotary dental and surgical instru-
ments (e.g., handpieces or ultrasonic scalers) and air-water
syringes creates a visible spray that contains primarily large-
particle droplets of water, saliva, blood, microorganisms, and
other debris. This spatter travels only a short distance and settles
out quickly, landing on the floor, nearby operatory surfaces,
DHCP, or the patient. The spray also might contain certain
aerosols (i.e., particles of respirable size, <10 µm). Aerosols can
remain airborne for extended periods and can be inhaled. How-
ever, they should not be confused with the large-particle spat-
ter that makes up the bulk of the spray from handpieces and
ultrasonic scalers. Appropriate work practices, including use of
dental dams (172) and high-velocity air evacuation, should
minimize dissemination of droplets, spatter, and aerosols (2).
Primary PPE used in oral health-care settings includes gloves,
surgical masks, protective eyewear, face shields, and protective
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clothing (e.g., gowns and jackets). All PPE should be removed
before DHCP leave patient-care areas (13). Reusable PPE (e.g.,
clinician or patient protective eyewear and face shields) should
be cleaned with soap and water, and when visibly soiled, dis-
infected between patients, according to the manufacturer’s
directions (2,13). Wearing gloves, surgical masks, protective
eyewear, and protective clothing in specified circumstances to
reduce the risk of exposures to bloodborne pathogens is man-
dated by OSHA (13). General work clothes (e.g., uniforms,
scrubs, pants, and shirts) are neither intended to protect against
a hazard nor considered PPE.
Masks, Protective Eyewear, Face Shields
A surgical mask that covers both the nose and mouth and
protective eyewear with solid side shields or a face shield should
be worn by DHCP during procedures and patient-care activi-
ties likely to generate splashes or sprays of blood or body flu-
ids. Protective eyewear for patients shields their eyes from
spatter or debris generated during dental procedures. A surgi-
cal mask protects against microorganisms generated by the
wearer, with >95% bacterial filtration efficiency, and also pro-
tects DHCP from large-particle droplet spatter that might
contain bloodborne pathogens or other infectious microor-
ganisms (173). The mask’s outer surface can become contami-
nated with infectious droplets from spray of oral fluids or from
touching the mask with contaminated fingers. Also, when a
mask becomes wet from exhaled moist air, the resistance to
airflow through the mask increases, causing more airflow to
pass around edges of the mask. If the mask becomes wet, it
should be changed between patients or even during patient
treatment, when possible (2,174).
When airborne infection isolation precautions (expanded
or transmission-based) are necessary (e.g., for TB patients), a
National Institute for Occupational Safety and Health
(NIOSH)-certified particulate-filter respirator (e.g., N95, N99,
or N100) should be used (20). N95 refers to the ability to
filter 1-µm particles in the unloaded state with a filter effi-
ciency of >95% (i.e., filter leakage <5%), given flow rates of
<50 L/min (i.e., approximate maximum airflow rate of HCP
during breathing). Available data indicate infectious droplet
nuclei measure 1–5 µm; therefore, respirators used in health-
care settings should be able to efficiently filter the smallest
particles in this range.
The majority of surgical masks are not NIOSH-certified as
respirators, do not protect the user adequately from exposure
to TB, and do not satisfy OSHA requirements for respiratory
protection (174,175). However, certain surgical masks (i.e.,
surgical N95 respirator) do meet the requirements and are cer-
tified by NIOSH as respirators. The level of protection a res-
pirator provides is determined by the efficiency of the filter
material for incoming air and how well the face piece fits or
seals to the face (e.g., qualitatively or quantitatively tested in a
reliable way to obtain a face-seal leakage of <10% and to fit
the different facial sizes and characteristics of HCP).
When respirators are used while treating patients with dis-
eases requiring airborne-transmission precautions (e.g., TB),
they should be used in the context of a complete respiratory
protection program (175). This program should include train-
ing and fit testing to ensure an adequate seal between the edges
of the respirator and the wearer’s face. Detailed information
regarding respirator programs, including fit-test procedures are
available at http://www.cdc.gov/niosh/99-143.html (174,176).
Protective Clothing
Protective clothing and equipment (e.g., gowns, lab coats,
gloves, masks, and protective eyewear or face shield) should be
worn to prevent contamination of street clothing and to pro-
tect the skin of DHCP from exposures to blood and body
substances (2,7,10,11,13,137). OSHA bloodborne pathogens
standard requires sleeves to be long enough to protect the fore-
arms when the gown is worn as PPE (i.e., when spatter and
spray of blood, saliva, or OPIM to the forearms is anticipated)
(13,14). DHCP should change protective clothing when it
becomes visibly soiled and as soon as feasible if penetrated by
blood or other potentially infectious fluids (2,13,14,137). All
protective clothing should be removed before leaving the work
area (13).
Gloves and Gloving
DHCP wear gloves to prevent contamination of their hands
when touching mucous membranes, blood, saliva, or OPIM,
and also to reduce the likelihood that microorganisms present
on the hands of DHCP will be transmitted to patients during
surgical or other patient-care procedures (1,2,7,10). Medical
gloves, both patient examination and surgeon’s gloves, are
manufactured as single-use disposable items that should be
used for only one patient, then discarded. Gloves should be
changed between patients and when torn or punctured.
Wearing gloves does not eliminate the need for handwashing.
Hand hygiene should be performed immediately before don-
ning gloves. Gloves can have small, unapparent defects or can
be torn during use, and hands can become contaminated dur-
ing glove removal (122,177–187). These circumstances increase
the risk of operative wound contamination and exposure of
the DHCP’s hands to microorganisms from patients. In addi-
tion, bacteria can multiply rapidly in the moist environments
underneath gloves, and thus, the hands should be dried thor-
oughly before donning gloves and washed again immediately
after glove removal.
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Types of Gloves
Because gloves are task-specific, their selection should be
based on the type of procedure to be performed (e.g., surgery
or patient examination) (Table 3). Sterile surgeon’s gloves must
meet standards for sterility assurance established by FDA and
are less likely than patient examination gloves to harbor patho-
gens that could contaminate an operative wound (188).
Appropriate gloves in the correct size should be readily acces-
sible (13).
Glove Integrity
Limited studies of the penetrability of different glove mate-
rials under conditions of use have been conducted in the den-
tal environment. Consistent with observations in clinical
medicine, leakage rates vary by glove material (e.g., latex, vinyl,
and nitrile), duration of use, and type of procedure performed
(182,184,186,189–191), as well as by manufacturer (192–
194). The frequency of perforations in surgeon’s gloves used
during outpatient oral surgical procedures has been determined
to range from 6% to 16% (181,185,195,196).
Studies have demonstrated that HCP and DHCP are fre-
quently unaware of minute tears in gloves that occur during
use (186,190,191,197). These studies determined that gloves
developed defects in 30 minutes–3 hours, depending on type
of glove and procedure. Investigators did not determine an
optimal time for changing gloves during procedures.
During dental procedures, patient examination and surgeon’s
gloves commonly contact multiple types of chemicals and
materials (e.g., disinfectants and antiseptics, composite resins,
and bonding agents) that can compromise the integrity of
latex as well as vinyl, nitrile, and other synthetic glove materi-
als (198–206). In addition, latex gloves can interfere with the
setting of vinyl polysiloxane impression materials (207–209),
although the setting is apparently not adversely affected by
synthetic vinyl gloves (207,208). Given the diverse selection
of dental materials on the market, dental practitioners should
consult glove manufacturers regarding the chemical compat-
ibility of glove materials.
If the integrity of a glove is compromised (e.g., punctured),
it should be changed as soon as possible (13,210,211). Wash-
ing latex gloves with plain soap, chlorhexidine, or alcohol can
lead to the formation of glove micropunctures (177,212,213)
and subsequent hand contamination (138). Because this con-
dition, known as wicking, can allow penetration of liquids
through undetected holes, washing gloves is not recommended.
After a hand rub with alcohol, the hands should be thoroughly
TABLE 3. Glove types and indications
Commercially available glove materials*























Nitrile and chloroprene (neoprene) blends
Nitrile & NRL blends
Butadiene methyl methacrylate





































* Physical properties can vary by material, manufacturer, and protein and chemical composition.
†
1 contains allergenic NRL proteins.
2 vulcanized rubber, contains allergenic rubber processing chemicals.
3 likely to have enhanced chemical or puncture resistance.
4 nonvulcanized and does not contain rubber processing chemicals.
5 inappropriate for use with methacrylates.
6 resistant to most methacrylates.
§
Medical or dental gloves include patient-examination gloves and surgeon’s (i.e., surgical) gloves and are medical devices regulated by the FDA. Only FDA-cleared medical or
dental patient-examination gloves and surgical gloves can be used for patient care.
Medical device regulated by the Food and Drug
Administration (FDA).
Nonsterile and sterile single-use disposable. Use
for one patient and discard appropriately.
Medical device regulated by the FDA.
Sterile and single-use disposable. Use for one
patient and discard appropriately.
Not a medical device regulated by the FDA.
Commonly referred to as utility, industrial, or
general purpose gloves. Should be puncture- or
chemical-resistant, depending on the task. Latex
gloves do not provide adequate chemical
protection.
Sanitize after use.
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dried before gloving, because hands still wet with an alcohol-
based hand hygiene product can increase the risk of glove per-
foration (192).
FDA regulates the medical glove industry, which includes
gloves marketed as sterile surgeon’s and sterile or nonsterile
patient examination gloves. General-purpose utility gloves are
also used in dental health-care settings but are not regulated
by FDA because they are not promoted for medical use. More
rigorous standards are applied to surgeon’s than to examina-
tion gloves. FDA has identified acceptable quality levels (e.g.,
maximum defects allowed) for glove manufacturers (214), but
even intact gloves eventually fail with exposure to mechanical
(e.g., sharps, fingernails, or jewelry) and chemical (e.g.,
dimethyacrylates) hazards and over time. These variables can
be controlled, ultimately optimizing glove performance, by
1) maintaining short fingernails, 2) minimizing or eliminat-
ing hand jewelry, and 3) using engineering and work-practice
controls to avoid injuries with sharps.
Sterile Surgeon’s Gloves and Double-Gloving
During Oral Surgical Procedures
Certain limited studies have determined no difference in
postoperative infection rates after routine tooth extractions
when surgeons wore either sterile or nonsterile gloves
(215,216). However, wearing sterile surgeon’s gloves during
surgical procedures is supported by a strong theoretical ratio-
nale (2,7,137). Sterile gloves minimize transmission of micro-
organisms from the hands of surgical DHCP to patients and
prevent contamination of the hands of surgical DHCP with
the patient’s blood and body fluids (137). In addition, sterile
surgeon’s gloves are more rigorously regulated by FDA and
therefore might provide an increased level of protection for
the provider if exposure to blood is likely.
Although the effectiveness of wearing two pairs of gloves in
preventing disease transmission has not been demonstrated,
the majority of studies among HCP and DHCP have demon-
strated a lower frequency of inner glove perforation and vis-
ible blood on the surgeon’s hands when double gloves are worn
(181,185,195,196,198,217–219). In one study evaluating
double gloves during oral surgical and dental hygiene proce-
dures, the perforation of outer latex gloves was greater during
longer procedures (i.e., >45 minutes), with the highest rate
(10%) of perforation occurring during oral surgery procedures
(196). Based on these studies, double gloving might provide
additional protection from occupational blood contact (220).
Double gloving does not appear to substantially reduce either
manual dexterity or tactile sensitivity (221–223). Additional
protection might also be provided by specialty products (e.g.,
orthopedic surgical gloves and glove liners) (224).
Contact Dermatitis and Latex
Hypersensitivity
Occupationally related contact dermatitis can develop from
frequent and repeated use of hand hygiene products, exposure
to chemicals, and glove use. Contact dermatitis is classified as
either irritant or allergic. Irritant contact dermatitis is com-
mon, nonallergic, and develops as dry, itchy, irritated areas on
the skin around the area of contact. By comparison, allergic
contact dermatitis (type IV hypersensitivity) can result from
exposure to accelerators and other chemicals used in the manu-
facture of rubber gloves (e.g., natural rubber latex, nitrile, and
neoprene), as well as from other chemicals found in the dental
practice setting (e.g., methacrylates and glutaraldehyde).
Allergic contact dermatitis often manifests as a rash beginning
hours after contact and, similar to irritant dermatitis, is usu-
ally confined to the area of contact.
Latex allergy (type I hypersensitivity to latex proteins) can
be a more serious systemic allergic reaction, usually beginning
within minutes of exposure but sometimes occurring hours
later and producing varied symptoms. More common reac-
tions include runny nose, sneezing, itchy eyes, scratchy throat,
hives, and itchy burning skin sensations. More severe symp-
toms include asthma marked by difficult breathing, coughing
spells, and wheezing; cardiovascular and gastrointestinal ail-
ments; and in rare cases, anaphylaxis and death (32,225). The
American Dental Association (ADA) began investigating the
prevalence of type I latex hypersensitivity among DHCP at
the ADA annual meeting in 1994. In 1994 and 1995,
approximately 2,000 dentists, hygienists, and assistants vol-
unteered for skin-prick testing. Data demonstrated that 6.2%
of those tested were positive for type I latex hypersensitivity
(226). Data from the subsequent 5 years of this ongoing cross-
sectional study indicated a decline in prevalence from 8.5% to
4.3% (227). This downward trend is similar to that reported
by other studies and might be related to use of latex gloves
with lower allergen content (228–230).
Natural rubber latex proteins responsible for latex allergy
are attached to glove powder. When powdered latex gloves are
worn, more latex protein reaches the skin. In addition, when
powdered latex gloves are donned or removed, latex protein/
powder particles become aerosolized and can be inhaled, con-
tacting mucous membranes (231). As a result, allergic patients
and DHCP can experience cutaneous, respiratory, and con-
junctival symptoms related to latex protein exposure. DHCP
can become sensitized to latex protein with repeated exposure
(232–236). Work areas where only powder-free, low-allergen
latex gloves are used demonstrate low or undetectable amounts
of latex allergy-causing proteins (237–239) and fewer symp-
toms among HCP related to natural rubber latex allergy.
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Because of the role of glove powder in exposure to latex pro-
tein, NIOSH recommends that if latex gloves are chosen, HCP
should be provided with reduced protein, powder-free gloves
(32). Nonlatex (e.g., nitrile or vinyl) powder-free and low-
protein gloves are also available (31,240). Although rare,
potentially life-threatening anaphylactic reactions to latex can
occur; dental practices should be appropriately equipped and
have procedures in place to respond to such emergencies.
DHCP and dental patients with latex allergy should not have
direct contact with latex-containing materials and should be
in a latex-safe environment with all latex-containing products
removed from their vicinity (31). Dental patients with histo-
ries of latex allergy can be at risk from dental products (e.g.,
prophylaxis cups, rubber dams, orthodontic elastics, and medi-
cation vials) (241). Any latex-containing devices that cannot
be removed from the treatment environment should be
adequately covered or isolated. Persons might also be allergic
to chemicals used in the manufacture of natural rubber latex
and synthetic rubber gloves as well as metals, plastics, or other
materials used in dental care. Taking thorough health histories
for both patients and DHCP, followed by avoidance of con-
tact with potential allergens can minimize the possibility of
adverse reactions. Certain common predisposing conditions
for latex allergy include previous history of allergies, a history
of spina bifida, urogenital anomalies, or allergies to avocados,
kiwis, nuts, or bananas. The following precautions should be
considered to ensure safe treatment for patients who have pos-
sible or documented latex allergy:
• Be aware that latent allergens in the ambient air can cause
respiratory or anaphylactic symptoms among persons with
latex hypersensitivity. Patients with latex allergy can be
scheduled for the first appointment of the day to mini-
mize their inadvertent exposure to airborne latex particles.
• Communicate with other DHCP regarding patients with
latex allergy (e.g., by oral instructions, written protocols,
and posted signage) to prevent them from bringing latex-
containing materials into the treatment area.
• Frequently clean all working areas contaminated with
latex powder or dust.
• Have emergency treatment kits with latex-free products
available at all times.
• If latex-related complications occur during or after a pro-
cedure, manage the reaction and seek emergency assistance
as indicated. Follow current medical emergency response
recommendations for management of anaphylaxis (32).
Sterilization and Disinfection
of Patient-Care Items
Patient-care items (dental instruments, devices, and equip-
ment) are categorized as critical, semicritical, or noncritical,
depending on the potential risk for infection associated with
their intended use (Table 4) (242). Critical items used to pen-
etrate soft tissue or bone have the greatest risk of transmitting
infection and should be sterilized by heat. Semicritical items
touch mucous membranes or nonintact skin and have a lower
risk of transmission; because the majority of semicritical items
in dentistry are heat-tolerant, they also should be sterilized by
using heat. If a semicritical item is heat-sensitive, it should, at
a minimum, be processed with high-level disinfection (2).
Noncritical patient-care items pose the least risk of trans-
mission of infection, contacting only intact skin, which can
serve as an effective barrier to microorganisms. In the majority
of cases, cleaning, or if visibly soiled, cleaning followed by disin-
fection with an EPA-registered hospital disinfectant is adequate.
When the item is visibly contaminated with blood or OPIM,
an EPA-registered hospital disinfectant with a tuberculocidal
claim (i.e., intermediate-level disinfectant) should be used
(2,243,244). Cleaning or disinfection of certain noncritical
patient-care items can be difficult or damage the surfaces; there-
fore, use of disposable barrier protection of these surfaces might
be a preferred alternative.
FDA-cleared sterilant/high-level disinfectants and EPA-
registered disinfectants must have clear label claims for intended
use, and manufacturer instructions for use must be followed
(245). A more complete description of the regulatory frame-
work in the United States by which liquid chemical germi-
cides are evaluated and regulated is included (Appendix A).






Penetrates soft tissue, contacts bone, enters into or contacts the blood-
stream or other normally sterile tissue.
Contacts mucous membranes or nonintact skin; will not penetrate soft
tissue, contact bone, enter into or contact the bloodstream or other
normally sterile tissue.
Contacts intact skin.
Dental instrument or item
Surgical instruments, periodontal scalers, scalpel blades, surgical dental
burs
Dental mouth mirror, amalgam condenser, reusable dental impression
trays, dental handpieces*
Radiograph head/cone, blood pressure cuff,  facebow, pulse oximeter
* Although dental handpieces are considered a semicritical item, they should always be heat-sterilized between uses and not high-level disinfected (246). See Dental Handpieces
and Other Devices Attached to Air or Waterlines for detailed information.
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Three levels of disinfection, high, intermediate, and low, are
used for patient-care devices that do not require sterility and
two levels, intermediate and low, for environmental surfaces
(242). The intended use of the patient-care item should deter-
mine the recommended level of disinfection. Dental practices
should follow the product manufacturer’s directions regarding
concentrations and exposure time for disinfectant activity rela-
tive to the surface to be disinfected (245). A summary of ster-
ilization and disinfection methods is included (Appendix C).
Transporting and Processing Contaminated
Critical and Semicritical Patient-Care Items
DHCP can be exposed to microorganisms on contaminated
instruments and devices through percutaneous injury, contact
with nonintact skin on the hands, or contact with mucous
membranes of the eyes, nose, or mouth. Contaminated
instruments should be handled carefully to prevent exposure
to sharp instruments that can cause a percutaneous injury.
Instruments should be placed in an appropriate container at
the point of use to prevent percutaneous injuries during trans-
port to the instrument processing area (13).
Instrument processing requires multiple steps to achieve ster-
ilization or high-level disinfection. Sterilization is a complex
process requiring specialized equipment, adequate space, quali-
fied DHCP who are provided with ongoing training, and regu-
lar monitoring for quality assurance (247). Correct cleaning,
packaging, sterilizer loading procedures, sterilization methods,
or high-level disinfection methods should be followed to
ensure that an instrument is adequately processed and safe for
reuse on patients.
Instrument Processing Area
DHCP should process all instruments in a designated cen-
tral processing area to more easily control quality and ensure
safety (248). The central processing area should be divided
into sections for 1) receiving, cleaning, and decontamination;
2) preparation and packaging; 3) sterilization; and 4) storage.
Ideally, walls or partitions should separate the sections to con-
trol traffic flow and contain contaminants generated during
processing. When physical separation of these sections cannot
be achieved, adequate spatial separation might be satisfactory
if the DHCP who process instruments are trained in work
practices to prevent contamination of clean areas (248). Space
should be adequate for the volume of work anticipated and
the items to be stored (248).
Receiving, Cleaning, and Decontamination
Reusable instruments, supplies, and equipment should be
received, sorted, cleaned, and decontaminated in one section
of the processing area. Cleaning should precede all disinfection
and sterilization processes; it should involve removal of debris
as well as organic and inorganic contamination. Removal of
debris and contamination is achieved either by scrubbing with
a surfactant, detergent, and water, or by an automated process
(e.g., ultrasonic cleaner or washer-disinfector) using chemical
agents. If visible debris, whether inorganic or organic matter, is
not removed, it will interfere with microbial inactivation and
can compromise the disinfection or sterilization process
(244,249–252). After cleaning, instruments should be rinsed
with water to remove chemical or detergent residue. Splashing
should be minimized during cleaning and rinsing (13). Before
final disinfection or sterilization, instruments should be handled
as though contaminated.
Considerations in selecting cleaning methods and equipment
include 1) efficacy of the method, process, and equipment;
2) compatibility with items to be cleaned; and 3) occupational
health and exposure risks. Use of automated cleaning equip-
ment (e.g., ultrasonic cleaner or washer-disinfector) does not
require presoaking or scrubbing of instruments and can
increase productivity, improve cleaning effectiveness, and
decrease worker exposure to blood and body fluids. Thus,
using automated equipment can be safer and more efficient
than manually cleaning contaminated instruments (253).
If manual cleaning is not performed immediately, placing
instruments in a puncture-resistant container and soaking them
with detergent, a disinfectant/detergent, or an enzymatic
cleaner will prevent drying of patient material and make clean-
ing easier and less time-consuming. Use of a liquid chemical
sterilant/high-level disinfectant (e.g., glutaraldehyde) as a hold-
ing solution is not recommended (244). Using work-practice
controls (e.g., long-handled brush) to keep the scrubbing hand
away from sharp instruments is recommended (14). To avoid
injury from sharp instruments, DHCP should wear puncture-
resistant, heavy-duty utility gloves when handling or manu-
ally cleaning contaminated instruments and devices (6).
Employees should not reach into trays or containers holding
sharp instruments that cannot be seen (e.g., sinks filled with
soapy water in which sharp instruments have been placed).
Work-practice controls should include use of a strainer-type
basket to hold instruments and forceps to remove the items.
Because splashing is likely to occur, a mask, protective eyewear
or face shield, and gown or jacket should be worn (13).
Preparation and Packaging
In another section of the processing area, cleaned instru-
ments and other dental supplies should be inspected, assembled
into sets or trays, and wrapped, packaged, or placed into con-
tainer systems for sterilization. Hinged instruments should be
processed open and unlocked. An internal chemical indicator
should be placed in every package. In addition, an external
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chemical indicator (e.g., chemical indicator tape) should be
used when the internal indicator cannot be seen from outside
the package. For unwrapped loads, at a minimum, an internal
chemical indicator should be placed in the tray or cassette with
items to be sterilized (254) (see Sterilization of Unwrapped
Instruments). Dental practices should refer to the
manufacturer’s instructions regarding use and correct place-
ment of chemical indicators (see Sterilization Monitoring).
Critical and semicritical instruments that will be stored should
be wrapped or placed in containers (e.g., cassettes or organiz-
ing trays) designed to maintain sterility during storage
(2,247,255–257).
Packaging materials (e.g., wraps or container systems) allow
penetration of the sterilization agent and maintain sterility of
the processed item after sterilization. Materials for maintain-
ing sterility of instruments during transport and storage
include wrapped perforated instrument cassettes, peel pouches
of plastic or paper, and sterilization wraps (i.e., woven and
nonwoven). Packaging materials should be designed for the
type of sterilization process being used (256–259).
Sterilization
The sterilization section of the processing area should
include the sterilizers and related supplies, with adequate space
for loading, unloading, and cool down. The area can also
include incubators for analyzing spore tests and enclosed stor-
age for sterile items and disposable (single-use) items (260).
Manufacturer and local building code specifications will
determine placement and room ventilation requirements.
Sterilization Procedures. Heat-tolerant dental instruments
usually are sterilized by 1) steam under pressure (autoclaving),
2) dry heat, or 3) unsaturated chemical vapor. All sterilization
should be performed by using medical sterilization equipment
cleared by FDA. The sterilization times, temperatures, and
other operating parameters recommended by the manufac-
turer of the equipment used, as well as instructions for correct
use of containers, wraps, and chemical or biological indica-
tors, should always be followed (243,247).
Items to be sterilized should be arranged to permit free cir-
culation of the sterilizing agent (e.g., steam, chemical vapor,
or dry heat); manufacturer’s instructions for loading the steril-
izer should be followed (248,260). Instrument packs should
be allowed to dry inside the sterilizer chamber before remov-
ing and handling. Packs should not be touched until they are
cool and dry because hot packs act as wicks, absorbing mois-
ture, and hence, bacteria from hands (247). The ability of
equipment to attain physical parameters required to achieve
sterilization should be monitored by mechanical, chemical,
and biological indicators. Sterilizers vary in their types of
indicators and their ability to provide readings on the mechani-
cal or physical parameters of the sterilization process (e.g., time,
temperature, and pressure). Consult with the sterilizer manu-
facturer regarding selection and use of indicators.
Steam Sterilization. Among sterilization methods, steam
sterilization, which is dependable and economical, is the most
widely used for wrapped and unwrapped critical and
semicritical items that are not sensitive to heat and moisture
(260). Steam sterilization requires exposure of each item to
direct steam contact at a required temperature and pressure
for a specified time needed to kill microorganisms. Two basic
types of steam sterilizers are the gravity displacement and the
high-speed prevacuum sterilizer.
The majority of tabletop sterilizers used in a dental practice
are gravity displacement sterilizers, although prevacuum ster-
ilizers are becoming more widely available. In gravity displace-
ment sterilizers, steam is admitted through steam lines, a steam
generator, or self-generation of steam within the chamber.
Unsaturated air is forced out of the chamber through a vent in
the chamber wall. Trapping of air is a concern when using
saturated steam under gravity displacement; errors in packag-
ing items or overloading the sterilizer chamber can result in
cool air pockets and items not being sterilized.
Prevacuum sterilizers are fitted with a pump to create a
vacuum in the chamber and ensure air removal from the ster-
ilizing chamber before the chamber is pressurized with steam.
Relative to gravity displacement, this procedure allows faster
and more positive steam penetration throughout the entire
load. Prevacuum sterilizers should be tested periodically for
adequate air removal, as recommended by the manufacturer.
Air not removed from the chamber will interfere with steam
contact. If a sterilizer fails the air removal test, it should not be
used until inspected by sterilizer maintenance personnel and
it passes the test (243,247). Manufacturer’s instructions, with
specific details regarding operation and user maintenance
information, should be followed.
Unsaturated Chemical-Vapor Sterilization. Unsaturated
chemical-vapor sterilization involves heating a chemical solu-
tion of primarily alcohol with 0.23% formaldehyde in a closed
pressurized chamber. Unsaturated chemical vapor sterilization
of carbon steel instruments (e.g., dental burs) causes less cor-
rosion than steam sterilization because of the low level of
water present during the cycle. Instruments should be dry
before sterilizing. State and local authorities should be con-
sulted for hazardous waste disposal requirements for the steril-
izing solution.
Dry-Heat Sterilization. Dry heat is used to sterilize mate-
rials that might be damaged by moist heat (e.g., burs and cer-
tain orthodontic instruments). Although dry heat has the
advantages of low operating cost and being noncorrosive, it is
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a prolonged process and the high temperatures required are
not suitable for certain patient-care items and devices (261).
Dry-heat sterilizers used in dentistry include static-air and
forced-air types.
• The static-air type is commonly called an oven-type steril-
izer. Heating coils in the bottom or sides of the unit cause hot
air to rise inside the chamber through natural convection.
• The forced-air type is also known as a rapid heat-transfer
sterilizer. Heated air is circulated throughout the chamber
at a high velocity, permitting more rapid transfer of
energy from the air to the instruments, thereby reducing
the time needed for sterilization.
Sterilization of Unwrapped Instruments. An unwrapped
cycle (sometimes called flash sterilization) is a method for ster-
ilizing unwrapped patient-care items for immediate use. The
time required for unwrapped sterilization cycles depends on
the type of sterilizer and the type of item (i.e., porous or non-
porous) to be sterilized (243). The unwrapped cycle in table-
top sterilizers is preprogrammed by the manufacturer to a
specific time and temperature setting and can include a drying
phase at the end to produce a dry instrument with much of
the heat dissipated. If the drying phase requirements are unclear,
the operation manual or manufacturer of the sterilizer should
be consulted. If the unwrapped sterilization cycle in a steam
sterilizer does not include a drying phase, or has only a mini-
mal drying phase, items retrieved from the sterilizer will be
hot and wet, making aseptic transport to the point of use more
difficult. For dry-heat and chemical-vapor sterilizers, a drying
phase is not required.
Unwrapped sterilization should be used only under certain
conditions: 1) thorough cleaning and drying of instruments
precedes the unwrapped sterilization cycle; 2) mechanical
monitors are checked and chemical indicators used for each
cycle; 3) care is taken to avoid thermal injury to DHCP or
patients; and 4) items are transported aseptically to the point
of use to maintain sterility (134,258,262). Because all implant-
able devices should be quarantined after sterilization until the
results of biological monitoring are known, unwrapped or flash
sterilization of implantable items is not recommended (134).
Critical instruments sterilized unwrapped should be trans-
ferred immediately by using aseptic technique, from the steril-
izer to the actual point of use. Critical instruments should not
be stored unwrapped (260). Semicritical instruments that are
sterilized unwrapped on a tray or in a container system should
be used immediately or within a short time. When sterile items
are open to the air, they will eventually become contaminated.
Storage, even temporary, of unwrapped semicritical instruments
is discouraged because it permits exposure to dust, airborne
organisms, and other unnecessary contamination before use
on a patient (260). A carefully written protocol for minimiz-
ing the risk of contaminating unwrapped instruments should
be prepared and followed (260).
Other Sterilization Methods. Heat-sensitive critical and
semicritical instruments and devices can be sterilized by
immersing them in liquid chemical germicides registered by
FDA as sterilants. When using a liquid chemical germicide for
sterilization, certain poststerilization procedures are essential.
Items need to be 1) rinsed with sterile water after removal to
remove toxic or irritating residues; 2) handled using sterile
gloves and dried with sterile towels; and 3) delivered to the
point of use in an aseptic manner. If stored before use, the
instrument should not be considered sterile and should be ster-
ilized again just before use. In addition, the sterilization pro-
cess with liquid chemical sterilants cannot be verified with
biological indicators (263).
Because of these limitations and because liquid chemical ste-
rilants can require approximately 12 hours of complete
immersion, they are almost never used to sterilize instruments.
Rather, these chemicals are more often used for high-level dis-
infection (249). Shorter immersion times (12–90 minutes) are
used to achieve high-level disinfection of semicritical instru-
ments or items. These powerful, sporicidal chemicals (e.g., glu-
taraldehyde, peracetic acid, and hydrogen peroxide) are highly
toxic (244,264,265). Manufacturer instructions (e.g., regard-
ing dilution, immersion time, and temperature) and safety
precautions for using chemical sterilants/high-level disinfec-
tants must be followed precisely (15,245). These chemicals
should not be used for applications other than those indicated
in their label instructions. Misapplications include use as an
environmental surface disinfectant or instrument-holding
solution.
When using appropriate precautions (e.g., closed contain-
ers to limit vapor release, chemically resistant gloves and aprons,
goggles, and face shields), glutaraldehyde-based products can
be used without tissue irritation or adverse health effects. How-
ever, dermatologic, eye irritation, respiratory effects, and skin
sensitization have been reported (266–268). Because of their
lack of chemical resistance to glutaraldehydes, medical gloves
are not an effective barrier (200,269,270). Other factors might
apply (e.g., room exhaust ventilation or 10 air exchanges/hour)
to ensure DHCP safety (266,271). For all of these reasons,
using heat-sensitive semicritical items that must be processed
with liquid chemical germicides is discouraged; heat-tolerant
or disposable alternatives are available for the majority of such
items.
Low-temperature sterilization with ethylene oxide gas (ETO)
has been used extensively in larger health-care facilities. Its
primary advantage is the ability to sterilize heat- and mois-
ture-sensitive patient-care items with reduced deleterious
effects. However, extended sterilization times of 10–48 hours
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and potential hazards to patients and DHCP requiring strin-
gent health and safety requirements (272–274) make this
method impractical for private-practice settings. Handpieces
cannot be effectively sterilized with this method because of
decreased penetration of ETO gas flow through a small lumen
(250,275). Other types of low-temperature sterilization (e.g.,
hydrogen peroxide gas plasma) exist but are not yet practical
for dental offices.
Bead sterilizers have been used in dentistry to sterilize small
metallic instruments (e.g., endodontic files). FDA has deter-
mined that a risk of infection exists with these devices because
of their potential failure to sterilize dental instruments and has
required their commercial distribution cease unless the manu-
facturer files a premarket approval application. If a bead steril-
izer is employed, DHCP assume the risk of employing a
dental device FDA has deemed neither safe nor effective (276).
Sterilization Monitoring. Monitoring of sterilization pro-
cedures should include a combination of process parameters,
including mechanical, chemical, and biological (247,248,277).
These parameters evaluate both the sterilizing conditions and
the procedure’s effectiveness.
Mechanical techniques for monitoring sterilization include
assessing cycle time, temperature, and pressure by observing
the gauges or displays on the sterilizer and noting these
parameters for each load (243,248). Some tabletop sterilizers
have recording devices that print out these parameters. Cor-
rect readings do not ensure sterilization, but incorrect read-
ings can be the first indication of a problem with the
sterilization cycle.
Chemical indicators, internal and external, use sensitive
chemicals to assess physical conditions (e.g., time and tem-
perature) during the sterilization process. Although chemical
indicators do not prove sterilization has been achieved, they
allow detection of certain equipment malfunctions, and they
can help identify procedural errors. External indicators applied
to the outside of a package (e.g., chemical indicator tape or
special markings) change color rapidly when a specific param-
eter is reached, and they verify that the package has been
exposed to the sterilization process. Internal chemical indica-
tors should be used inside each package to ensure the steriliz-
ing agent has penetrated the packaging material and actually
reached the instruments inside. A single-parameter internal
chemical indicator provides information regarding only one
sterilization parameter (e.g., time or temperature). Multipa-
rameter internal chemical indicators are designed to react to
>2 parameters (e.g., time and temperature; or time, tempera-
ture, and the presence of steam) and can provide a more reli-
able indication that sterilization conditions have been met
(254). Multiparameter internal indicators are available only
for steam sterilizers (i.e., autoclaves).
Because chemical indicator test results are received when the
sterilization cycle is complete, they can provide an early indi-
cation of a problem and where in the process the problem
might exist. If either mechanical indicators or internal or
external chemical indicators indicate inadequate processing,
items in the load should not be used until reprocessed (134).
Biological indicators (BIs) (i.e., spore tests) are the most
accepted method for monitoring the sterilization process
(278,279) because they assess it directly by killing known highly
resistant microorganisms (e.g., Geobacillus or Bacillus species),
rather than merely testing the physical and chemical condi-
tions necessary for sterilization (243). Because spores used in
BIs are more resistant and present in greater numbers than the
common microbial contaminants found on patient-care equip-
ment, an inactivated BI indicates other potential pathogens in
the load have been killed (280).
Correct functioning of sterilization cycles should be verified
for each sterilizer by the periodic use (at least weekly) of BIs
(2,9,134,243,278,279). Every load containing implantable
devices should be monitored with such indicators (248), and
the items quarantined until BI results are known. However, in
an emergency, placing implantable items in quarantine until
spore tests are known to be negative might be impossible.
Manufacturer’s directions should determine the placement
and location of BI in the sterilizer. A control BI, from the
same lot as the test indicator and not processed through the
sterilizer, should be incubated with the test BI; the control BI
should yield positive results for bacterial growth.
In-office biological monitoring is available; mail-in steril-
ization monitoring services (e.g., from private companies or
dental schools) can also be used to test both the BI and the
control. Although some DHCP have expressed concern that
delays caused by mailing specimens might cause false-negatives,
studies have determined that mail delays have no substantial
effect on final test results (281,282).
Procedures to follow in the event of a positive spore test
have been developed (243,247). If the mechanical (e.g., time,
temperature, and pressure) and chemical (i.e., internal or
external) indicators demonstrate that the sterilizer is function-
ing correctly, a single positive spore test probably does not
indicate sterilizer malfunction. Items other than implantable
devices do not necessarily need to be recalled; however the
spore test should be repeated immediately after correctly load-
ing the sterilizer and using the same cycle that produced the
failure. The sterilizer should be removed from service, and all
records reviewed of chemical and mechanical monitoring since
the last negative BI test. Also, sterilizer operating procedures
should be reviewed, including packaging, loading, and spore
testing, with all persons who work with the sterilizer to deter-
mine whether operator error could be responsible (9,243,247).
Vol. 52 / RR-17 Recommendations and Reports 25
Overloading, failure to provide adequate package separation,
and incorrect or excessive packaging material are all common
reasons for a positive BI in the absence of mechanical failure
of the sterilizer unit (260). A second monitored sterilizer in
the office can be used, or a loaner from a sales or repair com-
pany obtained, to minimize office disruption while waiting
for the repeat BI.
If the repeat test is negative and chemical and mechanical
monitoring indicate adequate processing, the sterilizer can be
put back into service. If the repeat BI test is positive, and pack-
aging, loading, and operating procedures have been confirmed
as performing correctly, the sterilizer should remain out of ser-
vice until it has been inspected, repaired, and rechallenged with
BI tests in three consecutive empty chamber sterilization cycles
(9,243). When possible, items from suspect loads dating back
to the last negative BI should be recalled, rewrapped, and
resterilized (9,283).
A more conservative approach has been recommended (247)
in which any positive spore test is assumed to represent steril-
izer malfunction and requires that all materials processed in
that sterilizer, dating from the sterilization cycle having the
last negative biologic indicator to the next cycle indicating sat-
isfactory biologic indicator results, should be considered
nonsterile and retrieved, if possible, and reprocessed or held in
quarantine until the results of the repeat BI are known. This
approach is considered conservative because the margin of
safety in steam sterilization is sufficient enough that infection
risk, associated with items in a load indicating spore growth, is
minimal, particularly if the item was properly cleaned and the
temperature was achieved (e.g., as demonstrated by accept-
able chemical indicator or temperature chart) (243). Published
studies are not available that document disease transmission
through a nonretrieved surgical instrument after a steam ster-
ilization cycle with a positive biological indicator (243). This
more conservative approach should always be used for steril-
ization methods other than steam (e.g., dry heat, unsaturated
chemical vapor, ETO, or hydrogen peroxide gas plasma) (243).
Results of biological monitoring should be recorded and ster-
ilization monitoring records (i.e., mechanical, chemical, and
biological) retained long enough to comply with state and
local regulations. Such records are a component of an overall
dental infection-control program (see Program Evaluation).
Storage of Sterilized Items and Clean Dental
Supplies
The storage area should contain enclosed storage for sterile
items and disposable (single-use) items (173). Storage prac-
tices for wrapped sterilized instruments can be either date- or
event-related. Packages containing sterile supplies should be
inspected before use to verify barrier integrity and dryness.
Although some health-care facilities continue to date every
sterilized package and use shelf-life practices, other facilities
have switched to event-related practices (243). This approach
recognizes that the product should remain sterile indefinitely,
unless an event causes it to become contaminated (e.g., torn
or wet packaging) (284). Even for event-related packaging,
minimally, the date of sterilization should be placed on the
package, and if multiple sterilizers are used in the facility, the
sterilizer used should be indicated on the outside of the pack-
aging material to facilitate the retrieval of processed items in
the event of a sterilization failure (247). If packaging is com-
promised, the instruments should be recleaned, packaged in
new wrap, and sterilized again.
Clean supplies and instruments should be stored in closed
or covered cabinets, if possible (285). Dental supplies and
instruments should not be stored under sinks or in other loca-
tions where they might become wet.
Environmental Infection Control
In the dental operatory, environmental surfaces (i.e., a sur-
face or equipment that does not contact patients directly) can
become contaminated during patient care. Certain surfaces,
especially ones touched frequently (e.g., light handles, unit
switches, and drawer knobs) can serve as reservoirs of micro-
bial contamination, although they have not been associated
directly with transmission of infection to either DHCP or
patients. Transfer of microorganisms from contaminated
environmental surfaces to patients occurs primarily through
DHCP hand contact (286,287). When these surfaces are
touched, microbial agents can be transferred to instruments,
other environmental surfaces, or to the nose, mouth, or eyes
of workers or patients. Although hand hygiene is key to mini-
mizing this transferal, barrier protection or cleaning and dis-
infecting of environmental surfaces also protects against
health-care–associated infections.
Environmental surfaces can be divided into clinical contact
surfaces and housekeeping surfaces (249). Because housekeep-
ing surfaces (e.g., floors, walls, and sinks) have limited risk of
disease transmission, they can be decontaminated with less rig-
orous methods than those used on dental patient-care items
and clinical contact surfaces (244). Strategies for cleaning and
disinfecting surfaces in patient-care areas should consider the
1) potential for direct patient contact; 2) degree and frequency
of hand contact; and 3) potential contamination of the sur-
face with body substances or environmental sources of micro-
organisms (e.g., soil, dust, or water).
Cleaning is the necessary first step of any disinfection pro-
cess. Cleaning is a form of decontamination that renders the
environmental surface safe by removing organic matter, salts,
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and visible soils, all of which interfere with microbial inactiva-
tion. The physical action of scrubbing with detergents and
surfactants and rinsing with water removes substantial num-
bers of microorganisms. If a surface is not cleaned first, the
success of the disinfection process can be compromised.
Removal of all visible blood and inorganic and organic matter
can be as critical as the germicidal activity of the disinfecting
agent (249). When a surface cannot be cleaned adequately, it
should be protected with barriers (2).
Clinical Contact Surfaces
Clinical contact surfaces can be directly contaminated from
patient materials either by direct spray or spatter generated
during dental procedures or by contact with DHCP’s gloved
hands. These surfaces can subsequently contaminate other




• dental radiograph equipment,
• dental chairside computers,







Barrier protection of surfaces and equipment can prevent
contamination of clinical contact surfaces, but is particularly
effective for those that are difficult to clean. Barriers include
clear plastic wrap, bags, sheets, tubing, and plastic-backed
paper or other materials impervious to moisture (260,288).
Because such coverings can become contaminated, they should
be removed and discarded between patients, while DHCP are
still gloved. After removing the barrier, examine the surface to
make sure it did not become soiled inadvertently. The surface
needs to be cleaned and disinfected only if contamination is
evident. Otherwise, after removing gloves and performing hand
hygiene, DHCP should place clean barriers on these surfaces
before the next patient (1,2,288).
If barriers are not used, surfaces should be cleaned and dis-
infected between patients by using an EPA-registered hospital
disinfectant with an HIV, HBV claim (i.e., low-level disinfec-
tant) or a tuberculocidal claim (i.e., intermediate-level disin-
fectant). Intermediate-level disinfectant should be used when
the surface is visibly contaminated with blood or OPIM
(2,244). Also, general cleaning and disinfection are recom-
mended for clinical contact surfaces, dental unit surfaces, and
countertops at the end of daily work activities and are required
if surfaces have become contaminated since their last cleaning
(13). To facilitate daily cleaning, treatment areas should be
kept free of unnecessary equipment and supplies.
Manufacturers of dental devices and equipment should pro-
vide information regarding material compatibility with liquid
chemical germicides, whether equipment can be safely
immersed for cleaning, and how it should be decontaminated
if servicing is required (289). Because of the risks associated
with exposure to chemical disinfectants and contaminated sur-
faces, DHCP who perform environmental cleaning and disin-
fection should wear gloves and other PPE to prevent
occupational exposure to infectious agents and hazardous
chemicals. Chemical- and puncture-resistant utility gloves
offer more protection than patient examination gloves when
using hazardous chemicals.
Housekeeping Surfaces
Evidence does not support that housekeeping surfaces (e.g.,
floors, walls, and sinks) pose a risk for disease transmission in
dental health-care settings. Actual, physical removal of micro-
organisms and soil by wiping or scrubbing is probably as criti-
cal, if not more so, than any antimicrobial effect provided by
the agent used (244,290). The majority of housekeeping sur-
faces need to be cleaned only with a detergent and water or an
EPA-registered hospital disinfectant/detergent, depending on
the nature of the surface and the type and degree of contami-
nation. Schedules and methods vary according to the area (e.g.,
dental operatory, laboratory, bathrooms, or reception rooms),
surface, and amount and type of contamination.
Floors should be cleaned regularly, and spills should be
cleaned up promptly. An EPA-registered hospital disinfectant/
detergent designed for general housekeeping purposes should
be used in patient-care areas if uncertainty exists regarding the
nature of the soil on the surface (e.g., blood or body fluid
contamination versus routine dust or dirt). Unless contami-
nation is reasonably anticipated or apparent, cleaning or dis-
infecting walls, window drapes, and other vertical surfaces is
unnecessary. However, when housekeeping surfaces are visibly
contaminated by blood or OPIM, prompt removal and sur-
face disinfection is appropriate infection-control practice and
required by OSHA (13).
Part of the cleaning strategy is to minimize contamination
of cleaning solutions and cleaning tools (e.g., mop heads or
cleaning cloths). Mops and cloths should be cleaned after use
and allowed to dry before reuse, or single-use, disposable mop
heads and cloths should be used to avoid spreading contami-
nation. Cost, safety, product-surface compatibility, and accept-
ability by housekeepers can be key criteria for selecting a
cleaning agent or an EPA-registered hospital disinfectant/
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detergent. PPE used during cleaning and housekeeping proce-
dures followed should be appropriate to the task.
In the cleaning process, another reservoir for microorgan-
isms can be dilute solutions of detergents or disinfectants,
especially if prepared in dirty containers, stored for long peri-
ods of time, or prepared incorrectly (244). Manufacturers’
instructions for preparation and use should be followed. Mak-
ing fresh cleaning solution each day, discarding any remaining
solution, and allowing the container to dry will minimize bac-
terial contamination. Preferred cleaning methods produce
minimal mists and aerosols or dispersion of dust in patient-
care areas.
Cleaning and Disinfection Strategies
for Blood Spills
The majority of blood contamination events in dentistry
result from spatter during dental procedures using rotary or
ultrasonic instrumentation. Although no evidence supports
that HBV, HCV, or HIV have been transmitted from a house-
keeping surface, prompt removal and surface disinfection of
an area contaminated by either blood or OPIM are appropri-
ate infection-control practices and required by OSHA (13,291).
Strategies for decontaminating spills of blood and other body
fluids differ by setting and volume of the spill (113,244). Blood
spills on either clinical contact or housekeeping surfaces should
be contained and managed as quickly as possible to reduce the
risk of contact by patients and DHCP (244,292). The person
assigned to clean the spill should wear gloves and other PPE as
needed. Visible organic material should be removed with
absorbent material (e.g., disposable paper towels discarded in
a leak-proof, appropriately labeled container). Nonporous sur-
faces should be cleaned and then decontaminated with either
an EPA-registered hospital disinfectant effective against HBV
and HIV or an EPA-registered hospital disinfectant with a
tuberculocidal claim (i.e., intermediate-level disinfectant). If
sodium hypochlorite is chosen, an EPA-registered sodium
hypochlorite product is preferred. However, if such products
are unavailable, a 1:100 dilution of sodium hypochlorite (e.g.,
approximately ¼ cup of 5.25% household chlorine bleach to
1 gallon of water) is an inexpensive and effective disinfecting
agent (113).
Carpeting and Cloth Furnishings
Carpeting is more difficult to clean than nonporous hard-
surface flooring, and it cannot be reliably disinfected, espe-
cially after spills of blood and body substances. Studies have
documented the presence of diverse microbial populations,
primarily bacteria and fungi, in carpeting (293–295). Cloth
furnishings pose similar contamination risks in areas of direct
patient care and places where contaminated materials are man-
aged (e.g., dental operatory, laboratory, or instrument process-
ing areas). For these reasons, use of carpeted flooring and fab-
ric-upholstered furnishings in these areas should be avoided.
Nonregulated and Regulated Medical Waste
Studies have compared microbial load and diversity of
microorganisms in residential waste with waste from multiple
health-care settings. General waste from hospitals or other
health-care facilities (e.g., dental practices or clinical/research
laboratories) is no more infective than residential waste
(296,297). The majority of soiled items in dental offices are
general medical waste and thus can be disposed of with ordi-
nary waste. Examples include used gloves, masks, gowns, lightly
soiled gauze or cotton rolls, and environmental barriers (e.g.,
plastic sheets or bags) used to cover equipment during treat-
ment (298).
Although any item that has had contact with blood, exu-
dates, or secretions might be infective, treating all such waste
as infective is neither necessary nor practical (244). Infectious
waste that carries a substantial risk of causing infection during
handling and disposal is regulated medical waste. A complete
definition of regulated waste is included in OSHA’s bloodborne
pathogens standard (13).
Regulated medical waste is only a limited subset of waste:
9%–15% of total waste in hospitals and 1%–2% of total waste
in dental offices (298,299). Regulated medical waste requires
special storage, handling, neutralization, and disposal and is
covered by federal, state, and local rules and regulations
(6,297,300,301). Examples of regulated waste found in den-
tal-practice settings are solid waste soaked or saturated with
blood or saliva (e.g., gauze saturated with blood after surgery),
extracted teeth, surgically removed hard and soft tissues, and
contaminated sharp items (e.g., needles, scalpel blades, and
wires) (13).
Regulated medical waste requires careful containment for
treatment or disposal. A single leak-resistant biohazard bag is
usually adequate for containment of nonsharp regulated medi-
cal waste, provided the bag is sturdy and the waste can be
discarded without contaminating the bag’s exterior. Exterior
contamination or puncturing of the bag requires placement in
a second biohazard bag. All bags should be securely closed for
disposal. Puncture-resistant containers with a biohazard label,
located at the point of use (i.e., sharps containers), are used as
containment for scalpel blades, needles, syringes, and unused
sterile sharps (13).
Dental health-care facilities should dispose of medical waste
regularly to avoid accumulation. Any facility generating regu-
lated medical waste should have a plan for its management
that complies with federal, state, and local regulations to
ensure health and environmental safety.
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Discharging Blood or Other Body Fluids
to Sanitary Sewers or Septic Tanks
All containers with blood or saliva (e.g., suctioned fluids)
can be inactivated in accordance with state-approved treat-
ment technologies, or the contents can be carefully poured
down a utility sink, drain, or toilet (6). Appropriate PPE (e.g.,
gloves, gown, mask, and protective eyewear) should be worn
when performing this task (13). No evidence exists that
bloodborne diseases have been transmitted from contact with
raw or treated sewage. Multiple bloodborne pathogens, par-
ticularly viruses, are not stable in the environment for long
periods (302), and the discharge of limited quantities of blood
and other body fluids into the sanitary sewer is considered a
safe method for disposing of these waste materials (6). State
and local regulations vary and dictate whether blood or other
body fluids require pretreatment or if they can be discharged
into the sanitary sewer and in what volume.
Dental Unit Waterlines, Biofilm,
and Water Quality
Studies have demonstrated that dental unit waterlines (i.e.,
narrow-bore plastic tubing that carries water to the high-speed
handpiece, air/water syringe, and ultrasonic scaler) can become
colonized with microorganisms, including bacteria, fungi, and
protozoa (303–309). Protected by a polysaccharide slime layer
known as a glycocalyx, these microorganisms colonize and rep-
licate on the interior surfaces of the waterline tubing and form
a biofilm, which serves as a reservoir that can amplify the num-
ber of free-floating (i.e., planktonic) microorganisms in water
used for dental treatment. Although oral flora (303,310,311)
and human pathogens (e.g., Pseudomonas aeruginosa
[303,305,312,313], Legionella species [303,306,313], and
nontuberculous Mycobacterium species [303,304]), have been
isolated from dental water systems, the majority of organisms
recovered from dental waterlines are common heterotrophic
water bacteria (305,314,315). These exhibit limited patho-
genic potential for immunocompetent persons.
Clinical Implications
Certain reports associate waterborne infections with dental
water systems, and scientific evidence verifies the potential for
transmission of waterborne infections and disease in hospital
settings and in the community (306,312,316). Infection or
colonization caused by Pseudomonas species or nontuberculous
mycobacteria can occur among susceptible patients through
direct contact with water (317–320) or after exposure to
residual waterborne contamination of inadequately reprocessed
medical instruments (321–323). Nontuberculous mycobac-
teria can also be transmitted to patients from tap water aero-
sols (324). Health-care–associated transmission of pathogenic
agents (e.g., Legionella species) occurs primarily through inha-
lation of infectious aerosols generated from potable water
sources or through use of tap water in respiratory therapy equip-
ment (325–327). Disease outbreaks in the community have
also been reported from diverse environmental aerosol-
producing sources, including whirlpool spas (328), swimming
pools (329), and a grocery store mist machine (330). Although
the majority of these outbreaks are associated with species of
Legionella and Pseudomonas (329), the fungus Cladosporium
(331) has also been implicated.
Researchers have not demonstrated a measurable risk of
adverse health effects among DHCP or patients from expo-
sure to dental water. Certain studies determined DHCP had
altered nasal flora (332) or substantially greater titers of
Legionella antibodies in comparisons with control populations;
however, no cases of legionellosis were identified among
exposed DHCP (333,334). Contaminated dental water might
have been the source for localized Pseudomonas aeruginosa
infections in two immunocompromised patients (312).
Although transient carriage of P. aeruginosa was observed in
78 healthy patients treated with contaminated dental treat-
ment water, no illness was reported among the group. In this
same study, a retrospective review of dental records also failed
to identify infections (312).
Concentrations of bacterial endotoxin <1,000 endotoxin
units/mL from gram-negative water bacteria have been detected
in water from colonized dental units (335). No standards exist
for an acceptable level of endotoxin in drinking water, but the
maximum level permissible in United States Pharmacopeia
(USP) sterile water for irrigation is only 0.25 endotoxin units/
mL (336). Although the consequences of acute and chronic
exposure to aerosolized endotoxin in dental health-care set-
tings have not been investigated, endotoxin has been associ-
ated with exacerbation of asthma and onset of hypersensitivity
pneumonitis in other occupational settings (329,337).
Dental Unit Water Quality
Research has demonstrated that microbial counts can reach
<200,000 colony-forming units (CFU)/mL within 5 days
after installation of new dental unit waterlines (305), and lev-
els of microbial contamination <106 CFU/mL of dental unit
water have been documented (309,338). These counts can
occur because dental unit waterline factors (e.g., system design,
flow rates, and materials) promote both bacterial growth and
development of biofilm.
Although no epidemiologic evidence indicates a public health
problem, the presence of substantial numbers of pathogens in
dental unit waterlines generates concern. Exposing patients or
DHCP to water of uncertain microbiological quality, despite
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the lack of documented adverse health effects, is inconsistent
with accepted infection-control principles. Thus in 1995, ADA
addressed the dental water concern by asking manufacturers
to provide equipment with the ability to deliver treatment water
with <200 CFU/mL of unfiltered output from waterlines (339).
This threshold was based on the quality assurance standard
established for dialysate fluid, to ensure that fluid delivery sys-
tems in hemodialysis units have not been colonized by indig-
enous waterborne organisms (340).
Standards also exist for safe drinking water quality as estab-
lished by EPA, the American Public Health Association
(APHA), and the American Water Works Association
(AWWA); they have set limits for heterotrophic bacteria of
<500 CFU/mL of drinking water (341,342). Thus, the num-
ber of bacteria in water used as a coolant/irrigant for nonsur-
gical dental procedures should be as low as reasonably
achievable and, at a minimum, <500 CFU/mL, the regulatory
standard for safe drinking water established by EPA and APHA/
AWWA.
Strategies To Improve Dental
Unit Water Quality
In 1993, CDC recommended that dental waterlines be
flushed at the beginning of the clinic day to reduce the micro-
bial load (2). However, studies have demonstrated this prac-
tice does not affect biofilm in the waterlines or reliably improve
the quality of water used during dental treatment
(315,338,343). Because the recommended value of <500 CFU/
mL cannot be achieved by using this method, other strategies
should be employed. Dental unit water that remains untreated
or unfiltered is unlikely to meet drinking water standards (303–
309). Commercial devices and procedures designed to improve
the quality of water used in dental treatment are available (316);
methods demonstrated to be effective include self-contained
water systems combined with chemical treatment, in-line
microfilters, and combinations of these treatments. Simply
using source water containing <500 CFU/mL of bacteria (e.g.,
tap, distilled, or sterile water) in a self-contained water system
will not eliminate bacterial contamination in treatment water
if biofilms in the water system are not controlled. Removal or
inactivation of dental waterline biofilms requires use of chemi-
cal germicides.
Patient material (e.g., oral microorganisms, blood, and saliva)
can enter the dental water system during patient treatment
(311,344). Dental devices that are connected to the dental
water system and that enter the patient’s mouth (e.g.,
handpieces, ultrasonic scalers, or air/water syringes) should be
operated to discharge water and air for a minimum of 20–30
seconds after each patient (2). This procedure is intended to
physically flush out patient material that might have entered
the turbine, air, or waterlines. The majority of recently manu-
factured dental units are engineered to prevent retraction of
oral fluids, but some older dental units are equipped with
antiretraction valves that require periodic maintenance. Users
should consult the owner’s manual or contact the manufac-
turer to determine whether testing or maintenance of
antiretraction valves or other devices is required. Even with
antiretraction valves, flushing devices for a minimum of 20–
30 seconds after each patient is recommended.
Maintenance and Monitoring
of Dental Unit Water
DHCP should be trained regarding water quality, biofilm
formation, water treatment methods, and appropriate main-
tenance protocols for water delivery systems. Water treatment
and monitoring products require strict adherence to mainte-
nance protocols, and noncompliance with treatment regimens
has been associated with persistence of microbial contamina-
tion in treated systems (345). Clinical monitoring of water
quality can ensure that procedures are correctly performed and
that devices are working in accordance with the manufacturer’s
previously validated protocol.
Dentists should consult with the manufacturer of their dental
unit or water delivery system to determine the best method for
maintaining acceptable water quality (i.e., <500 CFU/mL) and
the recommended frequency of monitoring. Monitoring of den-
tal water quality can be performed by using commercial self-
contained test kits or commercial water-testing laboratories.
Because methods used to treat dental water systems target the
entire biofilm, no rationale exists for routine testing for such
specific organisms as Legionella or Pseudomonas, except when
investigating a suspected waterborne disease outbreak (244).
Delivery of Sterile Surgical Irrigation
Sterile solutions (e.g., sterile saline or sterile water) should be
used as a coolant/irrigation in the performance of oral surgical
procedures where a greater opportunity exists for entry of
microorganisms, exogenous and endogenous, into the vascular
system and other normally sterile areas that support the oral
cavity (e.g., bone or subcutaneous tissue) and increased poten-
tial exists for localized or systemic infection (see Oral Surgical
Procedures). Conventional dental units cannot reliably deliver
sterile water even when equipped with independent water res-
ervoirs because the water-bearing pathway cannot be reliably
sterilized. Delivery devices (e.g., bulb syringe or sterile, single-
use disposable products) should be used to deliver sterile water
(2,121). Oral surgery and implant handpieces, as well as ultra-
sonic scalers, are commercially available that bypass the dental
unit to deliver sterile water or other solutions by using single-
use disposable or sterilizable tubing (316).
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Boil-Water Advisories
A boil-water advisory is a public health announcement that
the public should boil tap water before drinking it. When
issued, the public should assume the water is unsafe to drink.
Advisories can be issued after 1) failure of or substantial inter-
ruption in water treatment processes that result in increased
turbidity levels or particle counts and mechanical or equip-
ment failure; 2) positive test results for pathogens (e.g.,
Cryptosporidium, Giardia, or Shigella) in water; 3) violations
of the total coliform rule or the turbidity standard of the sur-
face water treatment rule; 4) circumstances that compromise
the distribution system (e.g., watermain break) coupled with
an indication of a health hazard; or 5) a natural disaster (e.g.,
flood, hurricane, or earthquake) (346). In recent years,
increased numbers of boil-water advisories have resulted from
contamination of public drinking water systems with water-
borne pathogens. Most notable was the outbreak of
cryptosporidiosis in Milwaukee, Wisconsin, where the
municipal water system was contaminated with the protozoan
parasite Cryptosporidium parvum. An estimated 403,000 per-
sons became ill (347,348).
During a boil-water advisory, water should not be delivered
to patients through the dental unit, ultrasonic scaler, or other
dental equipment that uses the public water system. This
restriction does not apply if the water source is isolated from
the municipal water system (e.g., a separate water reservoir or
other water treatment device cleared for marketing by FDA).
Patients should rinse with bottled or distilled water until the
boil-water advisory has been cancelled. During these advisory
periods, tap water should not be used to dilute germicides or
for hand hygiene unless the water has been brought to a roll-
ing boil for >1 minute and cooled before use (346,349–351).
For hand hygiene, antimicrobial products that do not require
water (e.g., alcohol-based hand rubs) can be used until the
boil-water notice is cancelled. If hands are visibly contami-
nated, bottled water and soap should be used for handwashing;
if bottled water is not immediately available, an antiseptic
towelette should be used (13,122).
When the advisory is cancelled, the local water utility should
provide guidance for flushing of waterlines to reduce residual
microbial contamination. All incoming waterlines from the
public water system inside the dental office (e.g., faucets, water-
lines, and dental equipment) should be flushed. No consensus
exists regarding the optimal duration for flushing procedures
after cancellation of the advisory; recommendations range from
1 to 5 minutes (244,346,351,352). The length of time needed
can vary with the type and length of the plumbing system lead-
ing to the office. After the incoming public water system lines
are flushed, dental unit waterlines should be disinfected accord-
ing to the manufacturer’s instructions (346).
Special Considerations
Dental Handpieces and Other Devices
Attached to Air and Waterlines
Multiple semicritical dental devices that touch mucous mem-
branes are attached to the air or waterlines of the dental unit.
Among these devices are high- and low-speed handpieces, pro-
phylaxis angles, ultrasonic and sonic scaling tips, air abrasion
devices, and air and water syringe tips. Although no epide-
miologic evidence implicates these instruments in disease trans-
mission (353), studies of high-speed handpieces using dye
expulsion have confirmed the potential for retracting oral flu-
ids into internal compartments of the device (354–358). This
determination indicates that retained patient material can be
expelled intraorally during subsequent uses. Studies using labo-
ratory models also indicate the possibility for retention of viral
DNA and viable virus inside both high-speed handpieces and
prophylaxis angles (356,357,359). The potential for contami-
nation of the internal surfaces of other devices (e.g., low-speed
handpieces and ultrasonic scalers), has not been studied, but
restricted physical access limits their cleaning. Accordingly, any
dental device connected to the dental air/water system that
enters the patient’s mouth should be run to discharge water,
air, or a combination for a minimum of 20–30 seconds after
each patient (2). This procedure is intended to help physically
flush out patient material that might have entered the turbine
and air and waterlines (2,356,357).
Heat methods can sterilize dental handpieces and other in-
traoral devices attached to air or waterlines (246,275,356,
357,360). For processing any dental device that can be
removed from the dental unit air or waterlines, neither surface
disinfection nor immersion in chemical germicides is an
acceptable method. Ethylene oxide gas cannot adequately ster-
ilize internal components of handpieces (250,275). In clinical
evaluations of high-speed handpieces, cleaning and lubrica-
tion were the most critical factors in determining performance
and durability (361–363). Manufacturer’s instructions for
cleaning, lubrication, and sterilization should be followed
closely to ensure both the effectiveness of the process and the
longevity of handpieces.
Some components of dental instruments are permanently
attached to dental unit waterlines and although they do not
enter the patient’s oral cavity, they are likely to become con-
taminated with oral fluids during treatment procedures. Such
components (e.g., handles or dental unit attachments of saliva
ejectors, high-speed air evacuators, and air/water syringes)
should be covered with impervious barriers that are changed
after each use. If the item becomes visibly contaminated dur-
ing use, DHCP should clean and disinfect with an EPA-
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registered hospital disinfectant (intermediate-level) before use
on the next patient.
Saliva Ejectors
 Backflow from low-volume saliva ejectors occurs when the
pressure in the patient’s mouth is less than that in the evacua-
tor. Studies have reported that backflow in low-volume suc-
tion lines can occur and microorganisms be present in the lines
retracted into the patient’s mouth when a seal around the
saliva ejector is created (e.g., by a patient closing lips around
the tip of the ejector, creating a partial vacuum) (364–366).
This backflow can be a potential source of cross-contamina-
tion; occurrence is variable because the quality of the seal
formed varies between patients. Furthermore, studies have dem-
onstrated that gravity pulls fluid back toward the patient’s
mouth whenever a length of the suction tubing holding the
tip is positioned above the patient’s mouth, or during simulta-
neous use of other evacuation (high-volume) equipment (364–
366). Although no adverse health effects associated with the
saliva ejector have been reported, practitioners should be aware
that in certain situations, backflow could occur when using a
saliva ejector.
Dental Radiology
When taking radiographs, the potential to cross-contami-
nate equipment and environmental surfaces with blood or
saliva is high if aseptic technique is not practiced. Gloves should
be worn when taking radiographs and handling contaminated
film packets. Other PPE (e.g., mask, protective eyewear, and
gowns) should be used if spattering of blood or other body
fluids is likely (11,13,367). Heat-tolerant versions of intraoral
radiograph accessories are available and these semicritical items
(e.g., film-holding and positioning devices) should be heat-
sterilized before patient use.
After exposure of the radiograph and before glove removal,
the film should be dried with disposable gauze or a paper towel
to remove blood or excess saliva and placed in a container (e.g.,
disposable cup) for transport to the developing area. Alterna-
tively, if FDA-cleared film barrier pouches are used, the film
packets should be carefully removed from the pouch to avoid
contamination of the outside film packet and placed in the
clean container for transport to the developing area.
Various methods have been recommended for aseptic trans-
port of exposed films to the developing area, and for removing
the outer film packet before exposing and developing the film.
Other information regarding dental radiography infection
control is available (260,367,368). However, care should be
taken to avoid contamination of the developing equipment.
Protective barriers should be used, or any surfaces that
become contaminated should be cleaned and disinfected with
an EPA-registered hospital disinfectant of low- (i.e., HIV and
HBV claim) to intermediate-level (i.e., tuberculocidal claim)
activity. Radiography equipment (e.g., radiograph tubehead
and control panel) should be protected with surface barriers
that are changed after each patient. If barriers are not used,
equipment that has come into contact with DHCP’s gloved
hands or contaminated film packets should be cleaned and
then disinfected after each patient use.
Digital radiography sensors and other high-technology
instruments (e.g., intraoral camera, electronic periodontal
probe, occlusal analyzers, and lasers) come into contact with
mucous membranes and are considered semicritical devices.
They should be cleaned and ideally heat-sterilized or high-
level disinfected between patients. However, these items vary
by manufacturer or type of device in their ability to be steril-
ized or high-level disinfected. Semicritical items that cannot
be reprocessed by heat sterilization or high-level disinfection
should, at a minimum, be barrier protected by using an FDA-
cleared barrier to reduce gross contamination during use. Use
of a barrier does not always protect from contamination (369–
374). One study determined that a brand of commercially
available plastic barriers used to protect dental digital radiog-
raphy sensors failed at a substantial rate (44%). This rate
dropped to 6% when latex finger cots were used in conjunc-
tion with the plastic barrier (375). To minimize the potential
for device-associated infections, after removing the barrier, the
device should be cleaned and disinfected with an EPA-
registered hospital disinfectant (intermediate-level) after each
patient. Manufacturers should be consulted regarding appro-
priate barrier and disinfection/sterilization procedures for digi-
tal radiography sensors, other high-technology intraoral devices,
and computer components.
Aseptic Technique for Parenteral
Medications
Safe handling of parenteral medications and fluid infusion
systems is required to prevent health-care–associated infections
among patients undergoing conscious sedation. Parenteral
medications can be packaged in single-dose ampules, vials or
prefilled syringes, usually without bacteriostatic/preservative
agents, and intended for use on a single patient. Multidose
vials, used for more than one patient, can have a preservative,
but both types of containers of medication should be handled
with aseptic techniques to prevent contamination.
Single-dose vials should be used for parenteral medications
whenever possible (376,377). Single-dose vials might pose a
risk for contamination if they are punctured repeatedly. The
leftover contents of a single-dose vial should be discarded and
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never combined with medications for use on another patient
(376,377). Medication from a single-dose syringe should not
be administered to multiple patients, even if the needle on the
syringe is changed (378).
The overall risk for extrinsic contamination of multidose
vials is probably minimal, although the consequences of con-
tamination might result in life-threatening infection (379). If
necessary to use a multidose vial, its access diaphragm should
be cleansed with 70% alcohol before inserting a sterile device
into the vial (380,381). A multidose vial should be discarded
if sterility is compromised (380,381).
Medication vials, syringes, or supplies should not be carried
in uniform or clothing pockets. If trays are used to deliver
medications to individual patients, they should be cleaned
between patients. To further reduce the chance of contamina-
tion, all medication vials should be restricted to a centralized
medication preparation area separate from the treatment area
(382).
All fluid infusion and administration sets (e.g., IV bags, tub-
ing, and connections) are single-patient use because sterility
cannot be guaranteed when an infusion or administration set
is used on multiple patients. Aseptic technique should be used
when preparing IV infusion and administration sets, and
entry into or breaks in the tubing should be minimized (378).
Single-Use or Disposable Devices
A single-use device, also called a disposable device, is
designed to be used on one patient and then discarded, not
reprocessed for use on another patient (e.g., cleaned, disin-
fected, or sterilized) (383). Single-use devices in dentistry are
usually not heat-tolerant and cannot be reliably cleaned.
Examples include syringe needles, prophylaxis cups and
brushes, and plastic orthodontic brackets. Certain items (e.g.,
prophylaxis angles, saliva ejectors, high-volume evacuator tips,
and air/water syringe tips) are commonly available in a dispos-
able form and should be disposed of appropriately after each
use. Single-use devices and items (e.g., cotton rolls, gauze, and
irrigating syringes) for use during oral surgical procedures
should be sterile at the time of use.
Because of the physical construction of certain devices (e.g.,
burs, endodontic files, and broaches) cleaning can be difficult.
In addition, deterioration can occur on the cutting surfaces of
some carbide/diamond burs and endodontic files during pro-
cessing (384) and after repeated processing cycles, leading to
potential breakage during patient treatment (385–388). These
factors, coupled with the knowledge that burs and endodon-
tic instruments exhibit signs of wear during normal use, might
make it practical to consider them as single-use devices.
Preprocedural Mouth Rinses
Antimicrobial mouth rinses used by patients before a dental
procedure are intended to reduce the number of microorgan-
isms the patient might release in the form of aerosols or spat-
ter that subsequently can contaminate DHCP and equipment
operatory surfaces. In addition, preprocedural rinsing can
decrease the number of microorganisms introduced in the
patient’s bloodstream during invasive dental procedures
(389,390).
No scientific evidence indicates that preprocedural mouth
rinsing prevents clinical infections among DHCP or patients,
but studies have demonstrated that a preprocedural rinse with
an antimicrobial product (e.g., chlorhexidine gluconate,
essential oils, or povidone-iodine) can reduce the level of oral
microorganisms in aerosols and spatter generated during rou-
tine dental procedures with rotary instruments (e.g., dental
handpieces or ultrasonic scalers) (391–399). Preprocedural
mouth rinses can be most beneficial before a procedure that
requires using a prophylaxis cup or ultrasonic scaler because
rubber dams cannot be used to minimize aerosol and spatter
generation and, unless the provider has an assistant, high-
volume evacuation is not commonly used (173).
The science is unclear concerning the incidence and nature
of bacteremias from oral procedures, the relationship of these
bacteremias to disease, and the preventive benefit of antimi-
crobial rinses. In limited studies, no substantial benefit has
been demonstrated for mouth rinsing in terms of reducing
oral microorganisms in dental-induced bacteremias (400,401).
However, the American Heart Association’s recommendations
regarding preventing bacterial endocarditis during dental pro-
cedures (402) provide limited support concerning
preprocedural mouth rinsing with an antimicrobial as an
adjunct for patients at risk for bacterial endocarditis. Insuffi-
cient data exist to recommend preprocedural mouth rinses to
prevent clinical infections among patients or DHCP.
Oral Surgical Procedures
The oral cavity is colonized with numerous microorganisms.
Oral surgical procedures present an opportunity for entry of
microorganisms (i.e., exogenous and endogenous) into the
vascular system and other normally sterile areas of the oral
cavity (e.g., bone or subcutaneous tissue); therefore, an
increased potential exists for localized or systemic infection.
Oral surgical procedures involve the incision, excision, or
reflection of tissue that exposes the normally sterile areas of
the oral cavity. Examples include biopsy, periodontal surgery,
apical surgery, implant surgery, and surgical extractions of teeth
(e.g., removal of erupted or nonerupted tooth requiring eleva-
tion of mucoperiosteal flap, removal of bone or section of tooth,
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and suturing if needed) (see Hand Hygiene, PPE, Single Use
or Disposable Devices, and Dental Unit Water Quality).
Handling of Biopsy Specimens
To protect persons handling and transporting biopsy speci-
mens, each specimen must be placed in a sturdy, leakproof
container with a secure lid for transportation (13). Care should
be taken when collecting the specimen to avoid contaminat-
ing the outside of the container. If the outside of the container
becomes visibly contaminated, it should be cleaned and disin-
fected or placed in an impervious bag (2,13). The container
must be labeled with the biohazard symbol during storage,
transport, shipment, and disposal (13,14).
Handling of Extracted Teeth
Disposal
Extracted teeth that are being discarded are subject to the
containerization and labeling provisions outlined by OSHA’s
bloodborne pathogens standard (13). OSHA considers
extracted teeth to be potentially infectious material that should
be disposed in medical waste containers. Extracted teeth sent
to a dental laboratory for shade or size comparisons should be
cleaned, surface-disinfected with an EPA-registered hospital
disinfectant with intermediate-level activity (i.e., tuberculocidal
claim), and transported in a manner consistent with OSHA
regulations. However, extracted teeth can be returned to
patients on request, at which time provisions of the standard
no longer apply (14). Extracted teeth containing dental amal-
gam should not be placed in a medical waste container that
uses incineration for final disposal. Commercial metal-
recycling companies also might accept extracted teeth with
metal restorations, including amalgam. State and local regula-
tions should be consulted regarding disposal of the amalgam.
Educational Settings
Extracted teeth are occasionally collected for use in preclini-
cal educational training. These teeth should be cleaned of vis-
ible blood and gross debris and maintained in a hydrated state
in a well-constructed closed container during transport. The
container should be labeled with the biohazard symbol (13,14).
Because these teeth will be autoclaved before clinical exercises
or study, use of the most economical storage solution (e.g.,
water or saline) might be practical. Liquid chemical germi-
cides can also be used but do not reliably disinfect both exter-
nal surface and interior pulp tissue (403,404).
Before being used in an educational setting, the teeth should
be heat-sterilized to allow safe handling. Microbial growth can
be eliminated by using an autoclave cycle for 40 minutes (405),
but because preclinical educational exercises simulate clinical
experiences, students enrolled in dental programs should still
follow standard precautions. Autoclaving teeth for preclinical
laboratory exercises does not appear to alter their physical prop-
erties sufficiently to compromise the learning experience
(405,406). However, whether autoclave sterilization of
extracted teeth affects dentinal structure to the point that the
chemical and microchemical relationship between dental
materials and the dentin would be affected for research pur-
poses on dental materials is unknown (406).
Use of teeth that do not contain amalgam is preferred in
educational settings because they can be safely autoclaved
(403,405). Extracted teeth containing amalgam restorations
should not be heat-sterilized because of the potential health
hazard from mercury vaporization and exposure. If extracted
teeth containing amalgam restorations are to be used, immer-
sion in 10% formalin solution for 2 weeks should be effective
in disinfecting both the internal and external structures of the
teeth (403). If using formalin, manufacturer MSDS should be
reviewed for occupational safety and health concerns and to
ensure compliance with OSHA regulations (15).
Dental Laboratory
Dental prostheses, appliances, and items used in their fabri-
cation (e.g., impressions, occlusal rims, and bite registrations)
are potential sources for cross-contamination and should be
handled in a manner that prevents exposure of DHCP, patients,
or the office environment to infectious agents. Effective com-
munication and coordination between the laboratory and den-
tal practice will ensure that appropriate cleaning and
disinfection procedures are performed in the dental office or
laboratory, materials are not damaged or distorted because of
disinfectant overexposure, and effective disinfection procedures
are not unnecessarily duplicated (407,408).
When a laboratory case is sent off-site, DHCP should pro-
vide written information regarding the methods (e.g., type of
disinfectant and exposure time) used to clean and disinfect
the material (e.g., impression, stone model, or appliance)
(2,407,409). Clinical materials that are not decontaminated
are subject to OSHA and U.S. Department of Transportation
regulations regarding transportation and shipping of infectious
materials (13,410).
Appliances and prostheses delivered to the patient should
be free of contamination. Communication between the labo-
ratory and the dental practice is also key at this stage to deter-
mine which one is responsible for the final disinfection process.
If the dental laboratory staff provides the disinfection, an EPA-
registered hospital disinfectant (low to intermediate) should
be used, written documentation of the disinfection method
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provided, and the item placed in a tamper-evident container
before returning it to the dental office. If such documentation
is not provided, the dental office is responsible for final disin-
fection procedures.
Dental prostheses or impressions brought into the labora-
tory can be contaminated with bacteria, viruses, and fungi
(411,412). Dental prostheses, impressions, orthodontic
appliances, and other prosthodontic materials (e.g., occlusal
rims, temporary prostheses, bite registrations, or extracted
teeth) should be thoroughly cleaned (i.e., blood and bioburden
removed), disinfected with an EPA-registered hospital disin-
fectant with a tuberculocidal claim, and thoroughly rinsed
before being handled in the in-office laboratory or sent to an
off-site laboratory (2,244,249,407). The best time to clean
and disinfect impressions, prostheses, or appliances is as soon
as possible after removal from the patient’s mouth before dry-
ing of blood or other bioburden can occur. Specific guidance
regarding cleaning and disinfecting techniques for various
materials is available (260,413–416). DHCP are advised to
consult with manufacturers regarding the stability of specific
materials during disinfection.
In the laboratory, a separate receiving and disinfecting area
should be established to reduce contamination in the produc-
tion area. Bringing untreated items into the laboratory increases
chances for cross infection (260). If no communication has
been received regarding prior cleaning and disinfection of a
material, the dental laboratory staff should perform cleaning
and disinfection procedures before handling. If during
manipulation of a material or appliance a previously undetec-
ted area of blood or bioburden becomes apparent, cleaning
and disinfection procedures should be repeated. Transfer of
oral microorganisms into and onto impressions has been docu-
mented (417–419). Movement of these organisms onto den-
tal casts has also been demonstrated (420). Certain microbes
have been demonstrated to remain viable within gypsum cast
materials for <7 days (421). Incorrect handling of contami-
nated impressions, prostheses, or appliances, therefore, offers
an opportunity for transmission of microorganisms (260).
Whether in the office or laboratory, PPE should be worn until
disinfection is completed (1,2,7,10,13).
If laboratory items (e.g., burs, polishing points, rag wheels, or
laboratory knives) are used on contaminated or potentially con-
taminated appliances, prostheses, or other material, they should
be heat-sterilized, disinfected between patients, or discarded (i.e.,
disposable items should be used) (260,407). Heat-tolerant items
used in the mouth (e.g., metal impression tray or face bow fork)
should be heat-sterilized before being used on another patient
(2,407). Items that do not normally contact the patient, pros-
thetic device, or appliance but frequently become contaminated
and cannot withstand heat-sterilization (e.g., articulators, case
pans, or lathes) should be cleaned and disinfected between
patients and according to the manufacturer’s instructions. Pres-
sure pots and water baths are particularly susceptible to con-
tamination with microorganisms and should be cleaned and
disinfected between patients (422). In the majority of instances,
these items can be cleaned and disinfected with an EPA-
registered hospital disinfectant. Environmental surfaces should
be barrier-protected or cleaned and disinfected in the same man-
ner as in the dental treatment area.
Unless waste generated in the dental laboratory (e.g., dis-
posable trays or impression materials) falls under the category
of regulated medical waste, it can be discarded with general
waste. Personnel should dispose of sharp items (e.g., burs, dis-




During surgical procedures that use a laser or electrosurgical
unit, the thermal destruction of tissue creates a smoke
byproduct. Laser plumes or surgical smoke represent another
potential risk for DHCP (423–425). Lasers transfer electro-
magnetic energy into tissues, resulting in the release of a heated
plume that includes particles, gases (e.g., hydrogen cyanide,
benzene, and formaldehyde), tissue debris, viruses, and offen-
sive odors. One concern is that aerosolized infectious material
in the laser plume might reach the nasal mucosa of the laser
operator and adjacent DHCP. Although certain viruses (e.g.,
varicella-zoster virus and herpes simplex virus) appear not to
aerosolize efficiently (426,427), other viruses and various bac-
teria (e.g., human papilloma virus, HIV, coagulase-negative
Staphylococcus, Corynebacterium species, and Neisseria species)
have been detected in laser plumes (428–434). However, the
presence of an infectious agent in a laser plume might not be
sufficient to cause disease from airborne exposure, especially if
the agent’s normal mode of transmission is not airborne. No
evidence indicates that HIV or HBV have been transmitted
through aerosolization and inhalation (435). Although con-
tinuing studies are needed to evaluate the risk for DHCP of
laser plumes and electrosurgery smoke, following NIOSH rec-
ommendations (425) and practices developed by the Associa-
tion of periOperative Registered Nurses (AORN) might be
practical (436). These practices include using 1) standard pre-
cautions (e.g., high-filtration surgical masks and possibly full
face shields) (437); 2) central room suction units with in-line
filters to collect particulate matter from minimal plumes; and
3) dedicated mechanical smoke exhaust systems with a high-
efficiency filter to remove substantial amounts of laser plume
particles. Local smoke evacuation systems have been recom-
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mended by consensus organizations, and these systems can
improve the quality of the operating field. Employers should
be aware of this emerging problem and advise employees of
the potential hazards of laser smoke (438). However, this con-
cern remains unresolved in dental practice and no recommen-
dation is provided here.
M. tuberculosis
Patients infected with M. tuberculosis occasionally seek
urgent dental treatment at outpatient dental settings. Under-
standing the pathogenesis of the development of TB will help
DHCP determine how to manage such patients.
M. tuberculosis is a bacterium carried in airborne infective
droplet nuclei that can be generated when persons with pul-
monary or laryngeal TB sneeze, cough, speak, or sing (439).
These small particles (1–5 µm) can stay suspended in the air
for hours (440). Infection occurs when a susceptible person
inhales droplet nuclei containing M. tuberculosis, which then
travel to the alveoli of the lungs. Usually within 2–12 weeks
after initial infection with M. tuberculosis, immune response
prevents further spread of the TB bacteria, although they can
remain alive in the lungs for years, a condition termed latent
TB infection. Persons with latent TB infection usually exhibit
a reactive tuberculin skin test (TST), have no symptoms of
active disease, and are not infectious. However, they can
develop active disease later in life if they do not receive treat-
ment for their latent infection.
Approximately 5% of persons who have been recently
infected and not treated for latent TB infection will progress
from infection to active disease during the first 1–2 years after
infection; another 5% will develop active disease later in life.
Thus, approximately 90% of U.S. persons with latent TB
infection do not progress to active TB disease. Although both
latent TB infection and active TB disease are described as TB,
only the person with active disease is contagious and presents
a risk of transmission. Symptoms of active TB disease include
a productive cough, night sweats, fatigue, malaise, fever, and
unexplained weight loss. Certain immunocompromising medi-
cal conditions (e.g., HIV) increase the risk that TB infection
will progress to active disease at a faster rate (441).
Overall, the risk borne by DHCP for exposure to a patient
with active TB disease is probably low (20,21). Only one report
exists of TB transmission in a dental office (442), and TST con-
versions among DHCP are also low (443,444). However, in
certain cases, DHCP or the community served by the dental
facility might be at relatively high risk for exposure to TB.
Surgical masks do not prevent inhalation of M. tuberculosis
droplet nuclei, and therefore, standard precautions are not
sufficient to prevent transmission of this organism. Recom-
mendations for expanded precautions to prevent transmission
of M. tuberculosis and other organisms that can be spread by
airborne, droplet, or contact routes have been detailed in other
guidelines (5,11,20).
TB transmission is controlled through a hierarchy of mea-
sures, including administrative controls, environmental con-
trols, and personal respiratory protection. The main
administrative goals of a TB infection-control program are early
detection of a person with active TB disease and prompt isola-
tion from susceptible persons to reduce the risk of transmis-
sion. Although DHCP are not responsible for diagnosis and
treatment of TB, they should be trained to recognize signs and
symptoms to help with prompt detection. Because potential
for transmission of M. tuberculosis exists in outpatient settings,
dental practices should develop a TB control program appro-
priate for their level of risk (20,21).
• A community risk assessment should be conducted peri-
odically, and TB infection-control policies for each dental
setting should be based on the risk assessment. The poli-
cies should include provisions for detection and referral
of patients who might have undiagnosed active TB; man-
agement of patients with active TB who require urgent
dental care; and DHCP education, counseling, and TST
screening.
• DHCP who have contact with patients should have a
baseline TST, preferably by using a two-step test at the
beginning of employment. The facility’s level of TB risk
will determine the need for routine follow-up TST.
• While taking patients’ initial medical histories and at
periodic updates, dental DHCP should routinely ask all
patients whether they have a history of TB disease or symp-
toms indicative of TB.
• Patients with a medical history or symptoms indicative of
undiagnosed active TB should be referred promptly for
medical evaluation to determine possible infectiousness.
Such patients should not remain in the dental-care facil-
ity any longer than required to evaluate their dental con-
dition and arrange a referral. While in the dental
health-care facility, the patient should be isolated from
other patients and DHCP, wear a surgical mask when not
being evaluated, or be instructed to cover their mouth and
nose when coughing or sneezing.
• Elective dental treatment should be deferred until a phy-
sician confirms that a patient does not have infectious TB,
or if the patient is diagnosed with active TB disease, until
confirmed the patient is no longer infectious.
• If urgent dental care is provided for a patient who has, or
is suspected of having active TB disease, the care should
be provided in a facility (e.g., hospital) that provides air-
borne infection isolation (i.e., using such engineering con-
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trols as TB isolation rooms, negatively pressured relative
to the corridors, with air either exhausted to the outside
or HEPA-filtered if recirculation is necessary). Standard
surgical face masks do not protect against TB transmis-
sion; DHCP should use respiratory protection (e.g., fit-
tested, disposable N-95 respirators).
• Settings that do not require use of respiratory protection
because they do not treat active TB patients and do not
perform cough-inducing procedures on potential active
TB patients do not need to develop a written respiratory
protection program.
• Any DHCP with a persistent cough (i.e., lasting >3 weeks),
especially in the presence of other signs or symptoms com-
patible with active TB (e.g., weight loss, night sweats,
fatigue, bloody sputum, anorexia, or fever), should be
evaluated promptly. The DHCP should not return to the
workplace until a diagnosis of TB has been excluded or
the DHCP is on therapy and a physician has determined
that the DHCP is noninfectious.
Creutzfeldt-Jakob Disease and Other
Prion Diseases
 Creutzfeldt-Jakob disease (CJD) belongs to a group of rap-
idly progressive, invariably fatal, degenerative neurological dis-
orders, transmissible spongiform encephalopathies (TSEs) that
affect both humans and animals and are thought to be caused
by infection with an unusual pathogen called a prion. Prions
are isoforms of a normal protein, capable of self-propagation
although they lack nucleic acid. Prion diseases have an incu-
bation period of years and are usually fatal within 1 year of
diagnosis.
Among humans, TSEs include CJD, Gerstmann-Straussler-
Scheinker syndrome, fatal familial insomnia, kuru, and vari-
ant CJD (vCJD). Occurring in sporadic, familial, and acquired
(i.e., iatrogenic) forms, CJD has an annual incidence in the
United States and other countries of approximately 1 case/
million population (445–448). In approximately 85% of
affected patients, CJD occurs as a sporadic disease with no
recognizable pattern of transmission. A smaller proportion of
patients (5%–15%) experience familial CJD because of inher-
ited mutations of the prion protein gene (448).
vCJD is distinguishable clinically and neuropathologically
from classic CJD, and strong epidemiologic and laboratory
evidence indicates a causal relationship with bovine spongiform
encephalopathy (BSE), a progressive neurological disorder of
cattle commonly known as mad cow disease (449–451). vCJD,
was reported first in the United Kingdom in 1996 (449) and
subsequently in other European countries (452). Only one
case of vCJD has been reported in the United States, in an
immigrant from the United Kingdom (453). Compared with
CJD patients, those with vCJD are younger (28 years versus
68 years median age at death), and have a longer duration of
illness (13 months versus 4.5 months). Also, vCJD patients
characteristically exhibit sensory and psychiatric symptoms that
are uncommon with CJD. Another difference includes the ease
with which the presence of prions is consistently demonstrated
in lymphoreticular tissues (e.g., tonsil) in vCJD patients by
immunohistochemistry (454).
CJD and vCJD are transmissible diseases, but not through
the air or casual contact. All known cases of iatrogenic CJD
have resulted from exposure to infected central nervous tissue
(e.g., brain and dura mater), pituitary, or eye tissue. Studies in
experimental animals have determined that other tissues have
low or no detectable infectivity (243,455,456). Limited
experimental studies have demonstrated that scrapie (a TSE in
sheep) can be transmitted to healthy hamsters and mice by
exposing oral tissues to infectious homogenate (457,458).
These animal models and experimental designs might not be
directly applicable to human transmission and clinical den-
tistry, but they indicate a theoretical risk of transmitting prion
diseases through perioral exposures.
According to published reports, iatrogenic transmission of
CJD has occurred in humans under three circumstances: after
use of contaminated electroencephalography depth electrodes
and neurosurgical equipment (459); after use of extracted
pituitary hormones (460,461); and after implant of contami-
nated corneal (462) and dura mater grafts (463,464) from
humans. The equipment-related cases occurred before the rou-
tine implementation of sterilization procedures used in health-
care facilities.
Case-control studies have found no evidence that dental
procedures increase the risk of iatrogenic transmission of TSEs
among humans. In these studies, CJD transmission was not
associated with dental procedures (e.g., root canals or extrac-
tions), with convincing evidence of prion detection in human
blood, saliva, or oral tissues, or with DHCP becoming occu-
pationally infected with CJD (465–467). In 2000, prions were
not found in the dental pulps of eight patients with
neuropathologically confirmed sporadic CJD by using elec-
trophoresis and a Western blot technique (468).
Prions exhibit unusual resistance to conventional chemical
and physical decontamination procedures. Considering this
resistance and the invariably fatal outcome of CJD, procedures
for disinfecting and sterilizing instruments potentially con-
taminated with the CJD prion have been controversial for years.
Scientific data indicate the risk, if any, of sporadic CJD trans-
mission during dental and oral surgical procedures is low to
nil. Until additional information exists regarding the trans-
missibility of CJD or vCJD, special precautions in addition to
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standard precautions might be indicated when treating known
CJD or vCJD patients; the following list of precautions is pro-
vided for consideration without recommendation
(243,249,277,469):
• Use single-use disposable items and equipment whenever
possible.
• Consider items difficult to clean (e.g., endodontic files,
broaches, and carbide and diamond burs) as single-use
disposables and discard after one use.
• To minimize drying of tissues and body fluids on a device,
keep the instrument moist until cleaned and decontaminated.
• Clean instruments thoroughly and steam-autoclave at 134ºC
for 18 minutes. This is the least stringent of sterilization
methods offered by the World Health Organization. The
complete list (469) is available at http://www.who.int/emc-
documents/tse/whocdscsraph2003c.html.
• Do not use flash sterilization for processing instruments
or devices.
Potential infectivity of oral tissues in CJD or vCJD patients is
an unresolved concern. CDC maintains an active surveillance
program on CJD. Additional information and resources are
available at http://www.cdc.gov/ncidod/diseases/cjd/cjd.htm.
Program Evaluation
The goal of a dental infection-control program is to provide
a safe working environment that will reduce the risk of health-
care–associated infections among patients and occupational
exposures among DHCP. Medical errors are caused by faulty
systems, processes, and conditions that lead persons to make
mistakes or fail to prevent errors being made by others (470).
Effective program evaluation is a systematic way to ensure pro-
cedures are useful, feasible, ethical, and accurate. Program evalu-
ation is an essential organizational practice; however, such
evaluation is not practiced consistently across program areas,
nor is it sufficiently well-integrated into the day-to-day man-
agement of the majority of programs (471).
A successful infection-control program depends on develop-
ing standard operating procedures, evaluating practices, routinely
documenting adverse outcomes (e.g., occupational exposures
to blood) and work-related illnesses in DHCP, and monitoring
health-care–associated infections in patients. Strategies and tools
to evaluate the infection-control program can include periodic
observational assessments, checklists to document procedures,
and routine review of occupational exposures to bloodborne
pathogens. Evaluation offers an opportunity to improve the
effectiveness of both the infection-control program and dental-
practice protocols. If deficiencies or problems in the implemen-
tation of infection-control procedures are identified, further
evaluation is needed to eliminate the problems. Examples of
infection-control program evaluation activities are provided
(Table 5).
TABLE 5. Examples of methods for evaluating infection-control programs
Evaluation activity
Conduct annual review of personnel records to ensure up-to-date immunizations.
Report occupational exposures to infectious agents. Document the steps that
occurred around the exposure and plan how such exposure can be prevented in
the future.
Ensure the postexposure management plan is clear, complete, and available at all
times to all DHCP. All staff should understand the plan, which should include toll-
free phone numbers for access to additional information.
Observe and document circumstances of appropriate or inappropriate
handwashing. Review findings in a staff meeting.
Observe and document the use of barrier precautions and careful handling of
sharps. Review findings in a staff meeting.
Monitor paper log of steam cycle and temperature strip with each sterilization load,
and examine results of weekly biologic monitoring. Take appropriate action when
failure of sterilization process is noted.
Conduct an annual review of the exposure control plan and consider new
developments in safer medical devices.
Monitor dental water quality as recommended by the equipment manufacturer,
using commercial self-contained test kits, or commercial water-testing laboratories.
Observe the safe disposal of regulated and nonregulated medical waste and take
preventive measures if hazardous situations occur.
Assess the unscheduled return of patients after procedures and evaluate them for
an infectious process. A trend might require formal evaluation.
Program element
Appropriate immunization of dental health-care personnel (DHCP).
Assessment of occupational exposures to infectious agents.
Comprehensive postexposure management plan and medical follow-up program
after occupational exposures to infectious agents.
Adherence to hand hygiene before and after patient care.
Proper use of personal protective equipment to prevent occupational exposures to
infectious agents.
Routine and appropriate sterilization of instruments using a biologic monitoring
system.
Evaluation and implementation of safer medical devices.
Compliance of water in routine dental procedures with current drinking U.S.
Environmental Protection Agency water standards (fewer than 500 CFU of
heterotrophic water bacteria).
Proper handling and disposal of medical waste.
Health-care–associated infections.
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Infection-Control Research
Considerations
Although the number of published studies concerning den-
tal infection control has increased in recent years, questions
regarding infection-control practices and their effectiveness
remain unanswered. Multiple concerns were identified by the
working group for this report, as well as by others during the
BOX. Dental infection-control research considerations
Education and promotion
• Design strategies to communicate, to the public and providers, the risk of disease transmission in dentistry.
• Promote use of protocols for recommended postexposure management and follow-up.
• Educate and train dental health-care personnel (DHCP) to screen and evaluate safer dental devices by using tested design
and performance criteria.
Laboratory-based research
• Develop animal models to determine the risk of transmitting organisms through inhalation of contaminated aerosols (e.g.,
influenza) produced from rotary dental instruments.
• Conduct studies to determine the effectiveness of gloves (i.e., material compatibility and duration of use).
• Develop devices with passive safety features to prevent percutaneous injuries.
• Study the effect of alcohol-based hand-hygiene products on retention of latex proteins and other dental allergens (e.g.,
methylmethacrylate, glutaraldehyde, thiurams) on the hands of DHCP after latex glove use.
• Investigate the applicability of other types of sterilization procedures (e.g., hydrogen peroxide gas plasma) in dentistry.
• Encourage manufacturers to determine optimal methods and frequency for testing dental-unit waterlines and maintaining
dental-unit water-quality standards.
• Determine the potential for internal contamination of low-speed handpieces, including the motor, and other devices con-
nected to dental air and water supplies, as well as more efficient ways to clean, lubricate, and sterilize handpieces and other
devices attached to air or waterlines.
• Investigate the infectivity of oral tissues in Creutzfeldt-Jakob disease (CJD) or variant CJD patients.
• Determine the most effective methods to disinfect dental impression materials.
• Investigate the viability of pathogenic organisms on dental materials (e.g., impression materials, acrylic resin, or gypsum
materials) and dental laboratory equipment.
• Determine the most effective methods for sterilization or disinfection of digital radiology equipment.
• Evaluate the effects of repetitive reprocessing cycles on burs and endodontic files.
• Investigate the potential infectivity of vapors generated from the various lasers used for oral procedures.
Clinical and population-based epidemiologic research and development
• Continue to characterize the epidemiology of blood contacts, particularly percutaneous injuries, and the effectiveness of
prevention measures.
• Further assess the effectiveness of double gloving in preventing blood contact during routine and surgical dental procedures.
• Continue to assess the stress placed on gloves during dental procedures and the potential for developing defects during
different procedures.
• Develop methods for evaluating the effectiveness and cost-effectiveness of infection-control interventions.
• Determine how infection-control guidelines affect the knowledge, attitudes, and practices of DHCP.
public comment period (Box). This list is not exhaustive and
does not represent a CDC research agenda, but rather is an
effort to identify certain concerns, stimulate discussion, and
provide direction for determining future action by clinical,
basic science, and epidemiologic investigators, as well as health
and professional organizations, clinicians, and policy makers.
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Recommendations
Each recommendation is categorized on the basis of existing
scientific data, theoretical rationale, and applicability. Rankings
are based on the system used by CDC and the Healthcare
Infection Control Practices Advisory Committee (HICPAC)
to categorize recommendations:
Category IA. Strongly recommended for implementation
and strongly supported by well-designed experimental, clini-
cal, or epidemiologic studies.
Category IB. Strongly recommended for implementation
and supported by experimental, clinical, or epidemiologic stud-
ies and a strong theoretical rationale.
Category IC. Required for implementation as mandated
by federal or state regulation or standard. When IC is used, a
second rating can be included to provide the basis of existing
scientific data, theoretical rationale, and applicability. Because
of state differences, the reader should not assume that the
absence of a IC implies the absence of state regulations.
Category II. Suggested for implementation and supported
by suggestive clinical or epidemiologic studies or a theoretical
rationale.
Unresolved issue. No recommendation. Insufficient evi-
dence or no consensus regarding efficacy exists.
I. Personnel Health Elements of an Infection-Control
Program
A. General Recommendations
1. Develop a written health program for DHCP
that includes policies, procedures, and guidelines
for education and training; immunizations;
exposure prevention and postexposure manage-
ment; medical conditions, work-related illness,
and associated work restrictions; contact derma-
titis and latex hypersensitivity; and maintenance
of records, data management, and confidential-
ity (IB) (5,16–18,22).
2. Establish referral arrangements with qualified
health-care professionals to ensure prompt and
appropriate provision of preventive services,
occupationally related medical services, and
postexposure management with medical follow-
up (IB, IC) (5,13,19,22).
B. Education and Training
1. Provide DHCP 1) on initial employment,
2) when new tasks or procedures affect the
employee’s occupational exposure, and 3) at a
minimum, annually, with education and train-
ing regarding occupational exposure to poten-
tially infectious agents and infection-control
procedures/protocols appropriate for and spe-
cific to their assigned duties (IB, IC) (5,11,13,
14,16,19,22).
2. Provide educational information appropriate in
content and vocabulary to the educational level,
literacy, and language of DHCP (IB, IC) (5,13).
C. Immunization Programs
1. Develop a written comprehensive policy regard-
ing immunizing DHCP, including a list of all
required and recommended immunizations (IB)
(5,17,18).
2. Refer DHCP to a prearranged qualified health-
care professional or to their own health-care pro-
fessional to receive all appropriate immunizations
based on the latest recommendations as well as
their medical history and risk for occupational
exposure (IB) (5,17).
D. Exposure Prevention and Postexposure Manage-
ment
1. Develop a comprehensive postexposure manage-
ment and medical follow-up program (IB, IC)
(5,13,14,19).
a. Include policies and procedures for prompt
reporting, evaluation, counseling, treatment,
and medical follow-up of occupational
exposures.
b. Establish mechanisms for referral to a quali-
fied health-care professional for medical
evaluation and follow-up.
c. Conduct a baseline TST, preferably by
using a two-step test, for all DHCP who
might have contact with persons with sus-
pected or confirmed infectious TB, regard-
less of the risk classification of the setting
(IB) (20).
E. Medical Conditions, Work-Related Illness, and
Work Restrictions
1. Develop and have readily available to all DHCP
comprehensive written policies regarding work
restriction and exclusion that include a statement
of authority defining who can implement such
policies (IB) (5,22).
2. Develop policies for work restriction and exclu-
sion that encourage DHCP to seek appropriate
preventive and curative care and report their
illnesses, medical conditions, or treatments that
can render them more susceptible to opportu-
nistic infection or exposures; do not penalize
DHCP with loss of wages, benefits, or job sta-
tus (IB) (5,22).
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3. Develop policies and procedures for evaluation,
diagnosis, and management of DHCP with sus-
pected or known occupational contact dermati-
tis (IB) (32).
4. Seek definitive diagnosis by a qualified health-
care professional for any DHCP with suspected
latex allergy to carefully determine its specific
etiology and appropriate treatment as well as
work restrictions and accommodations (IB) (32).
F. Records Maintenance, Data Management, and
Confidentiality
1. Establish and maintain confidential medical
records (e.g., immunization records and docu-
mentation of tests received as a result of occupa-
tional exposure) for all DHCP (IB, IC) (5,13).
2. Ensure that the practice complies with all appli-
cable federal, state, and local laws regarding
medical recordkeeping and confidentiality (IC)
(13,34).
II. Preventing Transmission of Bloodborne Pathogens
A. HBV Vaccination
1. Offer the HBV vaccination series to all DHCP
with potential occupational exposure to blood
or other potentially infectious material (IA, IC)
(2,13,14,19).
2. Always follow U.S. Public Health Service/CDC
recommendations for hepatitis B vaccination,
serologic testing, follow-up, and booster dosing
(IA, IC) (13,14,19).
3. Test DHCP for anti-HBs 1–2 months after
completion of the 3-dose vaccination series (IA,
IC) (14,19).
4. DHCP should complete a second 3-dose vac-
cine series or be evaluated to determine if they
are HBsAg-positive if no antibody response
occurs to the primary vaccine series (IA, IC)
(14,19).
5. Retest for anti-HBs at the completion of the sec-
ond vaccine series. If no response to the second
3-dose series occurs, nonresponders should be
tested for HBsAg (IC) (14,19).
6. Counsel nonresponders to vaccination who are
HBsAg-negative regarding their susceptibility to
HBV infection and precautions to take (IA, IC)
(14,19).
7. Provide employees appropriate education regard-
ing the risks of HBV transmission and the avail-
ability of the vaccine. Employees who decline
the vaccination should sign a declination form
to be kept on file with the employer (IC) (13).
B. Preventing Exposures to Blood and OPIM
1. General recommendations
a. Use standard precautions (OSHA’s blood-
borne pathogen standard retains the term
universal precautions) for all patient encoun-
ters (IA, IC) (11,13,19,53).
b. Consider sharp items (e.g., needles, scalers,
burs, lab knives, and wires) that are contami-
nated with patient blood and saliva as
potentially infective and establish engineer-
ing controls and work practices to prevent
injuries (IB, IC) (6,13,113).
c. Implement a written, comprehensive pro-
gram designed to minimize and manage
DHCP exposures to blood and body fluids
(IB, IC). (13,14,19,97).
2. Engineering and work-practice controls
a. Identify, evaluate, and select devices with
engineered safety features at least annually
and as they become available on the market
(e.g., safer anesthetic syringes, blunt suture
needle, retractable scalpel, or needleless IV
systems) (IC) (13,97,110–112).
b. Place used disposable syringes and needles,
scalpel blades, and other sharp items in
appropriate puncture-resistant containers
located as close as feasible to the area in which
the items are used (IA, IC) (2,7,13,19,113,
115).
c. Do not recap used needles by using both
hands or any other technique that involves
directing the point of a needle toward any
part of the body. Do not bend, break, or
remove needles before disposal (IA, IC)
(2,7,8,13,97,113).
d. Use either a one-handed scoop technique or
a mechanical device designed for holding the
needle cap when recapping needles (e.g.,
between multiple injections and before
removing from a nondisposable aspirating
syringe) (IA, IC) (2,7,8,13,14,113).
3. Postexposure management and prophylaxis
a. Follow CDC recommendations after percu-
taneous, mucous membrane, or nonintact
skin exposure to blood or other potentially
infectious material (IA, IC) (13,14,19).
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III. Hand Hygiene
A. General Considerations
1. Perform hand hygiene with either a
nonantimicrobial or antimicrobial soap and
water when hands are visibly dirty or contami-
nated with blood or other potentially infectious
material. If hands are not visibly soiled, an alco-
hol-based hand rub can also be used. Follow the
manufacturer’s instructions (IA) (123).
2. Indications for hand hygiene include
a. when hands are visibly soiled (IA, IC);
b. after barehanded touching of inanimate
objects likely to be contaminated by blood,
saliva, or respiratory secretions (IA, IC);
c. before and after treating each patient (IB);
d. before donning gloves (IB); and
e. immediately after removing gloves (IB, IC)
(7–9,11,13,113,120–123,125,126,138).
3. For oral surgical procedures, perform surgical
hand antisepsis before donning sterile surgeon’s
gloves. Follow the manufacturer’s instructions by
using either an antimicrobial soap and water, or
soap and water followed by drying hands and
application of an alcohol-based surgical hand-
scrub product with persistent activity (IB) (121–
123,127–133,144,145).
4. Store liquid hand-care products in either dispos-
able closed containers or closed containers that
can be washed and dried before refilling. Do not
add soap or lotion to (i.e., top off ) a partially
empty dispenser (IA) (9,120,122,149,150).
B. Special Considerations for Hand Hygiene and
Glove Use
1. Use hand lotions to prevent skin dryness associ-
ated with handwashing (IA) (153,154).
2. Consider the compatibility of lotion and anti-
septic products and the effect of petroleum or
other oil emollients on the integrity of gloves
during product selection and glove use (IB)
(2,14,122,155).
3. Keep fingernails short with smooth, filed edges
to allow thorough cleaning and prevent glove
tears (II) (122,123,156).
4. Do not wear artificial fingernails or extenders
when having direct contact with patients at high
risk (e.g., those in intensive care units or operat-
ing rooms) (IA) (123,157–160).
5. Use of artificial fingernails is usually not recom-
mended (II) (157–160).
6. Do not wear hand or nail jewelry if it makes
donning gloves more difficult or compromises
the fit and integrity of the glove (II) (123,142,
143).
IV. PPE
A. Masks, Protective Eyewear, and Face Shields
1. Wear a surgical mask and eye protection with
solid side shields or a face shield to protect
mucous membranes of the eyes, nose, and mouth
during procedures likely to generate splashing
or spattering of blood or other body fluids (IB,
IC) (1,2,7,8,11,13,137).
2. Change masks between patients or during
patient treatment if the mask becomes wet (IB)
(2).
3. Clean with soap and water, or if visibly soiled,
clean and disinfect reusable facial protective
equipment (e.g., clinician and patient protec-
tive eyewear or face shields) between patients (II)
(2).
B. Protective Clothing
1. Wear protective clothing (e.g., reusable or dis-
posable gown, laboratory coat, or uniform) that
covers personal clothing and skin (e.g., forearms)
likely to be soiled with blood, saliva, or OPIM
(IB, IC) (7,8,11,13,137).
2. Change protective clothing if visibly soiled (134);
change immediately or as soon as feasible if pen-
etrated by blood or other potentially infectious
fluids (IB, IC) (13).
3. Remove barrier protection, including gloves,
mask, eyewear, and gown before departing work
area (e.g., dental patient care, instrument pro-
cessing, or laboratory areas) (IC) (13).
C. Gloves
1. Wear medical gloves when a potential exists for
contacting blood, saliva, OPIM, or mucous
membranes (IB, IC) (1,2,7,8,13).
2. Wear a new pair of medical gloves for each
patient, remove them promptly after use, and
wash hands immediately to avoid transfer of
microorganisms to other patients or environ-
ments (IB) (1,7,8,123).
3. Remove gloves that are torn, cut, or punctured
as soon as feasible and wash hands before
regloving (IB, IC) (13,210,211).
4. Do not wash surgeon’s or patient examination
gloves before use or wash, disinfect, or sterilize
gloves for reuse (IB, IC) (13,138,177,212,213).
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5. Ensure that appropriate gloves in the correct size
are readily accessible (IC) (13).
6. Use appropriate gloves (e.g., puncture- and
chemical-resistant utility gloves) when cleaning
instruments and performing housekeeping tasks
involving contact with blood or OPIM (IB, IC)
(7,13,15).
7. Consult with glove manufacturers regarding the
chemical compatibility of glove material and
dental materials used (II).
D. Sterile Surgeon’s Gloves and Double Gloving
During Oral Surgical Procedures
1. Wear sterile surgeon’s gloves when performing
oral surgical procedures (IB) (2,8,137).
2. No recommendation is offered regarding the
effectiveness of wearing two pairs of gloves to
prevent disease transmission during oral surgi-
cal procedures. The majority of studies among
HCP and DHCP have demonstrated a lower fre-
quency of inner glove perforation and visible
blood on the surgeon’s hands when double gloves
are worn; however, the effectiveness of wearing
two pairs of gloves in preventing disease trans-
mission has not been demonstrated (Unresolved
issue).
V. Contact Dermatitis and Latex Hypersensitivity
A. General Recommendations
1. Educate DHCP regarding the signs, symptoms,
and diagnoses of skin reactions associated with fre-
quent hand hygiene and glove use (IB) (5,31,32).
2. Screen all patients for latex allergy (e.g., take
health history and refer for medical consulta-
tion when latex allergy is suspected) (IB) (32).
3. Ensure a latex-safe environment for patients and
DHCP with latex allergy (IB) (32).
4. Have emergency treatment kits with latex-free
products available at all times (II) (32).
VI. Sterilization and Disinfection of Patient-Care Items
A. General Recommendations
1. Use only FDA-cleared medical devices for ster-
ilization and follow the manufacturer’s instruc-
tions for correct use (IB) (248).
2. Clean and heat-sterilize critical dental instru-
ments before each use (IA) (2,137,243,244,
246,249,407).
3. Clean and heat-sterilize semicritical items before
each use (IB) (2,249,260,407).
4. Allow packages to dry in the sterilizer before they
are handled to avoid contamination (IB) (247).
5. Use of heat-stable semicritical alternatives is
encouraged (IB) (2).
6. Reprocess heat-sensitive critical and semi-criti-
cal instruments by using FDA-cleared sterilant/
high-level disinfectants or an FDA-cleared low-
temperature sterilization method (e.g., ethylene
oxide). Follow manufacturer’s instructions for use
of chemical sterilants/high-level disinfectants
(IB) (243).
7. Single-use disposable instruments are acceptable
alternatives if they are used only once and dis-
posed of correctly (IB, IC) (243,383).
8. Do not use liquid chemical sterilants/high-level
disinfectants for environmental surface disinfec-
tion or as holding solutions (IB, IC) (243,245).
9. Ensure that noncritical patient-care items are
barrier-protected or cleaned, or if visibly soiled,
cleaned and disinfected after each use with an
EPA-registered hospital disinfectant. If visibly
contaminated with blood, use an EPA-registered
hospital disinfectant with a tuberculocidal claim
(i.e., intermediate level) (IB) (2,243,244).
10. Inform DHCP of all OSHA guidelines for
exposure to chemical agents used for disinfec-
tion and sterilization. Using this report, identify
areas and tasks that have potential for exposure
(IC) (15).
B. Instrument Processing Area
1. Designate a central processing area. Divide the
instrument processing area, physically or, at a
minimum, spatially, into distinct areas for
1) receiving, cleaning, and decontamination;
2) preparation and packaging; 3) sterilization;
and 4) storage. Do not store instruments in an
area where contaminated instruments are held
or cleaned (II) (173,247,248).
2. Train DHCP to employ work practices that pre-
vent contamination of clean areas (II).
C. Receiving, Cleaning, and Decontamination Work
Area
1. Minimize handling of loose contaminated
instruments during transport to the instrument
processing area. Use work-practice controls (e.g.,
carry instruments in a covered container) to
minimize exposure potential (II). Clean all vis-
ible blood and other contamination from den-
tal instruments and devices before sterilization
or disinfection procedures (IA) (243,249–252).
2. Use automated cleaning equipment (e.g., ultra-
sonic cleaner or washer-disinfector) to remove
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debris to improve cleaning effectiveness and
decrease worker exposure to blood (IB) (2,253).
3. Use work-practice controls that minimize con-
tact with sharp instruments if manual cleaning
is necessary (e.g., long-handled brush) (IC) (14).
4. Wear puncture- and chemical-resistant/heavy-
duty utility gloves for instrument cleaning and
decontamination procedures (IB) (7).
5. Wear appropriate PPE (e.g., mask, protective
eyewear, and gown) when splashing or spraying
is anticipated during cleaning (IC) (13).
D. Preparation and Packaging
1. Use an internal chemical indicator in each pack-
age. If the internal indicator cannot be seen from
outside the package, also use an external indica-
tor (II) (243,254,257).
2. Use a container system or wrapping compatible
with the type of sterilization process used and
that has received FDA clearance (IB) (243,247,
256).
3. Before sterilization of critical and semicritical
instruments, inspect instruments for cleanliness,
then wrap or place them in containers designed
to maintain sterility during storage (e.g., cassettes
and organizing trays) (IA) (2,247,255,256).
E. Sterilization of Unwrapped Instruments
1. Clean and dry instruments before the unwrapped
sterilization cycle (IB) (248).
2. Use mechanical and chemical indicators for each
unwrapped sterilization cycle (i.e., place an
internal chemical indicator among the instru-
ments or items to be sterilized) (IB) (243,258).
3. Allow unwrapped instruments to dry and cool
in the sterilizer before they are handled to avoid
contamination and thermal injury (II) (260).
4. Semicritical instruments that will be used
immediately or within a short time can be ster-
ilized unwrapped on a tray or in a container sys-
tem, provided that the instruments are handled
aseptically during removal from the sterilizer and
transport to the point of use (II).
5. Critical instruments intended for immediate
reuse can be sterilized unwrapped if the instru-
ments are maintained sterile during removal from
the sterilizer and transport to the point of use
(e.g., transported in a sterile covered container)
(IB) (258).
6. Do not sterilize implantable devices unwrapped
(IB) (243,247).
7. Do not store critical instruments unwrapped (IB)
(248).
F. Sterilization Monitoring
1. Use mechanical, chemical, and biological moni-
tors according to the manufacturer’s instructions
to ensure the effectiveness of the sterilization
process (IB) (248,278,279).
2. Monitor each load with mechanical (e.g., time,
temperature, and pressure) and chemical indi-
cators (II) (243,248).
3. Place a chemical indicator on the inside of each
package. If the internal indicator is not visible
from the outside, also place an exterior chemi-
cal indicator on the package (II) (243,254,257).
4. Place items/packages correctly and loosely into
the sterilizer so as not to impede penetration of
the sterilant (IB) (243).
5. Do not use instrument packs if mechanical or
chemical indicators indicate inadequate process-
ing (IB) (243,247,248).
6. Monitor sterilizers at least weekly by using a bio-
logical indicator with a matching control (i.e.,
biological indicator and control from same lot
number) (IB) (2,9,243,247,278,279).
7. Use a biological indicator for every sterilizer load
that contains an implantable device. Verify
results before using the implantable device,
whenever possible (IB) (243,248).
8. The following are recommended in the case of a
positive spore test:
a. Remove the sterilizer from service and
review sterilization procedures (e.g., work
practices and use of mechanical and chemi-
cal indicators) to determine whether opera-
tor error could be responsible (II) (8).
b. Retest the sterilizer by using biological,
mechanical, and chemical indicators after
correcting any identified procedural prob-
lems (II).
c. If the repeat spore test is negative, and
mechanical and chemical indicators are
within normal limits, put the sterilizer back
in service (II) (9,243).
9. The following are recommended if the repeat
spore test is positive:
a. Do not use the sterilizer until it has been
inspected or repaired or the exact reason for
the positive test has been determined (II)
(9,243).
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b. Recall, to the extent possible, and reprocess
all items processed since the last negative
spore test (II) (9,243,283).
c. Before placing the sterilizer back in service,
rechallenge the sterilizer with biological
indicator tests in three consecutive empty
chamber sterilization cycles after the cause
of the sterilizer failure has been determined
and corrected (II) (9,243,283).
10. Maintain sterilization records (i.e., mechanical,
chemical, and biological) in compliance with
state and local regulations (IB) (243).
G. Storage Area for Sterilized Items and Clean
Dental Supplies
1. Implement practices on the basis of date- or
event-related shelf-life for storage of wrapped,
sterilized instruments and devices (IB) (243,
284).
2. Even for event-related packaging, at a minimum,
place the date of sterilization, and if multiple
sterilizers are used in the facility, the sterilizer
used, on the outside of the packaging material
to facilitate the retrieval of processed items in
the event of a sterilization failure (IB) (243,247).
3. Examine wrapped packages of sterilized instru-
ments before opening them to ensure the bar-
rier wrap has not been compromised during
storage (II) (243,284).
4. Reclean, repack, and resterilize any instrument
package that has been compromised (II).
5. Store sterile items and dental supplies in cov-
ered or closed cabinets, if possible (II) (285).
VII. Environmental Infection Control
A. General Recommendations
1. Follow the manufacturers’ instructions for cor-
rect use of cleaning and EPA-registered hospital
disinfecting products (IB, IC) (243–245).
2. Do not use liquid chemical sterilants/high-level
disinfectants for disinfection of environmental
surfaces (clinical contact or housekeeping) (IB,
IC) (243–245).
3. Use PPE, as appropriate, when cleaning and dis-
infecting environmental surfaces. Such equip-
ment might include gloves (e.g., puncture- and
chemical-resistant utility), protective clothing
(e.g., gown, jacket, or lab coat), and protective
eyewear/face shield, and mask (IC) (13,15).
B. Clinical Contact Surfaces
1. Use surface barriers to protect clinical contact
surfaces, particularly those that are difficult to
clean (e.g., switches on dental chairs) and change
surface barriers between patients (II) (1,2,260,
288).
2. Clean and disinfect clinical contact surfaces that
are not barrier-protected, by using an EPA-
registered hospital disinfectant with a low- (i.e.,
HIV and HBV label claims) to intermediate-level
(i.e., tuberculocidal claim) activity after each
patient. Use an intermediate-level disinfectant
if visibly contaminated with blood (IB)
(2,243,244).
C. Housekeeping Surfaces
1. Clean housekeeping surfaces (e.g., floors, walls,
and sinks) with a detergent and water or an EPA-
registered hospital disinfectant/detergent on a
routine basis, depending on the nature of the
surface and type and degree of contamination,
and as appropriate, based on the location in the
facility, and when visibly soiled (IB) (243,244).
2. Clean mops and cloths after use and allow to
dry before reuse; or use single-use, disposable
mop heads or cloths (II) (243,244).
3. Prepare fresh cleaning or EPA-registered disin-
fecting solutions daily and as instructed by the
manufacturer. (II) (243,244).
4. Clean walls, blinds, and window curtains in
patient-care areas when they are visibly dusty or
soiled (II) (9,244).
D. Spills of Blood and Body Substances
1. Clean spills of blood or OPIM and decontami-
nate surface with an EPA-registered hospital dis-
infectant with low- (i.e., HBV and HIV label
claims) to intermediate-level (i.e., tuberculocidal
claim) activity, depending on size of spill and
surface porosity (IB, IC) (13,113).
E. Carpet and Cloth Furnishings
1. Avoid using carpeting and cloth-upholstered
furnishings in dental operatories, laboratories,
and instrument processing areas (II) (9,293–
295).
F. Regulated Medical Waste
1. General Recommendations
a. Develop a medical waste management pro-
gram. Disposal of regulated medical waste
must follow federal, state, and local regula-
tions (IC) (13,301).
b. Ensure that DHCP who handle and dispose
of regulated medical waste are trained in
appropriate handling and disposal methods
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and informed of the possible health and
safety hazards (IC) (13).
2. Management of Regulated Medical Waste in
Dental Health-Care Facilities
a. Use a color-coded or labeled container that
prevents leakage (e.g., biohazard bag) to con-
tain nonsharp regulated medical waste (IC)
(13).
b. Place sharp items (e.g., needles, scalpel
blades, orthodontic bands, broken metal
instruments, and burs) in an appropriate
sharps container (e.g., puncture resistant,
color-coded, and leakproof). Close container
immediately before removal or replacement
to prevent spillage or protrusion of contents
during handling, storage, transport, or ship-
ping (IC) (2,8,13,113,115).
c. Pour blood, suctioned fluids or other liquid
waste carefully into a drain connected to a
sanitary sewer system, if local sewage dis-
charge requirements are met and the state
has declared this an acceptable method of
disposal. Wear appropriate PPE while per-
forming this task (IC) (7,9,13).
VIII. Dental Unit Waterlines, Biofilm, and Water Quality
A. General Recommendations
1. Use water that meets EPA regulatory standards
for drinking water (i.e., <500 CFU/mL of het-
erotrophic water bacteria) for routine dental
treatment output water (IB, IC) (341,342).
2. Consult with the dental unit manufacturer for
appropriate methods and equipment to main-
tain the recommended quality of dental water
(II) (339).
3. Follow recommendations for monitoring water
quality provided by the manufacturer of the unit
or waterline treatment product (II).
4. Discharge water and air for a minimum of 20–
30 seconds after each patient, from any device
connected to the dental water system that enters
the patient’s mouth (e.g., handpieces, ultrasonic
scalers, and air/water syringes) (II) (2,311,344).
5. Consult with the dental unit manufacturer on
the need for periodic maintenance of
antiretraction mechanisms (IB) (2,311).
B. Boil-Water Advisories
1. The following apply while a boil-water advisory
is in effect:
a. Do not deliver water from the public water
system to the patient through the dental
operative unit, ultrasonic scaler, or other
dental equipment that uses the public water
system (IB, IC) (341,342,346,349,350).
b. Do not use water from the public water sys-
tem for dental treatment, patient rinsing, or
handwashing (IB, IC) (341,342,346,349,
350).
c. For handwashing, use antimicrobial-
containing products that do not require
water for use (e.g., alcohol-based hand rubs).
If hands are visibly contaminated, use bottled
water, if available, and soap for handwashing
or an antiseptic towelette (IB, IC) (13,122).
2. The following apply when the boil-water
advisory is cancelled:
a. Follow guidance given by the local water
utility regarding adequate flushing of water-
lines. If no guidance is provided, flush den-
tal waterlines and faucets for 1–5 minutes
before using for patient care (IC) (244,346,
351,352).
b. Disinfect dental waterlines as recommended
by the dental unit manufacturer (II).
IX. Special Considerations
A. Dental Handpieces and Other Devices Attached
to Air and Waterlines
1. Clean and heat-sterilize handpieces and other
intraoral instruments that can be removed from
the air and waterlines of dental units between
patients (IB, IC) (2,246,275,356,357,360,407).
2. Follow the manufacturer’s instructions for clean-
ing, lubrication, and sterilization of handpieces
and other intraoral instruments that can be
removed from the air and waterlines of dental
units (IB) (361–363).
3. Do not surface-disinfect, use liquid chemical ste-
rilants, or ethylene oxide on handpieces and
other intraoral instruments that can be removed
from the air and waterlines of dental units (IC)
(2,246,250,275).
4. Do not advise patients to close their lips tightly
around the tip of the saliva ejector to evacuate
oral fluids (II) (364–366).
B. Dental Radiology
1. Wear gloves when exposing radiographs and
handling contaminated film packets. Use other
PPE (e.g., protective eyewear, mask, and gown)
as appropriate if spattering of blood or other
body fluids is likely (IA, IC) (11,13).
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2. Use heat-tolerant or disposable intraoral devices
whenever possible (e.g., film-holding and posi-
tioning devices). Clean and heat-sterilize heat-
tolerant devices between patients. At a
minimum, high-level disinfect semicritical heat-
sensitive devices, according to manufacturer’s
instructions (IB) (243).
3. Transport and handle exposed radiographs in an
aseptic manner to prevent contamination of
developing equipment (II).
4. The following apply for digital radiography
sensors:
a. Use FDA-cleared barriers (IB) (243).
b. Clean and heat-sterilize, or high-level disin-
fect, between patients, barrier-protected
semicritical items. If the item cannot toler-
ate these procedures then, at a minimum,
protect with an FDA-cleared barrier and
clean and disinfect with an EPA-registered
hospital disinfectant with intermediate-level
(i.e., tuberculocidal claim) activity, between
patients. Consult with the manufacturer for
methods of disinfection and sterilization of
digital radiology sensors and for protection
of associated computer hardware (IB) (243).
C. Aseptic Technique for Parenteral Medications
1. Do not administer medication from a syringe to
multiple patients, even if the needle on the
syringe is changed (IA) (378).
2. Use single-dose vials for parenteral medications
when possible (II) (376,377).
3. Do not combine the leftover contents of single-
use vials for later use (IA) (376,377).
4. The following apply if multidose vials are used:
a. Cleanse the access diaphragm with 70%
alcohol before inserting a device into the vial
(IA) (380,381).
b. Use a sterile device to access a multiple-dose
vial and avoid touching the access diaphragm.
Both the needle and syringe used to access
the multidose vial should be sterile. Do not
reuse a syringe even if the needle is changed
(IA) (380,381).
c. Keep multidose vials away from the imme-
diate patient treatment area to prevent inad-
vertent contamination by spray or spatter
(II).
d. Discard the multidose vial if sterility is com-
promised (IA) (380,381).
5. Use fluid infusion and administration sets (i.e.,
IV bags, tubings and connections) for one
patient only and dispose of appropriately (IB)
(378).
D. Single-Use (Disposable) Devices
1. Use single-use devices for one patient only and
dispose of them appropriately (IC) (383).
E. Preprocedural Mouth Rinses
1. No recommendation is offered regarding use of
preprocedural antimicrobial mouth rinses to
prevent clinical infections among DHCP or pa-
tients. Although studies have demonstrated that
a preprocedural antimicrobial rinse (e.g.,
chlorhexidine gluconate, essential oils, or povi-
done-iodine) can reduce the level of oral micro-
organisms in aerosols and spatter generated
during routine dental procedures and can
decrease the number of microorganisms intro-
duced in the patient’s bloodstream during inva-
sive dental procedures (391–399), the scientific
evidence is inconclusive that using these rinses
prevents clinical infections among DHCP or
patients (see discussion, Preprocedural Mouth
Rinses) (Unresolved issue).
F. Oral Surgical Procedures
1. The following apply when performing oral sur-
gical procedures:
a. Perform surgical hand antisepsis by using an
antimicrobial product (e.g., antimicrobial
soap and water, or soap and water followed
by alcohol-based hand scrub with persistent
activity) before donning sterile surgeon’s
gloves (IB) (127–132,137).
b. Use sterile surgeon’s gloves (IB) (2,7,121,
123,137).
c. Use sterile saline or sterile water as a cool-
ant/irrigatant when performing oral surgi-
cal procedures. Use devices specifically
designed for delivering sterile irrigating flu-
ids (e.g., bulb syringe, single-use disposable
products, and sterilizable tubing) (IB)
(2,121).
G. Handling of Biopsy Specimens
1. During transport, place biopsy specimens in a
sturdy, leakproof container labeled with the bio-
hazard symbol (IC) (2,13,14).
2. If a biopsy specimen container is visibly con-
taminated, clean and disinfect the outside of a
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container or place it in an impervious bag
labeled with the biohazard symbol, (IC) (2,13).
H. Handling of Extracted Teeth
1. Dispose of extracted teeth as regulated medical
waste unless returned to the patient (IC) (13,14).
2. Do not dispose of extracted teeth containing
amalgam in regulated medical waste intended
for incineration (II).
3. Clean and place extracted teeth in a leakproof
container, labeled with a biohazard symbol, and
maintain hydration for transport to educational
institutions or a dental laboratory (IC) (13,14).
4. Heat-sterilize teeth that do not contain amal-
gam before they are used for educational pur-
poses (IB) (403,405,406).
I. Dental Laboratory
1. Use PPE when handling items received in the
laboratory until they have been decontaminated
(IA, IC) (2,7,11,13,113).
2. Before they are handled in the laboratory, clean,
disinfect, and rinse all dental prostheses and
prosthodontic materials (e.g., impressions, bite
registrations, occlusal rims, and extracted teeth)
by using an EPA-registered hospital disinfectant
having at least an intermediate-level (i.e., tuber-
culocidal claim) activity (IB) (2,249,252,407).
3. Consult with manufacturers regarding the sta-
bility of specific materials (e.g., impression
materials) relative to disinfection procedures (II).
4. Include specific information regarding disinfec-
tion techniques used (e.g., solution used and
duration), when laboratory cases are sent off-
site and on their return (II) (2,407,409).
5. Clean and heat-sterilize heat-tolerant items used
in the mouth (e.g., metal impression trays and
face-bow forks) (IB) (2,407).
6. Follow manufacturers’ instructions for cleaning
and sterilizing or disinfecting items that become
contaminated but do not normally contact the
patient (e.g., burs, polishing points, rag wheels,
articulators, case pans, and lathes). If manufac-
turer instructions are unavailable, clean and heat-
sterilize heat-tolerant items or clean and disinfect
with an EPA-registered hospital disinfectant with
low- (HIV, HBV effectiveness claim) to inter-
mediate-level (tuberculocidal claim) activity,
depending on the degree of contamination (II).
J. Laser/Electrosurgery Plumes/Surgical Smoke
1. No recommendation is offered regarding prac-
tices to reduce DHCP exposure to laser plumes/
surgical smoke when using lasers in dental prac-
tice. Practices to reduce HCP exposure to laser
plumes/surgical smoke have been suggested,
including use of a) standard precautions (e.g.,
high-filtration surgical masks and possibly full
face shields) (437); b) central room suction units
with in-line filters to collect particulate matter
from minimal plumes; and c) dedicated
mechanical smoke exhaust systems with a high-
efficiency filter to remove substantial amounts
of laser-plume particles. The effect of the expo-
sure (e.g., disease transmission or adverse respi-
ratory effects) on DHCP from dental
applications of lasers has not been adequately
evaluated (see previous discussion, Laser/




a. Educate all DHCP regarding the recogni-
tion of signs, symptoms, and transmission
of TB (IB) (20,21).
b. Conduct a baseline TST, preferably by
using a two-step test, for all DHCP who
might have contact with persons with sus-
pected or confirmed active TB, regardless of
the risk classification of the setting (IB) (20).
c. Assess each patient for a history of TB as well
as symptoms indicative of TB and document
on the medical history form (IB) (20,21).
d. Follow CDC recommendations for 1)
developing, maintaining, and implementing
a written TB infection-control plan; 2) man-
aging a patient with suspected or active TB;
3) completing a community risk-assessment
to guide employee TSTs and follow-up; and
4) managing DHCP with TB disease (IB)
(2,21).
2. The following apply for patients known or sus-
pected to have active TB:
a. Evaluate the patient away from other patients
and DHCP. When not being evaluated, the
patient should wear a surgical mask or be
instructed to cover mouth and nose when
coughing or sneezing (IB) (20,21).
b. Defer elective dental treatment until the
patient is noninfectious (IB) (20,21).
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c. Refer patients requiring urgent dental treat-
ment to a previously identified facility with
TB engineering controls and a respiratory
protection program (IB) (20,21).
L. Creutzfeldt-Jakob Disease (CJD) and Other Prion
Diseases
1. No recommendation is offered regarding use of
special precautions in addition to standard pre-
cautions when treating known CJD or vCJD
patients. Potential infectivity of oral tissues in
CJD or vCJD patients is an unresolved issue.
Scientific data indicate the risk, if any, of spo-
radic CJD transmission during dental and oral
surgical procedures is low to nil. Until additional
information exists regarding the transmissibility
of CJD or vCJD during dental procedures, spe-
cial precautions in addition to standard precau-
tions might be indicated when treating known
CJD or vCJD patients; a list of such precau-
tions is provided for consideration without rec-
ommendation (see Creutzfeldt-Jakob Disease
and Other Prion Diseases) (Unresolved issue).
M. Program Evaluation
1. Establish routine evaluation of the infection-
control program, including evaluation of per-
formance indicators, at an established frequency
(II) (470-471).
Infection-Control Internet Resources




American Institute of Architects Academy of Architec-
ture for Health
http://www.aahaia.org
American Society of Heating, Refrigeration, Air-condi-
tioning Engineers
http://www.ashrae.org
Association for Professionals in Infection Control and
Epidemiology, Inc.
http://www.apic.org/resc/guidlist.cfm
CDC, Division of Healthcare Quality Promotion
http://www.cdc.gov/ncidod/hip
CDC, Division of Oral Health, Infection Control
http://www.cdc.gov/OralHealth/infectioncontrol/index.htm












Infectious Diseases Society of America
http://www.idsociety.org/PG/toc.htm
OSHA, Dentistry, Bloodborne Pathogens
http://www.osha.gov/SLTC/dentistry/index.html
http://www.osha.gov/SLTC/bloodbornepathogens/index.html
Organization for Safety and Asepsis Procedures
http://www.osap.org




The Division of Oral Health thanks the working group as well as
CDC and other federal and external reviewers for their efforts in
developing and reviewing drafts of this report and acknowledges that
all opinions of the reviewers might not be reflected in all of the
recommendations.
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Appendix A
Regulatory Framework for Disinfectants and Sterilants
When using the guidance provided in this report
regarding use of liquid chemical disinfectants and sterilants,
dental health-care personnel (DHCP) should be aware of fed-
eral laws and regulations that govern the sale, distribution,
and use of these products. In particular, DHCPs should know
what requirements pertain to them when such products are
used. Finally, DHCP should understand the relative roles of
the U.S. Environmental Protection Agency (EPA), the U.S.
Food and Drug Administration (FDA), the Occupational
Safety and Health Administration (OSHA) and CDC.
The choice of specific cleaning or disinfecting agents is largely
a matter of judgment, guided by product label claims and
instructions and government regulations. A single liquid chemi-
cal germicide might not satisfy all disinfection requirements
in a given dental practice or facility. Realistic use of liquid
chemical germicides depends on consideration of multiple fac-
tors, including the degree of microbial killing required; the
nature and composition of the surface, item, or device to be
treated; and the cost, safety, and ease of use of the available
agents. Selecting one appropriate product with a higher de-
gree of potency to cover all situations might be more conve-
nient.
In the United States, liquid chemical germicides (disinfec-
tants) are regulated by EPA and FDA (A-1–A-3). In health-
care settings, EPA regulates disinfectants that are used on
environmental surfaces (housekeeping and clinical contact
surfaces), and FDA regulates liquid chemical sterilants/
high-level disinfectants (e.g., glutaraldehyde, hydrogen perox-
ide, and peracetic acid) used on critical and semicritical patient-
care devices. Disinfectants intended for use on clinical contact
surfaces (e.g., light handles, radiographic-ray heads, or drawer
knobs) or housekeeping surfaces (e.g., floors, walls, or sinks)
are regulated in interstate commerce by the Antimicrobials
Division, Office of Pesticide Programs, EPA, under the
authority of the Federal Insecticide, Fungicide, and
Rodenticide Act (FIFRA) of 1947, as amended in 1996 (A-4).
Under FIFRA, any substance or mixture of substances intended
to prevent, destroy, repel, or mitigate any pest, including
microorganisms but excluding those in or on living man or
animals, must be registered before sale or distribution. To
obtain a registration, a manufacturer must submit specific data
regarding the safety and the effectiveness of each product.
EPA requires manufacturers to test formulations by using
accepted methods for microbicidal activity, stability, and tox-
icity to animals and humans. Manufacturers submit these data
to EPA with proposed labeling. If EPA concludes a product
may be used without causing unreasonable adverse effects, the
product and its labeling are given an EPA registration num-
ber, and the manufacturer may then sell and distribute the
product in the United States. FIFRA requires users of prod-
ucts to follow the labeling directions on each product explicitly.
The following statement appears on all EPA-registered prod-
uct labels under the Directions for Use heading: “It is a viola-
tion of federal law to use this product inconsistent with its
labeling.” This means that DHCP must follow the safety pre-
cautions and use directions on the labeling of each registered
product. Not following the specified dilution, contact time,
method of application, or any other condition of use is con-
sidered misuse of the product.
FDA, under the authority of the 1976 Medical Devices
Amendment to the Food, Drug, and Cosmetic Act, regulates
chemical germicides if they are advertised and marketed for
use on specific medical devices (e.g., dental unit waterline or
flexible endoscope). A liquid chemical germicide marketed for
use on a specific device is considered, for regulatory purposes,
a medical device itself when used to disinfect that specific medi-
cal device. Also, this FDA regulatory authority over a particu-
lar instrument or device dictates that the manufacturer is
obligated to provide the user with adequate instructions for
the safe and effective use of that device. These instructions
must include methods to clean and disinfect or sterilize the
item if it is to be marketed as a reusable medical device.
OSHA develops workplace standards to help ensure safe and
healthful working conditions in places of employment. OSHA
is authorized under Pub. L. 95-251, and as amended, to en-
force these workplace standards. In 1991, OSHA published
Occupational Exposure to Bloodborne Pathogens; final rule
[29 CFR Part 1910.1030] (A-5). This standard is designed to
help prevent occupational exposures to blood or other poten-
tially infectious substances. Under this standard, OSHA has
interpreted that, to decontaminate contaminated work sur-
faces, either an EPA-registered hospital tuberculocidal disin-
fectant or an EPA-registered hospital disinfectant labeled as
effective against human immunodeficiency virus (HIV) and
hepatitis B virus (HBV) is appropriate. Hospital disinfectants
with such HIV and HBV claims can be used, provided sur-
faces are not contaminated with agents or concentration of
agents for which higher level (i.e., intermediate-level) disin-
fection is recommended. In addition, as with all disinfectants,
effectiveness is governed by strict adherence to the label
instructions for intended use of the product.
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CDC is not a regulatory agency and does not test, evaluate,
or otherwise recommend specific brand-name products of
chemical germicides. This report is intended to provide over-
all guidance for providers to select general classifications of
products based on certain infection-control principles. In this
report, CDC provides guidance to practitioners regarding
appropriate application of EPA- and FDA-registered liquid
chemical disinfectants and sterilants in dental health-care set-
tings.
CDC recommends disinfecting environmental surfaces or
sterilizing or disinfecting medical equipment, and DHCP
should use products approved by EPA and FDA unless no
such products are available for use against certain microorgan-
isms or sites. However, if no registered or approved products
are available for a specific pathogen or use situation, DHCP
are advised to follow the specific guidance regarding unregis-
tered or unapproved (e.g., off-label) uses for various chemical
germicides. For example, no antimicrobial products are regis-
tered for use specifically against certain emerging pathogens
(e.g., Norwalk virus), potential terrorism agents (e.g., variola
major or Yersinia pestis), or Creutzfeldt-Jakob disease agents.
One point of clarification is the difference in how EPA and
FDA classify disinfectants. FDA adopted the same basic ter-
minology and classification scheme as CDC to categorize
medical devices (i.e., critical, semicritical, and noncritical) and
to define antimicrobial potency for processing surfaces (i.e.,
sterilization, and high-, intermediate- and low-level disinfec-
tion) (A-6). EPA registers environmental surface disinfectants
based on the manufacturer’s microbiological activity claims
when registering its disinfectant. This difference has led to con-
fusion on the part of users because the EPA does not use the
terms intermediate- and low-level disinfectants as used in CDC
guidelines.
CDC designates any EPA-registered hospital disinfectant
without a tuberculocidal claim as a low-level disinfectant and
any EPA-registered hospital disinfectant with a tuberculocidal
claim as an intermediate-level disinfectant. To understand this
comparison, one needs to know how EPA registers disinfec-
tants. First, to be labeled as an EPA hospital disinfectant, the
product must pass Association of Official Analytical Chemists
(AOAC) effectiveness tests against three target organisms: Sal-
monella choleraesuis for effectiveness against gram-negative
bacteria; Staphylococcus aureus for effectiveness against gram-
positive bacteria; and Pseudomonas aeruginosa for effectiveness
against a primarily nosocomial pathogen. Substantiated label
claims of effectiveness of a disinfectant against specific micro-
organisms other than the test microorganisms are permitted,
but not required, provided that the test microorganisms are
likely to be present in or on the recommended use areas and
surfaces. Therefore, manufacturers might also test specifically
against organisms of known concern in health-care practices
(e.g., HIV, HBV, hepatitis C virus [HCV], and herpes) al-
though it is considered likely that any product satisfying AOAC
tests for hospital disinfectant designation will also be effective
against these relatively fragile organisms when the product is
used as directed by the manufacturer.
Potency against Mycobacterium tuberculosis has been recog-
nized as a substantial benchmark. However, the tuberculocidal
claim is used only as a benchmark to measure germicidal
potency. Tuberculosis is not transmitted via environmental sur-
faces but rather by the airborne route. Accordingly, use of such
products on environmental surfaces plays no role in prevent-
ing the spread of tuberculosis. However, because mycobacte-
ria have among the highest intrinsic levels of resistance among
the vegetative bacteria, viruses, and fungi, any germicide with
a tuberculocidal claim on the label is considered capable of
inactivating a broad spectrum of pathogens, including such
less-resistant organisms as bloodborne pathogens (e.g., HBV,
HCV, and HIV). It is this broad-spectrum capability, rather
than the product’s specific potency against mycobacteria, that
is the basis for protocols and regulations dictating use of
tuberculocidal chemicals for surface disinfection.
EPA also lists disinfectant products according to their
labeled use against these organisms of interest as follows:
• List B. Tuberculocide products effective against Mycobac-
terium species.
• List C. Products effective against human HIV-1 virus.
• List D. Products effective against human HIV-1 virus and
HBV.
• List E. Products effective against Mycobacterium species,
human HIV-1 virus, and HBV.
• List F. Products effective against HCV.
Microorganisms vary in their resistance to disinfection and
sterilization, enabling CDC’s designation of disinfectants as
high-, intermediate-, and low-level, when compared with EPA’s
designated organism spectrum (Figure). However, exceptions
to this general guide exist, and manufacturer’s label claims and
instructions should always be followed.
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FIGURE. Decreasing order of resistance of microorganisms to germicidal chemicals
Source: Adapted from Bond WW, Ott BJ, Franke K, McCracken JE. Effective use of liquid chemical germicides on medical devices; instrument design
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Appendix B
Immunizations Strongly Recommended for Health-Care Personnel (HCP)
Major precautions


















(IM) in the deltoid; 0,1,6 -
second dose administered 1
month after first dose; third dose
administered 4 months after
second. Booster doses are not
necessary for persons who have
developed adequate antibodies
to hepatitis B surface antigen
(anti-HBs).
Annual single-dose vaccination
IM with current vaccine.
One dose administered
subcutaneously (SC); second
dose >4 weeks later.
One dose SC; no booster.
One dose SC; no booster.
Two 0.5 mL doses SC 4–8
weeks apart if aged >13 years.
No therapeutic or adverse effects on hepatitis
B virus (HBV)-infected persons; cost-
effectiveness of prevaccination screening for
susceptibility to HBV depends on costs of
vaccination and antibody testing and
prevalence of immunity in the group of
potential vaccinees; health-care personnel who
have ongoing contact with patients or blood
should be tested 1–2 months after completing
the vaccination series to determine serologic
response. If vaccination does not induce
adequate anti-HBs (>10 mIU/mL), a second
vaccine series should be administered.
Recommended for women who will be in the
second or third trimesters of pregnancy during
the influenza season and women in any stage
of pregnancy who have chronic medical
conditions that are associated with an
increased risk of influenza.§
Measles, mumps, rubella (MMR) is the
recommended vaccine, if recipients are also
likely to be susceptible to rubella or mumps;
persons vaccinated during 1963–1967 with
1) measles killed-virus vaccine alone,
2) killed-virus vaccine followed by live-virus
vaccine, or 3) a vaccine of unknown type,
should be revaccinated with two doses of
live-virus measles vaccine.
MMR is the recommended vaccine.
Women pregnant when vaccinated or who
become pregnant within 4 weeks of
vaccination should be counseled regarding
theoretic risks to the fetus; however, the risk
of rubella vaccine-associated malformations
among these women is negligible. MMR is the
recommended vaccine.
Because 71%–93% of U.S.-born persons
without a history of varicella are immune,
serologic testing before vaccination might be
cost-effective.
Health-care personnel (HCP)
at risk for exposure to blood
and body fluids.
HCP who have contact with
patients at high risk or who
work in chronic-care facilities;
HCP aged >50 years or who
have high-risk medical
conditions.
HCP who were born during or
after 1957 without documenta-
tion of 1) receipt of 2 doses of
live vaccine on or after their first
birthday, 2) physician-diagnosed
measles, or 3) laboratory
evidence of immunity. Vaccine
should also be considered for
all HCP who have no proof of
immunity, including those born
before 1957.
HCP believed susceptible can
be vaccinated; adults born
before 1957 can be considered
immune.
HCP, both male and female,
who lack documentation of
receipt of live vaccine on or
after their first birthday, or lack
of laboratory evidence of
immunity can be vaccinated.
Adults born before 1957 can
be considered immune, except
women of childbearing age.
HCP without reliable history of
varicella or laboratory evidence
of varicella immunity.
Sources: Adapted from Bolyard EA, Hospital Infection Control Practices Advisory Committee. Guidelines for infection control in health care personnel, 1998. Am J Infect Control
1998;26:289–354.
CDC. Immunization of health-care workers: recommendations of the Advisory Committee on Immunization Practices (ACIP) and the Hospital Infection Control Practices
Advisory Committee (HICPAC). MMWR 1997;46(No. RR-18).
CDC. Prevention and control of influenza: recommendations of the Advisory Committee on Immunization Practices (ACIP). MMWR 2003;52:1-34.
CDC. Using live, attenuated influenza vaccine for prevention and control of influenza: supplemental recommendations of the Advisory Committee on Immunization Practices
(ACIP). MMWR 2003;52(No. RR-13).
* A federal standard issued in December 1991 under the Occupational Safety and Health Act mandates that hepatitis B vaccine be made available at the employer’s expense to
all HCP occupationally exposed to blood or other potentially infectious materials. The Occupational Safety and Health Administration requires that employers make available
hepatitis B vaccinations, evaluations, and follow-up procedures in accordance with current CDC recommendations.
†
Persons immunocompromised because of immune deficiencies, HIV infection, leukemia, lymphoma, generalized malignancy; or persons receiving immunosuppressive therapy
with corticosteroids, alkylating drugs, antimetabolites; or persons receiving radiation.
§
Vaccination of pregnant women after the first trimester might be preferred to avoid coincidental association with spontaneous abortions, which are most common during the first
trimester. However, no adverse fetal effects have been associated with influenza vaccination.
¶
A live attenuated influenza vaccine (LAIV) is FDA-approved for healthy persons aged 5-49 years. Because of the possibility of transmission of vaccine viruses from recipients
of LAIV to other persons and in the absence of data on the risk of illness and among immunocompromised persons infected with LAIV viruses, the inactivated influenza vaccine
is preferred for HCP who have close contact with immunocompromised persons.
History of anaphylactic reaction to
common baker’s yeast. Pregnancy
is not a contraindication.
History of anaphylactic hypersensi-
tivity to eggs or to other compo-
nents of the vaccine.
Pregnancy; immunocompromised†
state (including human immunode-
ficiency virus [HIV]-infected
persons with severe immunosup-
pression); history of anaphylactic
reactions after gelatin ingestion or




state; history of anaphylactic
reaction after gelatin ingestion or
receipt of neomycin.
Pregnancy; immunocompromised†
state; history of anaphylactic
reaction after receipt of neomycin.
Pregnancy; immunocompromised†
state; history of anaphylactic
reaction after receipt of neomycin
or gelatin; recent receipt of
antibody-containing blood products;
salicylate use should be avoided
for 6 weeks after vaccination.
66 MMWR December 19, 2003
Appendix C




Process Result Method Examples patient-care item surfaces
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isms, but not necessarily
high numbers of bacterial
spores.
Destroys vegetative bacteria
and the majority of fungi and
viruses. Inactivates
Mycobacterium bovis.§ Not
necessarily capable of killing
bacterial spores.
Destroys the majority of
vegetative bacteria, certain











Steam, dry heat, unsaturated chemical vapor
Ethylene oxide gas, plasma sterilization
Chemical sterilants. Glutaraldehyde,
glutaraldehydes with phenol, hydrogen




Glutaraldehyde, glutaraldehyde with phenol,
hydrogen peroxide, hydrogen peroxide with
peracetic acid, ortho-phthalaldehyde
U.S. Environmental Protection Agency (EPA)-
registered hospital disinfectant with label claim
of tuberculocidal activity (e.g., chlorine-
containing products, quaternary ammonium
compounds with alcohol, phenolics, iodophors,
EPA-registered chlorine-based product¶)
EPA-registered hospital disinfectant with no
label claim regarding tuberculocidal activity.**
The Occupational Safety and Health Administra-
tion also requires label claims of human
immunodeficiency virus (HIV) and hepatitis B
virus (HBV) potency for clinical contact surfaces

























* EPA and the Food and Drug Administration (FDA) regulate chemical germicides used in health-care settings. FDA regulates chemical sterilants used on critical and semicritical
medical devices, and the EPA regulates gaseous sterilants and liquid chemical disinfectants used on noncritical surfaces. FDA also regulates medical devices, including
sterilizers. More information is available at 1) http://www.epa.gov/oppad001/chemregindex.htm, 2) http://www.fda.gov/cdrh/index.html, and 3) http://www.fda.gov/cdrh/ode/
germlab.html.
† Contact time is the single critical variable distinguishing the sterilization process from high-level disinfection with FDA-cleared liquid chemical sterilants. FDA defines a high-level
disinfectant as a sterilant used under the same contact conditions as sterilization except for a shorter immersion time (C-1).
§ The tuberculocidal claim is used as a benchmark to measure germicidal potency. Tuberculosis (TB) is transmitted via the airborne route rather than by environmental surfaces
and, accordingly, use of such products on environmental surfaces plays no role in preventing the spread of TB. Because mycobacteria have among the highest intrinsic levels of
resistance among vegetative bacteria, viruses, and fungi, any germicide with a tuberculocidal claim on the label (i.e., an intermediate-level disinfectant) is considered capable of
inactivating a broad spectrum of pathogens, including much less resistant organisms, including bloodborne pathogens (e.g., HBV, hepatitis C virus [HCV], and HIV). It is this
broad-spectrum capability, rather than the product’s specific potency against mycobacteria, that is the basis for protocols and regulations dictating use of tuberculocidal
chemicals for surface disinfection.
¶ Chlorine-based products that are EPA-registered as intermediate-level disinfectants are available commercially. In the absence of an EPA-registered chlorine-based product, a
fresh solution of sodium hypochlorite (e.g., household bleach) is an inexpensive and effective intermediate-level germicide. Concentrations ranging from 500 ppm to 800 ppm of
chlorine (1:100 dilution of 5.25% bleach and tap water, or approximately ¼ cup of 5.25% bleach to 1 gallon of water) are effective on environmental surfaces that have been
cleaned of visible contamination. Appropriate personal protective equipment (e.g., gloves and goggles) should be worn when preparing hypochlorite solutions (C-2,C-3). Caution
should be exercised, because chlorine solutions are corrosive to metals, especially aluminum.
** Germicides labeled as “hospital disinfectant” without a tuberculocidal claim pass potency tests for activity against three representative microorganisms: Pseudomonas aeruginosa,
Staphylococcus aureus, and Salmonella choleraesuis.
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1. Read this MMWR (Vol. 52, RR-17), which contains the correct answers to
the questions beginning on the next page.
2. Go to the MMWR Continuing Education Internet site at <http://
www.cdc.gov/mmwr/cme/conted.html>.
3. Select which exam you want to take and select whether you want to register
for CME, CEU, or CNE credit.
4. Fill out and submit the registration form.
5. Select exam questions. To receive continuing education credit, you must
answer all of the questions. Questions with more than one correct answer
will instruct you to “Indicate all that apply.”
6. Submit your answers no later than December 19, 2006.
7. Immediately print your Certificate of Completion for your records.
By Mail or Fax
1. Read this MMWR (Vol. 52, RR-17), which contains the correct answers to
the questions beginning on the next page.
2. Complete all registration information on the response form, including your
name, mailing address, phone number, and e-mail address, if available.
3. Indicate whether you are registering for CME, CEU, or CNE credit.
4. Select your answers to the questions, and mark the corresponding letters on
the response form. To receive continuing education credit, you must
answer all of the questions. Questions with more than one correct answer
will instruct you to “Indicate all that apply.”
5. Sign and date the response form or a photocopy of the form and send no
later than December 19, 2006, to
Fax: 404-639-4198  Mail: MMWR CE Credit
Office of Scientific and Health Communications
Epidemiology Program Office, MS C-08
Centers for Disease Control and Prevention
1600 Clifton Rd, N.E.
Atlanta, GA 30333
6. Your Certificate of Completion will be mailed to you within 30 days.
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1. The components of a personnel health infection control program
in a dental setting should include which of the following?
A. Infection control education and training for dental staff.
B. Appropriate immunizations against vaccine-preventable diseases.
C. Exposure prevention and postexposure management strategies.
D. Policies regarding work-related illness and work restrictions.
E. Confidentiality of work-related medical evaluations for dental staff.
F. All of the above.
2. Which of the following is true regarding standard infection-control
precautions?
A. Standard precautions are strategies used to reduce the risk of
transmission of pathogens in the health-care setting.
B. Standard precautions should be used in caring for all patients,
regardless of their infectious status.
C. Expanded or transmission-based precautions are used beyond
standard precautions to interrupt the spread of certain pathogens.
D. Standard precautions apply to exposure to blood, all body fluids and
secretions (except sweat), nonintact skin, and mucous membranes.
E. All of the above.
F. None of the above.
3. Factors to consider in assessing need for follow-up after an occupational
blood or body fluid exposure include . . .
A. the type of exposure.
B. the type of body fluid.
C. the bloodborne pathogen infection status of the source.
D. the susceptibility of the exposed person.
E. all of the above.
F. none of the above.
4. Which of the following is not usually worn as personal protective
equipment when anticipating spatter of blood or body fluids?
A. Jacket with long sleeves.
B. Gloves.
C. Head covering.
D. Protective eyewear or face shield.
E. Face mask.
5. Which of the following is not true regarding gloves?
A. Certain hand lotions can affect the integrity of gloves.
B. Wearing gloves replaces the need for handwashing.
C. Sterile surgical gloves are recommended for oral surgical procedures.
D. The Food and Drug Administration (FDA) has identified glove failure
rates for manufacturers.
E. Certain glove materials can interfere with the setting of impression
materials.
6. Which of the following statements regarding processing of contaminated
instruments is true?
A. Instruments should be processed in an area separate from where clean
instruments are stored.
B. Personnel should wear heavy-duty utility gloves.
C. Instruments only need cleaning if they have visible contamination.
D. Instruments should be heat-sterilized unless they are heat-sensitive.
E. Cleaning an instrument precedes all sterilization and disinfection
processes.
F. A, B, D, and E are correct.
Goal and Objectives
This MMWR provides recommendations regarding infection control practices for dentistry settings. These recommendations were prepared by CDC staff after
consultation with staff from other federal agencies and specialists in dental infection control. The goal of this report is to minimize the risk of disease transmission
in dental health-care settings through improved understanding and practice of evidence-based infection control strategies. Upon completion of this continuing
education activity, the reader should be able to 1) list the major components of a personnel health infection-control program in the dental setting; 2) list key measures
for preventing transmission of bloodborne pathogens; 3) describe key elements of instrument processing and sterilization; 4) describe dental water quality concepts;
and 5) demonstrate the importance of developing an infection-control program evaluation.
To receive continuing education credit, please answer all of the following questions.
7. Which of the following statements is true regarding monitoring the
correct functioning of a sterilizer?
A. A chemical indicator should be placed in a visible area of the package
before sterilization processing.
B. A biological indicator spore test should be processed through a sterilizer
cycle at least once a week.
C. A biological indicator control test matching the same lot of the spore
test should be submitted with the sterilizer spore test.
D. Mechanical assessments of sterilizer cycle time and temperature should
be monitored.
E. All of the above.
8. Low- to intermediate–level disinfectants used to clean environmental
surfaces . . . (Indicate all that apply.)
A. rapidly inactivate human immunodeficiency virus and hepatitis B
virus on clinical contact and housekeeping surfaces.
B. must be FDA-registered.
C. are used after prompt removal of blood or body substance
contamination on a surface.
D. are appropriate to disinfect floors, depending on type of contamination.
E. all of the above.
F. A, C, and D are correct.
9. Which of the following statements is true regarding dental unit
waterlines?
A. If municipal water is the source that enters the dental unit waterline,
output will always meet drinking water quality.
B. Flushing the waterlines for >2 minutes at the beginning of the day
reduces the biofilm in the waterlines.
C. Dentists should consult with the manufacturer of the dental unit or
water delivery system to determine the best method for maintaining
optimal water quality.
D. Dental unit waterlines can reliably deliver optimal water quality when
used for irrigation during a surgical procedure.
E. All of the above.
F. A, B, and D are correct.
10. Which of the following is true regarding a dental clinic infection
control program evaluation?
A. A method to ensure a safe working environment should be in place to
reduce the risk of health-care–associated infections among patients
and occupational exposures among dental health-care personnel.
B. Evaluation of a program should include documenting periodic
observational assessments, reviewing completed checklists, and
reviewing occupational exposures.
C. An evaluation program does not improve an infection control program.
D. A and B are correct.
E. A and C are correct.
F. All of the above.
11. Indicate your work setting.
A. Private dental practice.
B. Hospital dental setting.
C. Academic institution.
D. Laboratory.
E. Other public health setting.
F. Other.










































































































12. Which best describes your professional activities?
A. Dentist. D. Dental office staff.
B. Dental hygienist. E. Other medical profession.
C. Dental laboratory staff.
13. I plan to use these recommendations as the basis for . . .  (Indicate all
that apply.)
A. health education materials. D. public policy.
B. insurance reimbursement policies. E. other.
C. local practice guidelines.
14. Each month, approximately how many dental patients do you treat?
A. None. D. 51–100.
B. 1–10. E. 101–200.
C. 11–50. F. >200.
15. How much time did you spend reading this report and completing the
exam?
A. <2.0 hours. C. >3.0 hours but <4.0.
B. >2.0 hours but <3.0 hours. D. >4.0 hours.
16. After reading this report, I am confident I can list the major
components of a personnel health infection control program in the
dental setting.
A. Strongly agree. D. Disagree.
B. Agree. E. Strongly disagree.
C. Neither agree nor disagree.
17. After reading this report, I am confident I can list key measures for
preventing transmission of bloodborne pathogens.
A. Strongly agree. D. Disagree.
B. Agree. E. Strongly disagree.
C. Neither agree nor disagree.
18. After reading this report, I am confident I can describe key elements of
instrument processing and sterilization.
A. Strongly agree. D. Disagree.
B. Agree. E. Strongly disagree.
C. Neither agree nor disagree.
19. After reading this report, I am confident I can describe dental water
quality concepts.
A. Strongly agree. D. Disagree.
B. Agree. E. Strongly disagree.
C. Neither agree nor disagree.
20. After reading this report, I am confident I can demonstrate the importance
of developing an infection-control program evaluation.
A. Strongly agree. D. Disagree.
B. Agree. E. Strongly disagree.
C. Neither agree nor disagree.
21. The objectives are relevant to the goal of this report.
A. Strongly agree. D. Disagree.
B. Agree. E. Strongly disagree.




























































































































































































































































































































































































































































































































































































































































































































(Continued on pg CE-4)
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22. The teaching strategies used in this report (text, figures, boxes, and
tables) were useful.
A. Strongly agree. D. Disagree.
B. Agree. E. Strongly disagree.
C. Neither agree nor disagree.
23. Overall, the presentation of the report enhanced my ability to
understand the material.
A. Strongly agree. D. Disagree.
B. Agree. E. Strongly disagree.
C. Neither agree nor disagree.
24. These recommendations will affect my practice.
A. Strongly agree. D. Disagree.
B. Agree. E. Strongly disagree.
C. Neither agree nor disagree.
25. The content of this activity was appropriate for my educational needs.
A. Strongly agree. D. Disagree.
B. Agree. E. Strongly disagree.
C. Neither agree nor disagree.
26. The availability of continuing education credit influenced my
decision to read this report.
A. Strongly agree. D. Disagree.
B. Agree. E. Strongly disagree.
C. Neither agree nor disagree.
27. How did you learn about this continuing education activity?
A. Internet.
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This report summarizes West Nile virus (WNV) surveillance
data reported to CDC through ArboNET and by states and
other jurisdictions as of August 7, 2002.
United States
During the reporting period of July 31–August 7, a total of
68 laboratory-positive human cases of WNV-associated ill-
ness were reported from Louisiana (n=40), Mississippi (n=23),
Texas (n=four), and Illinois (n=one). During the same
period, WNV infections were reported in 447 dead crows,
263 other dead birds, 42 horses, and 183 mosquito pools.
During 2002, a total of 112 human cases with laboratory
evidence of recent WNV infection have been reported from
Louisiana (n=71), Mississippi (n=28), Texas (n=12), and Illi-
nois (n=one). Five deaths have been reported, all from Louisi-
ana. Among the 98 cases with available data, 59 (60%)
occurred among men; the median age was 55 years (range:
3–88 years), and the dates of illness onset ranged from June 10
to July 29.In addition, 1,076 dead crows and 827 other dead birds
with WNV infection were reported from 34 states, New York
City, and the District of Columbia (Figure 1); 87 WNV
infections in horses have been reported from 12 states
(Alabama, Florida, Georgia, Illinois, Kentucky, Louisiana,
Minnesota, Mississippi, North Dakota, South Dakota, Ten-
nessee, and Texas). During 2002, WNV seroconversions have
been reported in 52 sentinel chicken flocks from Florida,
Nebraska, and Pennsylvania; and 425 WNV-positive mos-
quito pools have been reported from 12 states (Alabama, Geor-
gia, Illinois, Indiana, Massachusetts, Mississippi, New Jersey,
Ohio, Pennsylvania, South Dakota, Texas, and Virginia), New
York City, and the District of Columbia.
West Nile Virus Activity — United States, July 31–August 7, 2002,
and Louisiana, January 1–August 7, 2002
INSIDE
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Outbreak of Salmonella Serotype Javiana Infections —
Orlando, Florida, June 2002
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Recent human WNV infection and animal WNV activity
Animal WNV activity only
District ofColumbia
* As of August 7, 2002.
FIGURE 1. Areas reporting West Nile virus (WNV) activity —
United States, 2002*
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